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ABSTRACT
The generation of mature myelinating and non-myelinating Schwann cells from 
immature Schwann cells is regulated by signals from the axon. In the absence of 
axonal signals, for example during nerve injury, Schwann cells will return to an 
immature-like phenotype. However, Schwann cells retain the ability to re-differentiate 
after injury, demonstrating remarkable plasticity throughout adult life. Although these 
cellular transformations are normally beneficial, during diseases of the peripheral 
nervous system, they are often disrupted producing negative consequences.
In this thesis, I have demonstrated a synergistic relationship between two 
signals, cyclic adenosine monophosphate (cyclic AMP) and p-neuregulin-1 (NRG1) 
in inducing myelin differentiation in cultured mouse Schwann cells. Furthermore, I 
found that the cyclic-AMP response element binding protein (CREB) family of 
transcription factors are required for this differentiation. Second, I have investigated 
the role of the transcription factor c-Jun in controlling Schwann cell responses after 
nerve injury. Using in vivo and in vitro approaches, I have found that c-Jun is an 
axonal-regulated injury factor that controls Schwann cell demyelination and 
dedifferentiation. Furthermore, Schwann cell derived c-Jun is crucial for adequate 
nerve regeneration and repair after injury. Finally, I investigated the functional 
properties of a mutant form of the myelin-related transcription factor Egr2 (Krox-20), 
which leads to severe congenital hypomyelinating neuropathy in humans. I found that 
mutant Egr2 is not transcriptionally inactive but retains residual wild-type Egr2 
functions. More importantly, mutant Egr2 also demonstrates aberrant effects in 
Schwann cells, enhancing DNA synthesis, both in the presence and absence o f the 
putative axonal mitogen, p-neuregulin 1. This is in stark contrast to wild-type Egr2, 
which causes withdrawal from the cell cycle.
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CHAPTER 1: GENERAL INTRODUCTION
1.1 Schwann cells and their origins in peripheral nervous system development.
Schwann cells constitute the major form of glial cell in the mammalian 
peripheral nervous system (PNS). Other forms of glial cell in the PNS include, 
satellite cells found in dorsal root ganglia (DRG) and ganglia of the sympathetic and 
parasympathetic nervous system, olfactory ensheathing cells that associate with axons 
of the olfactory nerve, terminal glia (teloglia) which are present at the neuromuscular 
junction, enteric glia of the enteric nervous system and specialised glia that 
accompany sensory nerve endings in the skin, such as Pacinian corpuscles (lessen and 
Mirsky, 2005).
In the adult mammalian PNS nerve trunks there are two forms of Schwann cell, 
the myelinating Schwann cell, which associates in a 1:1 relationship and wraps a 
myelin sheath around axons greater than 1pm in diameter and, non-myelinating 
Schwann cells that associate with a variable number of small calibre axons (less than 
lpM  in diameter) that form troughs in its cytoplasm (Jessen and Mirsky, 2005).
Schwann cells in the spinal nerves are derived from migratory neural crest cells, 
which originate from the tips of the neural folds during neural tube formation (Le 
Douarin et al., 1991; Anderson, 1997). In contrast, a majority of Schwann cells in the 
dorsal and ventral roots are derived from Boundary cap cells, which themselves are 
derived from neural crest cells, and are positioned at the dorsal and ventral root entry 
and exit points to the spinal cord early during development (Maro et al., 2004).
The generation of myelinating and non-myelinating Schwann cells from neural 
crest cells occurs via two intermediary cellular stages. Firstly, Schwann cell 
precursors are formed from neural crest cells and are present around embryonic day
16
(E) 14-15 in rat peripheral nerves. Schwann cell precursors in turn lead to the 
generation of immature Schwann cells by E l7-18 (Jessen et al., 1994; Dong et al., 
1995). In murine peripheral nerves, these developmental transitions occur two days 
earlier, thus Schwann cell precursors are present at E l2-13 and immature Schwann 
cells at E l 5/16 (Dong et al., 1999). These two cell types are phenotypically distinct 
from one another, in terms of antigenic expression, survival mechanisms, morphology 
and relationship to the axons and the extracellular matrix (Fig. 1.1) (Woodhoo et al., 
2004; Jessen and Mirsky, 2005).
1.1.1. The Schwann cell precursor
Neural crest cells are specified to be Schwann cell precursors through the 
process of gliogenesis. The transcription factor Sox-10 is crucial in regulating this 
process, since a targeted mutation in Sox-10 leads to a complete lack of Schwann 
cells and satellite cells in the PNS whereas neurogenesis is initially unaffected 
(Britsch et al., 2001).
At E l4, rat Schwann cell precursors are identified generally at the periphery but 
sometimes within the developing nerve, surrounding large bundles of small diameter 
axons. These cells usually extended processes deep into the axon bundles that contact 
processes from other Schwann cell precursors. Nerves at this time point contain little 
extracellular matrix (ECM) and no apparent connective tissue or blood vessels (Jessen 
et al., 1994; Jessen and Mirsky, 2005). Furthermore, in vitro Schwann cell precursors 
demonstrate a radically different appearance to immature Schwann cells, often 
forming groups of cells and adopting a flattened shape as opposed to a bi- or tripolar 
morphology seen with cultured Schwann cells (Jessen et al., 1994). In addition, 
Schwann cell precursors appear to require p-neuregulin-1 (NRG1) signalling (see
17
section 1.5.2 for summary) through its receptors erbB2 and erbB3 in order to survive 
both in vitro and in vivo (Dong et al., 1995; Meyer and Birchmeier, 1995; 
Riethmacher et al., 1997; Woldeyesus et al., 1999; Morris et al., 1999; Garrat et al., 
2000). Additionally, in mice lacking both type I and type II NRG1 isoforms Schwann 
cell precursors develop normally whereas mice lacking NRG1 type III have severely 
reduced numbers of Schwann cell precursors (Meyer et al., 1997; Wolpowitz et al., 
2000). The source of NRG1 type III during development appears to be the motor and 
sensory neurons, which are present in the nerve at the same time as the Schwann cell 
precursors (Ho et al., 1995; Meyer et al., 1997; Yang et al., 1998; Wanner et al., 
2006a). In summary this data suggests that Schwann cell precursors rely on NRG1 
type III expressed on growing axons for their survival during PNS development.
There are several known functions of Schwann cell precursors in PNS 
development. Firstly, they provide the source of progenitors from which immature 
Schwann cells and endoneurial fibroblasts are generated (Joseph et al., 2004; Jessen 
and Mirsky, 2005). They also appear to support the survival of growing neurons since 
in mouse mutants that lack Schwann cell precursors there is substantial death of both 
motor and sensory neurons (Riethmacher et al., 1997; Woldeyesus et al., 1999; 
Britsch et al., 2001; Sonnenberg-Riethmacher et al., 2001). In addition, Schwann cell 
precursors appear important for axon fasciculation and nerve compaction, forming a 
tight cellular cluster around advancing growth cones of neurons before they innervate 
their targets (Woldeyesus et al., 1999; Morris et al., 1999; Wolpowitz et al., 2000; 
Wanner et al., 2006a).
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Figure 1.1 Antigenic and phenotypic profile of cells in the Schwann cell lineage 
during embryogenesis.
Yellow box -  antigens present in the whole of the early Schwann cell lineage; Blue 
box -  antigens present only in crest cells and Schwann cell precursors; Purple box -  
antigens present only in Schwann cell precursors; Grey box -  antigens present in 
Schwann cell precursors and Schwann cells; Brown box -  antigens present only in 
Schwann cells. Adapted from Mirsky et al., (2008).
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1.1.2 Regulation of the Schwann cell precursor to Schwann cell transition
As mentioned above, immature Schwann cells will have been generated from 
Schwann cell precursors by E 17/18 in the rat and E15/16 in the mouse PNS. This 
transition is marked by many changes, particularly in antigenic profile, proliferative 
and survival responses and motility (Fig. 1.1) (Jessen et al., 1994; Dong et al., 1995; 
Meier et al., 1999; Jessen and Mirsky, 2005). Moreover, many aspects of this cellular 
transition can be faithfully recapitulated in vitro using Schwann cell precursors from 
E14 rats or E12 mice cultured in medium containing NRG-1 (Jessen et al., 1994; 
Dong et al., 1995, 1999). The fact that these experiments use NRG-1 demonstrates 
that NRG-1 is sufficient for both precursor survival and maturation in vitro (Dong et 
al., 1995, 1999). Additionally, fibroblast growth factor 2 (FGF2) can accelerate 
precursor maturation in the presence of NRG-1 (Dong et al., 1995). Furthermore, 
endothelin acting through endothelin B receptors and overexpression of the 
transcription factor AP-2cx appears to antagonize NRG-1 induced precursor 
differentiation (Brennan et al., 2000; Stewart et al., 2001). Interestingly, in growth 
factor deficient medium, expression of the anti-apoptotic gene, bcl-2, in Schwann cell 
precursors, in order to promote survival, is sufficient to allow the generation of 
immature Schwann cells after 4 days in culture (V.Sahni, unpublished observations). 
This suggests that there may be cell intrinsic mechanisms for Schwann cell precursor 
maturation.
In vivo, loss of endothelin B receptors in the spotting lethal rat leads to 
generation of Schwann cells ahead of schedule, confirming a role for endothelin in 
antagonizing Schwann cell precursor maturation (Brennan et al., 2000). Additionally, 
mutation of components of the Notch pathway demonstrates its requirement for the
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correct timing of Schwann cell generation from precursors (A. Woodhoo, unpublished 
observations).
1.1.3 The immature Schwann cell
The generation of immature Schwann cells at E l7/18 in the rat and E l5/16 in 
the mouse PNS correlates with changes in the cytoarchitecture of the nerve including 
the development of fibroblasts, connective tissue and blood vessels within the 
endoneurium and the development of a well-defined perineurial sheath surrounding 
the nerve (Jessen and Mirsky, 2005). At this time point Schwann cells are associated 
with discrete compact bundles of axons similar to ‘axon-Schwann cell families’ 
observed in newborn rat nerves. These axon-Schwann cell units also demonstrate a 
noticeable basal lamina with associated collagen fibrils (Webster and Favilla, 1984; 
Jessen and Mirsky, 2005). Additionally, at this stage there is control over overall 
numbers of Schwann cells, through proliferation and survival mechanisms, 
presumably to match the numbers of Schwann cells with the numbers of axons before 
myelination (Webster, 1973; Jessen and Mirsky, 2005).
1.1.3.1 Mechanisms of Schwann cell proliferation.
Cell proliferation is a characteristic of both the Schwann cell precursor and the 
immature Schwann cell. However, the peak of proliferation, measured by BrdU 
incorporation, occurs at the immature Schwann cell stage, E l 8/E 19 in the rat and E l 5 
in the mouse sciatic nerve (Stewart et al., 1993; Yu et al., 2005). As Schwann cells 
begin to myelinate they drop out of the cell cycle (Webster et al., 1973; Stewart et al., 
1993), hence proliferation rates in the sciatic nerve fall sharply after birth, although
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cells destined to become non-myelinating Schwann cells continue to proliferate into 
the second postnatal week (Asbury, 1967; Stewart et al., 1993).
Direct contact with axons, in vitro, or treatment of Schwann cells with axon- 
enriched fractions can induce Schwann cell proliferation (Salzer et al., 1980a, 1980b). 
The mitogen that mediates the majority of this proliferation in vitro was identified as 
NRG1 (Morrissey et al., 1995), yet, crucially, definitive evidence from in vivo studies 
demonstrating that NRG1 is a Schwann cell mitogen is still lacking. In zebrafish, 
mutation of erbB3 or pharmacologically blocking NRGl/erbB signalling reduced both 
Schwann cell precursor and immature Schwann cell proliferation (Lyons et al., 2005). 
However, conditional mutation of the mouse erbB2 receptor in Schwann cells actually 
lead to an increase in postnatal Schwann cell proliferation, most probably due to the 
delay in myelination seen in these mice (see section 1.5.2.1), although embryonic 
proliferation levels were not assessed (Garratt et al., 2000).
Another mitogen that has been shown to play a role in Schwann cell 
proliferation is Transforming growth factor |3 (TGF|3). Addition of TGFp to cultured 
Schwann cells can augment NRG1 induced proliferation and conditional mutation of 
TGF-(3 receptor type II in mouse Schwann cells reduces proliferation rates at E l 8 in 
the sciatic nerve (D’Antonio et al., 2006b). Additionally, laminin (a component of the 
basal lamina, see section 1.5.1) also appears to regulate developmental Schwann cell 
proliferation. Mice lacking the laminin yi chain specifically in Schwann cells or mice 
lacking both laminin cm and 014 chains show substantially reduced levels of immature 
Schwann cell proliferation embryonically and during the postnatal period (Yu et al., 
2005; Yang et al., 2005). Interestingly proliferation at E13, the Schwann cell 
precursor stage, was normal in laminin yi mutant embryos demonstrating that laminin 
does not affect precursor proliferation (Yu et al., 2005; Jessen and Mirsky, 2005).
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The intracellular signalling mechanisms involved in regulating developmental 
Schwann cell proliferation are only beginning to be identified. Recently, two studies 
identified a requirement for focal adhesion kinase (FAK) and a member of the 
RhoGTPase family, cdc42, in vivo, in embryonic and perinatal Schwann cell division 
(Grove et al., 2007; Benninger et al., 2007). Furthermore, another study showed that 
cyclin dependent kinase 4 (cdk4) was required for postnatal but not embryonic 
Schwann cell proliferation at E l8 demonstrating that there may be subtle mechanistic 
differences in the two types of proliferation (Atanasoski et al., 2008).
1.1.3.2 Mechanisms of Schwann cell survival and death
During PNS development there appears to be significant levels of apoptotic 
Schwann cell death at late time points during embryogenesis and also perinataly 
(Syroid et al., 1996; Grinspan et al., 1996; D’Antonio et al., 2006b). Whereas 
Schwann cell precursors cannot survive in the absence of axons or NRGl (see section 
1.1.1), the majority of immature Schwann cells survive after loss of axonal contact by 
either culturing or nerve transection (Grinspan et al., 1996). NRGl, however, can still 
act as a survival signal for immature Schwann cells because exogenous NRGl 
application can reduce the percentage of apoptotic Schwann cells in uninjured and 
transected neonatal nerves and at denervated neuromuscular junctions (Grinspan et 
al., 1996; Trachtenberg and Thompson, 1996). Laminin also acts as a survival signal 
for immature Schwann cells, since there is a considerable increase in apoptotic 
Schwann cell death, marked by TUNEL labelling, in laminin y} mutant mice (Yu et 
al., 2005). Identification of autocrine survival circuits that contribute to survival of 
immature Schwann cells but not precursors in culture is likely to be an important 
mechanism of how immature Schwann cells survive in the absence of axons (Meier
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et al., 1999). Schwann cell survival is also likely to depend upon the activity of the 
Ets and Stat, particularly Stat3, family of transcription factors (Parkinson et al., 2002; 
C. Davis, unpublished observations).
In addition to survival signals, signals that initiate Schwann cell death have also 
been identified. TGF|3 can induce death in neonatal Schwann cells in culture and 
conditional mutation of the TGF-(3 receptor type II reduces Schwann cell death rates 
at E l8 in the developing nerve and after neonatal nerve transection (Parkinson et al., 
2001; D ’Antonio et al., 2006b). Nerve growth factor (NGF) acting through the p75NIR 
receptor has also been shown to induce Schwann cell death in culture (Soilu- 
Hanninen et al., 1999). However, p75NTR does not play a role in developmental 
Schwann cell death as levels of apoptosis in control and p75NTR null mice were 
equivalent (Syroid et al., 2000). p75NrR may play a role in Schwann cell death after 
nerve injury, though, since there was a significant reduction in the number of 
apoptotic cells after nerve transection in both neonatal and adult p75N1R null mice 
compared to controls (Ferri and Bisby, 1999; Syroid et al., 2000).
1.2 Postnatal Schwann cell differentiation
1.2.1 Myelination
In the newborn rodent sciatic nerve axons are present in axon ‘Schwann cell 
families’, which, as mentioned previously are axon bundles surrounded by Schwann 
cells and a continuous basal lamina (Webster and Favilla, 1984; Jessen and Mirsky, 
2005). Axons to be myelinated (> lpm  in diameter) appear at the edge of these axon 
bundles and are enveloped by a radial Schwann cell process, eventually associating in 
a 1:1 relationship with the Schwann cell and its basal lamina. This process has been 
termed radial sorting (Webster, 1971; Webster et al., 1973; Webster and Favilla,
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1984). However the precise mechanism behind how only axons above lpM  are 
selected and myelinated is still largely unknown. Schwann cells destined to myelinate 
can be identified by expression of galactocerebroside (gal-C) from E l9, in the rat 
sciatic nerve (Jessen et al., 1985). Although gal-C is eventually expressed by non­
myelinating Schwann cells (see section 1.2.2) antibodies to gal-C can block 
myelination in Schwann cell/DRG cocultures at the 1:1 stage, before myelin is formed 
(Ranscht et al., 1987; Owens et al., 1990). Myelin sheath formation is then believed to 
occur through the inner Schwann cell mesaxon or process spiralling around the axon 
to generate successive myelin wraps (Webster, 1971; Bunge et al., 1989). The process 
of myelination is strongly correlated with the cessation of cell division. Although it 
has been shown that Schwann cells do not proliferate once compact myelin formation 
begins, it is likely that Schwann cells cease proliferation at the 1:1 stage since 
proliferating Schwann cells are seldom seen in 1:1 association with axons (Martin and 
Webster, 1973; Webster et al., 1973; Stewart et al., 1993).
The formation of myelinating Schwann cells is accompanied by an extensive 
change in gene expression. Genes required for the formation of the myelin sheath, 
such as Krox-20, Protein zero (Po) and many genes associated with lipid and 
cholesterol biosynthesis are upregulated whereas expression of molecules that 
characterise the immature Schwann cell, like LI, p75NTR and NCAM are 
downregulated (Fig. 1.2)(Nagarajan et al., 2002; Verheijen et al., 2003; Jessen and 
Mirsky, 2005).
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Figure 1.2: Antigenic profile of immature, myelinating and non-myelinating 
Schwann cells.
White box -  antigens present in immature Schwann cells and mature myelinating and 
non-myelinating Schwann cells; Blue box -  antigens expressed by mature non­
myelinating Schwann cells; Orange box -  antigens present in immature and non­
myelinating Schwann cells but downregulated in myelinating Schwann cells; Green 
box -  antigens expressed only in mature myelinating Schwann cells. Notice that gal-C 
is expressed by both mature myelinating and non-myelinating Schwann cells. 
Adapted from Mirsky et al., (2008).
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1.2.2 Non-myelinating Schwann cell differentiation
In contrast to myelinating Schwann cells, non-myelinating Schwann cells 
maintain expression of most immature Schwann cell genes, however they do 
downregulate basal expression of the Po gene, which is seen in precursors and 
immature Schwann cells (Fig. 1 2)(Lee et al., 1997; Jessen and Mirsky, 2005). Non­
myelinating Schwann cells also upregulate expression of galactocerebroside (gal-C) 3 
weeks after birth, shortly before they form mature Remak fibres characterised by 
small calibre axons lying in troughs in the Schwann cell cytoplasm (Diner et al., 1965; 
Jessen et al., 1985). One marker that appears to be exclusively expressed by non­
myelinating Schwann cells in normal adult nerves is ai|3i integrin (Stewart et al., 
1997).
1.3 The general structure of a myelinated fibre.
Myelination of axons is likely to have evolved to allow the advantage of 
rapidity of action potential signalling while minimizing the size of the axon (Colman 
et al., 2001). Myelinated axons are completely insulated by myelin sheaths apart from 
at Nodes of Ranvier, gaps of less than 1pm, where axons are exposed to the 
extracellular environment. These nodes are rich in voltage gated sodium channels and 
in combination with the reduced capacitance or increased resistance provided by the 
internodal myelin sheath, facilitate salutatory conduction of action potentials between 
nodes of Ranvier (Arroyo and Scherer, 2000; Sherman and Brophy, 2005).
Each Schwann cell internode is divided into two distinct domains, compact 
myelin and non-compact myelin, usually with the nucleus in the centre of the 
internode. Compact myelin accounts for the majority of the internode, appearing as a 
lamellar structure of alternating dark and light lines with a periodicity of about 13 -
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19 nm using electron microscopy (Kirschner and Sidman, 1976; Kirschner and 
Hollingshead, 1980). The dark major dense lines (MDL) are 2.5 nm thick and are 
separated from each other by the light interperiod lines (IPL). The MDL consists of 
two intracellular lipid bilayers fused together whereas the IPL represents the fusion of 
the two opposed extracellular surfaces of the Schwann cell plasma membrane. 
Compact myelin is highly specialised containing many proteins and lipids required for 
its maintenance (see section 1.4).
Non-compact myelin consists of the Schmidt Lantermann incisures (SLI), 
internodal cytoplasmic channels that connect the abaxonal membrane (which is in 
contact with the basal lamina) with the adaxonal membrane (which is contact with the 
axon), and the paranodal loops (Fig. 1.3, A and B). The paranodal loops are situated 
adjacent to the node of Ranvier, where the MDL opens up to accommodate 
cytoplasm. These loops or glial end feet are attached by septate like junctions to the 
axonal membrane. Heterodimers of contactin and Caspr (contactin associated protein) 
expressed on the axonal membrane are likely to bind Neurofascin 155, expressed on 
the glial end feet to form these junctions (Sherman and Brophy, 2005). These 
junctions have been suggested to anchor the myelin membrane to the axon and also 
provide a diffusion barrier into the periaxonal space (Arroyo and Scherer, 2000). 
Beyond the paranodal loops, Schwann cell microvilli project from the abaxonal 
membrane to contact the axolemma (Fig. 1.3, B). Next to the paranodal loops is the 
juxtaparanodal region (Fig. 1.3, B), which is anchored by homophilic interaction of the 
cell adhesion molecule TAG-1, expressed on both the glial and axonal membrane. In 
addition TAG-1 binds in cis to Caspr-2 on the axonal juxtaparanodal membrane 
(Traka et al., 2002, 2003). The axonal membrane in this region contains K+ channels, 
which are mainly thought to dampen excitability of myelinated fibres preventing
28
ectopic impulses. In addition the juxtaparanodal Schwann cell membrane also 
contains K+ channels, which have been suggested to act to remove accumulations of 
periaxonal potassium ions (Arroyo and Scherer, 2000).
1.4 The molecular composition of PNS myelin.
Myelin membrane is composed of about 70-80% lipids and 20-30% proteins. 
Cholesterol accounts for about 20-30% of the total lipids in PNS myelin. Other 
significant lipid constituents of PNS myelin are the galactolipids, gal-C and 
galactosulfatide (Sgal-C) accounting for 15-20% and phospholipids account for 
between 50-60% of total myelin lipids (Garbay et al., 2 0 0 0 ). The major protein 
constituents of PNS compact myelin are Po (50-70% of total PNS myelin protein), 
myelin basic protein (MBP, 5-15% of total PNS myelin protein) and peripheral 
myelin protein 22 (PMP22, 2-5% of total PNS myelin protein)(Garbay et al., 2000). 
Po is a 28kDa integral membrane glycoprotein with an Ig-like extracellular domain 
that acts as the major adhesion molecule of the IPL and potentially contributes to the 
formation of the MDL too, since Schwann cells in mice lacking Po form membrane 
spirals around axons but the majority of myelin does not compact (Giese et al., 1992; 
Martini et al., 1995a). Individual Po molecules were shown to be likely to form 
tetramers in cis and then these tetramers bind each other in trans, demonstrating how 
P0 contributes to cell membrane adhesion (Shapiro et al., 1996). Interestingly, P 0 null 
mice also lack SLIs. Furthermore, replacing Proteolipid protein (PLP/DM20) with P0 
in central nervous system (CNS) myelin, which normally lacks SLIs, is sufficient to 
induce SLI formation. This data suggests that Po is important in instructing SLI 
formation, though the mechanism is unknown (Yin et al., 2008). MBP is a 
cytoplasmic protein that is also involved in myelin compaction and the formation of
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the MDL (Martini et al., 1995b; Nave, 2001). Four main isoforms are expressed in the 
PNS, with apparent sizes of 21.5, 18.5, 17 and 14kDa. The naturally occurring mouse 
mutant shiverer, which lacks expression of all MBP isoforms (Roach et al., 1983; 
Molineaux et al., 1986), does not show any major abnormalities in PNS myelin 
compaction though homozygous shiverer mutant nerves do contain twice the number 
of SLIs compared to wild-type nerves (Rosenbluth, 1980; Gould et al., 1995). 
However, mice lacking both Po and MBP are unable to form any compact myelin 
demonstrating the requirement for both of these proteins in myelin sheath compaction 
(Martini et al., 1995b). PMP22 is an intrinsic membrane 22kDa glycoprotein that is 
crucial for correct peripheral nerve myelination (Adlkofer et al., 1995). Furthermore 
numerous mutations in the human PMP22 gene have been shown to be responsible 
for a variety of different inherited peripheral neuropathies (Suter and Scherer, 2003; 
see section 1.7.1). Despite this relatively little is known about how PMP22 contributes 
to myelin formation with roles suggested in cell adhesion, proliferation and basal 
lamina integrity (Zoidl et al., 1995; Nave, 2001; Amici et al., 2006). Other proteins 
that are found in PNS compact myelin are P2 (1-10% of total PNS myelin protein), 
PLP/DM20 (<0.5% of total PNS myelin protein) and myelin and lymphocyte protein 
(MAL/MVP17) (Garbay et al., 2000; Nave, 2001).
The main protein constituents of non-compact myelin are myelin associated 
glycoprotein (MAG), connexin 32 (Cx32), periaxin, E-cadherin and nectin-like (Neel) 
proteins (Garbay et al., 2000; Maurel et al., 2007; Spiegel et al., 2007). MAG is a 
lOOkDa glycoprotein with two isoforms and bears substantial homology to other cell 
adhesion molecules such as LI and neural cell adhesion molecule (NCAM). MAG is 
found mainly in the periaxonal Schwann cell membrane but also in the paranodal 
loops, the external and internal mesaxons and the SLIs. MAG deficient mice show
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minimal myelin abnormalities but do demonstrate an axonal phenotype consisting of 
reduced axonal calibres, neurofilament phosphorylation and spacing (Montag et al., 
1994; Li et al., 1994; Yin et al., 1998). This may identify a role for MAG in glial axon 
signalling. Cx32 is a gap junction protein and is located in Schwann cell paranodal 
loops and SLIs, probably forming gap junctions between adjacent myelin lamellae 
(Scherer et al., 1995a). Periaxin is a 170kDa glycoprotein that is localised at the 
adaxonal membrane in the mature myelin sheath (Gillespie et al., 1994; Scherer et al., 
1995b; Dytrych et al., 1998). It is attached to the dystroglycan complex through 
dystrophin related protein-2 (DRP-2) and thus is able to link laminin-2 in the basal 
lamina to the actin cytoskeleton (Sherman et al., 2001). Normally this complex is 
located at appositions between the abaxonal surface of the Schwann cell and the 
myelin sheath, leading to the formation of cytoplasmic channels between these 
appositions, called ‘Cajal bands’. Periaxin is required for the formation of these Cajal 
bands and also appears necessary for internodal elongation, as the nerve is stretched 
postnataly by limb growth (Court et al., 2004). E-cadherin, a Ca2+-dependent adhesion 
molecule is located in the inner and outer mesaxon, SLIs and paranodal loops (Fannon 
et al., 1995). E-cadherin forms adherens junctions in non-compact myelin by binding 
homophilically to itself in trans on the apposing membrane thus stabilizing the myelin 
sheath (Shapiro et al., 1995; Arroyo and Scherer, 2000; Garbay et al., 2000). Neel 
proteins, through heterophilic interactions with other Neel family members, have 
recently been identified to play a role in axon-glia interactions during myelination. 
Necl4 is expressed by myelinating Schwann cells along the length of the internode in 
apposition to N ecll, which is expressed on the internodal surface of the axon. Necll 
and 4 have been shown to interact and inhibition of Necl4 expression in Schwann
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cells can block myelination in Schwann cell/DRG cocultures (Maurel et al., 2007; 
Spiegel et al., 2007).
In addition, Schwann cell microvilli present over the node of Ranvier also 
demonstrate molecular specialisations. Gliomedin, which is a type II transmembrane 
protein is cleaved from the surface of the Schwann cell microvilli and incorporated as 
a multimer into the extra-cellular matrix (ECM). There it mediates interactions 
between the Schwann cell microvilli and the axonally expressed cell adhesion 
molecules (CAMs), Neurofascin 186 and NrCAM (Eshed et al., 2005, 2007). 
Gliomedin is required for proper node formation in vitro (Eshed et al., 2005). 
Addtionally, dystroglycan and laminin, both components of the basal lamina (see 
section 1.5.1) are required for proper microvilli organisation and Sodium channel 
clustering at the node, in vivo (Saito et al., 2003; Occhi et al., 2005). Furthermore, 
ERM proteins (ezrin-radixin-meosin) are expressed at the microvilli, colocalise with 
actin filaments and are thought to be important in the formation of the microvilli 
(Melandez-Vasquez et al., 2001; Scherer et al., 2001; Gatto et al., 2003).
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Figure 1.3: Representation of a Schwann cell internode and node.
(A) A myelinating Schwann cell unravelled demonstrating the various cellular 
domains that constitute the compact myelin, and non-compact myelin. Blue -  area on 
axon occupied by node of Ranvier; Red -  area on axon occupied by the paranodal 
loops; Green -  area on axon occupied by the juxtaparanodal region; yellow -  refers to 
gap junctions in SLIs and paranodal loops; purple -  adherens junctions in paranodal 
myelin. (B) A representation of the node of Ranvier, paranode and juxtaparanode. 
Adapted from Arroyo and Scherer, (2000).
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1.5 The regulation of myelination.
Over the last fifteen years major advances have been made in identifying signals 
that regulate Schwann cell myelination. Recent evidence has demonstrated that 
signals from the basal lamina, which include laminins binding to their receptors, the 
integrins, are crucial in regulating radial sorting whereas NRG1 type III expressed on 
the axonal membrane regulates myelin membrane wrapping (Feltri and Wrabetz, 
2005; Nave and Salzer, 2006). Furthermore, a number of transcription factors have 
been identified that control Schwann cell gene expression during myelination, such as 
Krox-20, Oct- 6  (Pou3fl), Sox 10 and NFkB (Jessen and Mirsky, 2005). In addition to 
signals that positively regulate myelination there also appears to be molecules that can 
negatively regulate myelin differentiation too (Jessen and Mirsky, 2005; see Chapter 
4).
1.5.1 Laminins, integrins, Rho GTPases and downstream pathways.
The basal lamina forms a continuous tube around the internodes of a myelinated 
axon (Feltri and Wrabetz, 2005). Schwann cell/DRG co-culture experiments 
demonstrated that the formation but not the maintenance of the basal lamina by 
Schwann cells was reliant on axonal contact (Bunge et al., 1982; Clark and Bunge, 
1989). Whereas, basal lamina formation appears not to be a prerequisite for myelin 
formation either in vitro (Podratz et al., 1998, 2001) or in vivo (Madrid et al., 1975; 
Nakagawa et al., 2001), laminin, a major constituent of the basal lamina, is required 
for myelination (Yu et al., 2005; Yang et al., 2005). Laminins are a family of 
extracellular matrix proteins that exist as trimers made up of an a - ,  (3-, and y-subunit, 
with each subunit encoded by a different gene. There are five a-subunits, four 13- 
subunits and three y-subunits (Feltri and Wrabetz, 2005). In the PNS, both laminin 2
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(composed of the subunits (X2 P1Y1) and laminin 8  (composed of the subunits oMpiyi) 
are expressed in the endoneurial basal lamina during development, in the adult nerve 
and also after injury (Wallquist et al., 2002). In addition, laminin 015 (potentially 
forming laminin 10) is present at the nodes of Ranvier and laminin y3 (potentially 
forming laminin 12) mRNA is upregulated in Schwann cells after nerve injury 
(Wallquist et al., 2002; Feltri and Wrabetz, 2005).
The role of laminins 2 and 8  during Schwann cell development has been 
discerned through studying mice with spontaneous mutations or genetic inactivation 
of various laminin subunits. Dystrophic mice that are homozygous for the Lama2dy 
allele do not produce the 012-subunit and hence laminin- 2  (merosin)(Feltri and 
Wrabetz, 2005). These mice develop a peripheral neuropathy characterized by the 
presence of unsorted bundles of naked axons, which are more commonly observed in 
the proximal compared to the distal PNS, particularly in the ventral roots (Bradley and 
Jenkison, 1973; Stirling, 1975). They also demonstrate other myelin abnormalities 
such as shorter internodes and widened Nodes of Ranvier (Bradley et al., 1977; Jaros 
and Jenkison, 1983). In addition, mice with targeted inactivation of the Lama2 gene 
(that produces the a 2 -subunit) have thinner myelin sheaths, predominantly in the 
nerve roots, but show fewer amyelinated or unsorted axons compared to the 
dystrophic mouse mutant (Nakagawa et al., 2 0 0 1 ). This may be due to differential 
expression of the 015-subunit in the ventral roots of dystrophic and Lama2 null mice 
(Nakagawa et al., 2001). Mice lacking expression of laminin 8  due to targeted 
inactivation of the Lama4 gene showed similar myelin abnormalities in the tibial 
nerve, such as unsorted axons, to a mouse strain which lacks functional laminin 2  
(dy2J) (Wallquist et al., 2005; Yang et al., 2005). However, whereas mice without 
laminin 2 show a more severe phenotype in the spinal roots Lama4 null mice
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demonstrated a very mild phenotype. This is potentially explained by a greater 
requirement for laminin2 than laminin8 in axonal sorting and myelination of the 
ventral root (Yang et al., 2005). Importantly, mice lacking expression of both 
laminin2 and 8, produced by generating Lama2, Lama4 double knockout mice, or 
mice with Schwann cell specific ablation of the laminin-yi subunit demonstrated 
markedly reduced axonal sorting and myelination in the nerves and their roots (Chen 
and Strickland, 2003; Yu et al., 2005; Yang et al., 2005).
Inactivation of laminin receptors also leads to axonal sorting and myelination 
defects (Feltri and Wrabetz, 2005). There are two types of laminin receptor expressed 
on Schwann cells, integrins and dystroglycan (DG). Integrins are dimers consisting of 
an a -  and p-transmembrane subunits whereas DG consists of an extracellular 
a-subunit and a p-transmembrane subunit (Feltri and Wrabetz, 2005). Schwann cell 
precursors and immature Schwann cells express c^Pi-, (X2 P1- and 0 1 3pi -integrins 
(Hsiao et al., 1991; Milner et al., 1997; Previtali et a l., 2003a) whereas cx6 P4 -integrin 
and DG appear during the pro-myelin stage (when Schwann cells associate in 1:1 
ratio with axons) at birth (Previtali et al., 2003a), and avPi-integrin is expressed later 
by mature myelinating Schwann cells (Previtali et al., 2003c). As mentioned 
previously, mature non-myelinating Schwann cells express the dual collagen/1 aminin 
receptor, aipi-integrin (Stewart et al., 1997). Conditional inactivation of pi-integrin 
in Schwann cells leads to the majority of Schwann cells being unable to sort and 
hence myelinate axons (Feltri et al., 2002). Similarly, function blocking antibodies to 
Pi-integrin block myelination in Schwann cell/DRG cocultures (Fernandez-Valle et 
al., 1994). Schwann cells without DG or P4 -integrin hardly show any sorting defects 
but do demonstrate abnormally folded myelin sheaths, which is more severe in DG 
conditionally-null mice and characterised by a late onset neuropathy (Saito et al.,
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2003; Nodari et al., 2008). In contrast, mice lacking a 7 -integrin in Schwann cells do 
not appear to have any deficit in axonal sorting or myelination (Previtali et a l., 
2003c).
ECM/Integrin signalling can cooperate with growth factor signalling in many 
cell types to regulate, in particular, proliferation, motility and survival (ffrench- 
Constant and Colognato, 2004; Guo and Giancotti, 2004). The majority of integrins 
activate FAX and thus the Src family kinases, leading to activation of downstream 
effectors such as Rho GTPases and MAPK pathways, which in turn regulate the actin 
cytoskeleton (Guo and Giancotti, 2004).
The mechanism, by which laminin-Pi-integrin signalling, in Schwann cells, acts 
to regulate axon sorting is only beginning to be elucidated. One study demonstrated 
that the failure of Schwann cells without pi-integrin to extend radial lamellipodia 
might be linked to the failure of these Schwann cells to sort axons in vivo (Feltri et al ., 
2002; Nodari et al., 2007). In the absence of Pi-integrin, activation of the small 
GTPases, Racl and Rho A but not cdc42, is reduced (Nodari et al., 2007). Conditional 
inactivation o f Racl in Schwann cells produced a similar defect to f$i-integrin null 
mice in axonal sorting and myelination (Nodari et al., 2007; Benninger et al., 2007). 
Furthermore, adenovirally expressed Racl injected into the sciatic nerve of /?;- 
integrin null mice partially rescued the phenotype of pi-integrin null Schwann cells 
(Nodari et al., 2007). Ablation of both FAX and cdc42 in Schwann cells also produces 
significant axonal sorting defects although this may be in part due to the reduced 
Schwann cell proliferation seen in these mutants (Grove et al., 2007; Benninger et al., 
2007; see section 1.1.3.1). Finally, in vitro studies from Schwann cell/DRG cocultures 
have also identified a potential role for the p38 mitogen activated protein kinase 
(p38MAPX) and phosphatidyl-inositol-3 kinase (PI3-X) pathways and the actin
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cytoskeleton in Schwann cell axon ensheathment and myelination (Fernandez-Valle et 
al., 1997; Maurel and Salzer, 2000; Fragoso et al., 2003; Haines et al., 2008).
1.5.2 An overview of NRG1 signalling
Neuregulins are members of a family of proteins containing an epidermal 
growth factor (EGF)-like domain that bind to and activate membrane-associated 
receptor tyrosine kinases, which are related to the EGF receptor. Four NRG genes 
have so far been identified in vertebrates (NRG1-4) although so far, only NRG1 has 
been shown to be important in PNS development (Buonanno and Fischbach, 2001).
The NRG1 gene is about 1.4 megabases long, with only 0.3% of it encoding 
proteins. At least 15 different NRG1 isoforms can be generated due to alternative 
splicing and multiple promoters. Common to all the isoforms is the EGF-like domain, 
which is sufficient for activation of the receptors. The differential structural 
characterisitics of the NRG1 isoforms that are known to be important for in vivo 
function include the type of EGF-domain (a  or p) and the N-terminal sequence (type 
I, II, or III) and whether the protein is synthesised as a transmembrane or non­
membrane protein (Fig. 1.4) (Falls, 2003). Mice lacking all NRG1 isoforms with an a -  
type EGF-like domain do not show any abnormalities in PNS development and 
demonstrate normal survival and lifespan (Li et al ., 2002). In addition, only loss of the 
NRG1 type III isoform but not type I or II isoforms demonstrates PNS defects (Meyer 
et al., 1997; Wolpowitz et al., 2000). Thus, it appears that the (3-NRG1 type III 
isoform is the most important NRG isoform in PNS development (see section 1.1.1), 
however this does not preclude roles for NRG1 type I and type II in the postnatal or 
adult PNS.
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NRG1 can bind the ErbB receptors, ErbB3, which does not have a kinase 
domain and ErbB4. Both receptors can, in turn, heterodimerize with ErbB2, which 
cannot directly bind NRG1 but does possess a kinase domain. In Schwann cells 
ErbB2-ErbB3 heterodimers are thought to be the relevant NRG1 receptor since ErbB4 
expression is hardly detectable in the PNS and ErbB2 is unable to homodimerise 
easily (Nave and Salzer, 2006). Binding of NRG1 to ErbB3 induces ErbB2-ErbB3 
heterodimerisation, receptor cross phosphorylation, recruitment of SH3-containing 
adaptor molecules and activation of many different downstream signalling pathways 
including the mitogen-activated protein kinase (MAPK), PI3-K, p38MAPK, 
phospholipase-Cy (PLCy) and Janus kinase pathways (Citri et al., 2003; Nave and 
Salzer, 2006).
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Figure 1.4: Overview of the main neuregulinl isoforms in the PNS.
NRG1 type I and II have a single transmembrane domain in contrast to NRG1 type III 
has two transmembrane domains. Cleavage by metalloproteases (MP) leads to release 
of type I and II from the cellular surface to signal in a paracrine fashion whereas type 
III remains tethered through its cysteine rich domain (CRD) and acts as a juxtacrine 
signal. The cytoplasmic domain can also be cleaved and may signal to the nucleus 
(Falls, 2003). Adapted from Nave and Salzer, (2006).
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1.5.2.1 The role of NRGl/erbB signalling in myelination.
In addition to regulating embryonic Schwann cell development (see section 
1.1.1), NRG1 signalling has recently been demonstrated to modulate PNS myelination 
(Nave and Salzer, 2006). Blocking ErbB2-ErbB3 signalling in mice, specifically in 
Schwann cells either using Cre-loxP technology or by expressing a dominant-negative 
ErbB molecule leads to delayed onset of myelination and thinner myelin sheaths 
(Garratt et al., 2000; Chen et al., 2006). Pharmacologically blocking ErbB signalling 
in zebrafish demonstrated that postmigratory Schwann cells required ErbB signalling 
to commit to a myelinating fate and express Krox-20 and MBP (Lyons et al., 2005). 
In addition, mice that are heterozygous for NRG1 type III, which are viable, have 
thinner myelin sheaths than control animals whereas mice heterozygous for ErbB2 
had normal myelin sheaths (Garratt et al., 2000; Michailov et al., 2004; Taveggia et 
al., 2005). This suggests that the level of NRG1 expressed on the axon rather than the 
level of ErbB receptors on the Schwann cell was rate limiting (Michailov et al ., 2004). 
In support of this, transgenic mice that overexpress NRG1 type III on peripheral 
axons develop thicker myelin sheaths, with a greater number of myelin wraps than 
control mice (Michailov et al., 2004). Importantly, although NRGl-erbB signalling is 
involved in regulating myelin sheath thickness, it is not required for the maintenance 
of myelin sheaths in the adult (Atanasoski et al., 2006).
NRG1 type III also appears to regulate axonal sorting and the enseathment fate 
of axons. In NRG1 type III heterozygotes there are fewer myelinated axons than in 
controls and larger collections of unsorted axons > lpm  in diameter that would 
normally be myelinated (Taveggia et al., 2005). Similarly, axons in DRG cultures 
from NRG1 type III null embryos are not properly segregated, ensheathed or 
myelinated by wild-type Schwann cells in vitro (Taveggia et al., 2005).
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Further experiments suggested that axonal NRG1 type III might be sufficient to 
induce Schwann cell myelination. Firstly, the level of NRG1 type III expressed on 
axons of different types of neuron correlates with axonal calibre and the extent to 
which they are myelinated. Thus, expression of NRG1 type III by lentiviral transfer 
into sympathetic cervical ganglion neurons, which are normally mostly unmyelinated, 
was sufficient to induce a small degree of myelination in vitro (Taveggia et al., 2005). 
Also NRG1 type III overexpressing mice contain a number of axons < lpm  in 
diameter that are myelinated (Michailov et al., 2004; Nave and Salzer, 2006). 
However, these observations are difficult to interpret given the potential role of NRG 1 
in axonal sorting, ensheathment and potentially proliferation (Taveggia et al., 2005; 
section 1.1.3.1). It is possible that a graded level of NRG 1 type III is required for 
initially sorting, then enseathment and subsequently myelination of axons, although 
this remains to be tested. It is also important to note that while NRG1 type III can 
promote Schwann cell myelination in vivo it is insufficient to induce myelin gene 
expression in Schwann cell monocultures suggesting that other signals are likely to be 
involved (Taveggia et al., 2005; see Chapter 3).
Other experiments, using a dominant-negative erbB construct have also 
indicated a role for NRG1 signalling in non-myelinating Schwann cell survival and 
consequently the survival of the C-fibre sensory axons that they ensheath (Chen et al.,
2003).
1.5.3 Other signals that regulate PNS myelination.
Brain-derived neurotrophic factor (BDNF) treatment can enhance myelination 
in Schwann cell/DRG cocultures through binding to the p75NTR receptor. Furthermore 
lack of p75NTR in null animals or injection of a p75NTR function blocking antibody
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lead to reduced myelin sheath wrapping compared to control animals (Cosgaya et al., 
2002). Overexpression of BDNF in vivo generated thicker myelin sheaths over time, 
however axon calibre was also increased but to a lesser extent than myelin sheath 
thickness (Tolwani et al., 2004), arguing for a role for BDNF and p75N1R in regulating 
myelination. The p75NTR receptor has been shown to associate with the cell polarity 
protein, par-3, at the axo-glial interface in Schwann cells. Disruption of this 
asymmetric par-3 localisation was shown to inhibit myelination in Schwann cell/DRG 
cocultures (Chan et al., 2006), although it is unknown whether par-3 plays a role in 
myelination in vivo.
The claw paw  phenotype in mice is due to a spontaneous mutation causing a 
delay in radial sorting, Krox-20 upregulation and myelination and deficits in limb 
posture (Henry et al., 1991; Darbas et al., 2004). The claw paw mutation was recently 
shown to be due to a repetitive element insertion in Lgi4, a member of the leucine- 
rich-glioma-inactivated family of genes. This mutation leads to Lgi4clp being retained 
within the endoplasmic reticulum instead of being glycosylated and secreted. 
Schwann cell/DRG cocultures from claw paw  mice could not be induced to myelinate 
unless Lgi4 protein was added to the culture medium suggesting that the claw paw  
mutation is due to a loss of function of Lgi4 (Bermingham et al., 2006).
Ablation of ADAM22, a member of the ADAM (a disintegrin and 
metalloproteinase domain) family of proteins leads to severe hypomyelination and 
ataxia in the PNS. The authors suggested that the myelination deficits seen in the 
absence of ADAM22 may be due to an impairment in integrin signalling, though this 
remains to be tested (Sagane et al., 2005). Interestingly, ADAM22 has also been 
identified as a transmembrane receptor for Lgil, regulating synaptic transmission in
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the CNS (Fukata et al., 2006), suggesting that ADAM22 and Lgi4 may also 
potentially interact in the PNS.
Additionally, mice lacking the |3-secretase, BACE1 (beta-site amyloid precursor 
protein-cleaving enzyme 1) develop hypomyelination in both the CNS and the PNS 
(Willem et al., 2006; Hu et al., 2008). BACE1 has been shown to cleave NRG1 type 
III, in vitro (Willem et al., 2006), although it remains untested whether NRG1 type III 
is a physiological substrate in vivo and whether its cleavage is a requirement for PNS 
myelination (see Fig. 1.4).
1.5.4 Transcription factors that regulate myelination.
1.5.4.1 Krox-20.
Krox-20 (Egr2) is a member of a family of transcription factors called early 
growth response genes (Egr), which all share a highly conserved DNA binding 
domain consisting of three zinc fingers that recognise GC-rich sequences. In addition 
to Egr2, this family includes Egrl (Krox-24), Egr3 and Egr4 (Vesque and Charnay, 
1992; Crosby et al., 1992). Krox-20 was originally identified as a transcription factor 
that is induced upon serum treatment and GO to G1 cell cycle transition in fibroblasts 
(Chavrier et al., 1988). In Schwann cells, Krox-20 expression is activated at E l 5.5 in 
the mouse sciatic nerve, judged by expression of a lacZ reporter gene and at E l 8  in 
the rat sciatic nerve, shown by immunohistochemistry. These time points broadly 
correspond to the Schwann cell precursor to immature Schwann cell transition in both 
species (see section l.l)(M urphy et al., 1996; Parkinson et al., 2003). Furthermore 
Krox-20 expression is regulated by axonal contact in vitro and in vivo, thus after 
nerve injury Krox-20 expression is lost from myelinating Schwann cells (Murphy et 
al., 1996; Topilko et al., 1997). Control of Krox- 2 0  expression is regulated by the
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immature Schwann cell element (ISE), active in immature Schwann cells from E l 5.5 
and the myelinating Schwann cell element (MSE), which is active in cells preparing 
to myelinate from E l8.5 (Ghislain et al., 2002). Further studies identified that the 
transcription factors Sox 10 and Oct-6/Brn2 can cooperate to activate the MSE 
element, in vitro (Ghislain and Chamay, 2006), suggesting that these factors are likely 
to regulate Krox-20 expression in myelinating Schwann cells in vivo. In support of 
this MSE activity was found to be minimal in Oct-6 null mice demonstrating a 
requirement for Oct- 6  in activation of the Krox-20 MSE (Ghislain et al ., 2002).
In the absence of Krox-20, or in Egr2h0lljO (a hypomorphic Egr2 allele) mice, 
Schwann cells sort axons but arrest at the pro-myelin stage, forming a 1:1 relationship 
but only wrapping 1.5 times around the axon (Topilko et al., 1994; Le et al., 2005a). 
Moreover, Krox-20 null or Egr2ljilho mice do not express high levels of the ‘late 
myelin proteins’, Po or MBP but do express the early myelin associated proteins, 
MAG and periaxin (Topilko et al., 1994; Parkinson et al., 2003; Le et al., 2005a). 
Furthermore constant Krox-20 expression is required for Schwann cells to maintain 
the myelinating state in the adult PNS (Decker et al., 2006).
Adenoviral expression of Krox-20 in both cultured rat and mouse Schwann cell 
was sufficient to induce mRNA and protein expression of a number of myelin related 
genes, including Po, PMP22, MBP, MAG, periaxin and Cx32 (Nagarajan et al., 2001; 
Parkinson et al., 2003). Recently, using ChIP (chromatin immunoprecipitation) 
assays, Krox-20 has been shown to bind to intron elements o f a number of genes 
upregulated during PNS myelination in vivo, including Po, M BP , MAG  and desert 
hedgehog (Dhh)(Le Blanc et al., 2006; Jang et al., 2006). Additionally, Krox-20 was 
shown to directly induce Po expression through binding to an intron element in vitro 
(LeBlanc et al., 2006). Krox-20 has also been shown to induce expression of a
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number of genes involved in lipid and cholesterol metabolism which are also highly 
expressed during myelination (Nagarajan et al., 2001; Nagarajan et al., 2002; 
Verheijen et al., 2003). In fact Krox-20 can act synergistically with the sterol 
regulatory element binding proteins 1 and 2 (SREBP1 and 2), which are also 
upregulated during myelination, to induce expression of cholesterol/lipid biosynthetic 
genes, such as 3-hydroxyl-3-methylglutaryl coenzyme A reductase 
(HMGCR)(Nagarajan et al., 2002; Verheijen et al., 2003; LeBlanc et al., 2005).
In addition to regulating genes important for myelin sheath formation, Krox-20 
also demonstrates several other important functions in Schwann cells. Firstly, Krox- 
2 0  expression is sufficient to downregulate expression of many non-myelin genes or 
immature genes, such as L I, c-Jun and Sox-2 (Parkinson et al., 2003, 2004, 2008). 
Expression of these genes is normally downregulated in Schwann cells that begin to 
myelinate at birth, but in postnatal Krox-20 null or Egr2holho nerves they remain 
expressed at high levels (Parkinson et al., 2003, 2004; Le et al., 2005a). Another role 
for Krox-20 appears to be in arresting proliferation and promoting myelinating 
Schwann cell survival (Zorick et al., 1999; Parkinson et al., 2004). In Krox-20 null or 
Egr2holho mice postnatal Schwann cell proliferation and death are greatly elevated, 
even at postnatal day 1 2  (P 1 2 ), when levels of proliferation and death are minimal in 
control nerves (Zorick et al., 1999; Le et al., 2005a). Furthermore, adenoviral Krox-20 
expression is sufficient to inhibit NRG1 induced Schwann cell proliferation and 
protect Schwann cells against cell death induced by TGF|3 addition or serum 
withdrawal (Parkinson et al., 2004).
A number of co-factors have been identified that modulate the activity of Krox- 
20, these include, Nabl and 2 (NGFI-A binding 1 and 2), Ddx20 and HCF-1. Whereas 
Nab 1/2 and Ddx20 are thought to act as corepressors of Krox-20 targets, HCF-1 is
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thought to act as a co-activator (Russo et al., 1995; Svaren et al., 1996; Luciano and 
Wilson, 2003; Gillian and Svaren, 2004). Generation of Nab 1/2 double knockout mice 
demonstrated a similar PNS phenotype, though not as severe, to Krox-20 null or 
Egr2Loll'° mice, with hypomyelination and reduced expression of myelin genes, 
increased postnatal Schwann cell proliferation and arrest at the promyelinating stage 
(Le et al., 2005b). Further evidence to underline the importance of Krox-20/Nabl/2 
interaction in PNS myelination comes from the fact that expression of a mutant form 
of Krox-20 (I268F), that prevents binding of Nabs to Krox-20, in both mice and 
humans leads to congenital hypomyelinating neuropathy, characterised by severe 
hypomyelination (Warner et al., 1998; Desmazieres et al., 2008). Interestingly, in the 
absence of the Krox-20/Nabl/2 interaction there appears to be not only reduction in 
expression of myelin associated genes, like Po and M BP  but also aberrant increased 
expression of other genes, such as parathyroid hormone like peptide (pthrp) and Id-2 
(inhibitor of DNA binding 2) (Le et al., 2005b; Desmazieres et al., 2008). Recently, 
studies have demonstrated the mechanism by which Nabs may mediate repression of 
certain target genes in Schwann cells during myelination. Interaction between Nabs 
and the chromodomain helicase DNA binding protein 4 (CHD4) subunit of the 
nucleosome remodelling and deacetylase chromatin remodelling (NuRD) complex is 
required for Nabs to mediate gene repression (Srinivasan et al., 2006). Furthermore, it 
was shown by ChIP analysis that Krox-20, Nabs and the CHD4 subunit of the NuRD 
complex were all recruited to Krox-20 binding sites in the promoters of genes that 
were repressed during myelination, such as Id-2 and Rad  (Mager et al., 2008). Exactly 
how Krox-20/Nabl/2 interactions regulate myelin gene expression, however, has yet 
to be determined.
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1.5.4.2 Oct-6.
The POU domain protein Oct- 6  (SCIP/ Tst-l/Pou3fl) was isolated from a 
cDNA library from a rat sciatic nerve (Monuki et al., 1989). In the rat PNS, Oct- 6  is 
present in Schwann cell precursors and immature Schwann cells (Blanchard et al., 
1996). The peak of Oct- 6  expression occurs shortly after birth, with the majority of 
expression occurring in Schwann cells that are at the pro-myelin or 1:1 stage and 
some expression in myelinating Schwann cells (Blanchard et al., 1996; Arroyo et al., 
1998). Oct- 6  expression is progressively downregulated after this period, being 
expressed in few cells by P30, though it is still detected in some non-myelinating 
Schwann cells (Monuki et al., 1990; Scherer et al., 1994a; Blanchard et al., 1996; 
Arroyo et al., 1998). Oct- 6  expression has been shown to be regulated by the presence 
of axons, in vitro and in vivo (Scherer et al., 1994a; Mandemakers et al., 2000). A 
Schwann cell specific enhancer (SCE) was identified that was sufficient to drive the 
correct spatial and temporal expression of Oct- 6  in the PNS (Mandemakers et al., 
2000). Furthermore, genetic deletion of the SCE in mice was sufficient to replicate the 
phenotype of the Oct-6 null mouse (Ghazvini et al., 2002).
In Oct-6 null mice myelinating Schwann cell differentiation is arrested at the 
promyelin stage with limited expression of myelin genes such as Po and MBP 
although periaxin and MAG expression appeared normal (Jaegle et al., 1996; 
Bermingham et al., 1996). This block in differentiation is only transient, however, 
with myelination proceeding during the second postnatal week and nerves of 
surviving adult Oct-6 null mice indistinguishable from wild-type controls (Jaegle et 
al., 1996). The reason why ablation of Oct- 6  leads only to a delay in myelination was 
partly explained by the fact another POU domain protein, Brn-2, which has a similar 
expression pattern and virtually identical DNA binding characteristics to Oct-6 , was
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transiently upregulated in Oct- 6  null nerves. Additionally, transgenic expression of 
Bm2 in Oct- 6  null mice partially rescued the delay in myelination whereas ablation of 
both Oct- 6  and Brn-2 led to a much more severe phenotype (Jaegle et al., 2003). 
Krox-20 appears to be a direct transcriptional target for Oct-6/Brn2, explaining how 
Oct-6/Brn2 is likely to contribute to myelination (Ghislain and Charnay, 2006; see 
section 1.5.4.1). More recent experiments have shown that constant overexpression of 
Oct- 6  during Schwann cell development and myelination leads to a hypomyelinating 
phenotype and eventual axon loss (Ryu et al., 2007). This potentially demonstrates the 
requirement for the correct level and or the correct temporal downregulation of Oct- 6  
expression in order for myelination to proceed.
1.5.4.3 SoxlO.
In addition to the role of SoxlO in early glial development (see section 1.1.1), 
more recent evidence suggests that SoxlO also plays an active role in the regulation of 
myelination. Firstly, some patients suffering from Waardenburg-Hirschsprung 
disease, due to mutations in SoxlO, develop myelin abnormalities characteristic of 
peripheral neuropathies (Inoue et al., 2002). Furthermore, SoxlO and Krox-20 have 
been shown to cooperate to activate the Cx32 promoter and mutations in the SoxlO 
binding site have been shown to underlie some forms of X-linked Charcot-Marie- 
Tooth neuropathy (CMT)(Bondurand et al., 2001). SoxlO has also been shown to 
regulate expression of the Po promoter and was demonstrated to act synergistically 
with Krox - 2 0  to induce very high expression levels of the P 0 gene through an intron 
element (Peirano et al., 2 0 0 0 ; LeBlanc et al., 2006). Additionally, as mentioned above 
SoxlO acts in tandem with Oct-6/Brn2 to induce expression of Krox-20 through 
activation of the MSE (Ghislain et al., 2002; Ghislain and Charnay, 2006). Recently,
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evidence from studies of mice expressing mutated forms of Sox 10, with deletion of 
specific domains, has demonstrated a direct role for Sox 10 in myelination. Deletion of 
the dimerization domain prevented Schwann cells from entering the pro-myelinating 
stage, judged by Oct- 6  expression, on schedule whereas deletion of the K2 
transactivation domain led to Schwann cells being able to express Oct- 6  but not 
upregulate expression of MBP  and Po mRNA at E l8.5 (Schreiner et al., 2007). Thus 
Sox 10 appears to employ different mechanisms for target gene regulation at different 
points in the Schwann cell lineage.
1.5.4.4 NFkB.
The transcription factor, N F k B  has been shown to be highly expressed in pre­
myelinating Schwann cells but is subsequently downregulated after P12 (Nickols et 
al., 2003; Yoon et al., 2008). Blocking the activated nuclear subunit of N F k B ,  
phosphorylated p65 in Schwann cells, inhibited Schwann cell/DRG coculture 
myelination and prevented activation of Oct- 6  (Nickols et al., 2003). Further work has 
demonstrated that the upstream activator of N F k B  in Schwann cells is likely to be 
protein kinase A (PKA)(see chapter 3)(Yoon et al., 2008).
1.6 Injury and regeneration in the nervous system.
One of the most striking properties of the mammalian PNS is its ability to 
regenerate after injury. This is in sharp contrast to the mammalian CNS, which shows 
limited regeneration. These observations were originally detailed by Ramon y Cajal, 
who went on to show that even though peripheral nerves have the capacity to fully 
regenerate they were unable to grow through CNS tissue, such as an optic nerve graft 
(Cajal, 1928). Over fifty years later Aguayo and colleagues performed the converse
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experiment. They showed that injured CNS axons, which are unable to grow into 
CNS tissue, could grow through a transplanted piece of sciatic nerve from the PNS 
(David and Aguayo, 1981). These results, taken together, show that the proximal 
stumps of severed axons, in both the PNS and the CNS, have the inherent capacity to 
re-grow but that only the PNS and not the CNS environment is conducive to axonal 
regeneration in mammals. This idea is corroborated by evidence from studies which 
lesion either branch of dorsal root ganglion (DRG) neurons, whose cell bodies lie 
outside of the CNS and send projections into the CNS (the gracile and cuneate tracts 
of the spinal cord) and into the PNS. Whereas injuring the CNS branch of DRG 
neurones does not result in axonal regeneration, lesion of the PNS branch of the same 
neurons will result in robust regeneration (Raivich and Makwana, 2007). 
Interestingly, the CNS of non-mammalian animals can regenerate after injury and it 
has been postulated that the loss of CNS regenerative capacity in mammals may be 
due to the increased morphological and cellular complexity of their neuronal circuitry 
(Lamer et al., 1995; Pizzi and Crowe, 2007).
When an axon is severed in either the PNS or the CNS the distal stump of that 
axon begins to degenerate, the surrounding glia react to the injury and an 
inflammatory response is initiated (Stoll et al., 2 0 0 2 ). Seminal observations by 
Augustus Waller of the frog glossopharyngeal and hypoglossal nerves after 
transection demonstrated that, using his words, there was a ‘disorganization’ and 
‘curdling of the medulla of the nerve (axons)’, (Waller, 1850). The term Wallerian 
degeneration refers to the axonal destruction that follows nerve transection. It is 
sometimes also used to describe the broader cellular and biochemical events that 
occur when a nerve is injured.
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1.6.1 Axonal Degeneration.
Axonal degeneration occurs within 24 to 48 hours after nerve insult in the rat or 
the mouse (Lubinska, 1977; Beirowski et al., 2005). Interestingly, the nature of how 
axons degenerate depends upon the type of injury. After peripheral nerve transection, 
axons degenerate anterogradely (Lubinska, 1977; Lunn et al., 1990; Beirowski et al., 
2005) whereas after peripheral nerve crush axons degenerate retrogradely (Lunn et al., 
1990; Beirowski et al., 2005). Furthermore, it appears that large diameter axons 
degenerate faster than small diameter axons (Ranvier, 1878; Lubinska, 1977). Early 
experiments demonstrated that the rate of axonal degeneration could be altered by 
factors such as temperature, axonal transport and calcium influx into the axon 
(Coleman, 2005).
The discovery that axonal degeneration is delayed by 2 to 3 weeks upon 
transection of either PNS or CNS nerves in the C57BL/6/01a (referred to as, 
Wallerian degeneration slow, Wlds) strain of mice (Lunn et al., 1989; Perry et al., 
1991) has underlined the idea that axonal degeneration is an active process rather than 
being a passive atrophy of the severed distal axon. Positional cloning identified the 
Wlds mutation as a 85Kb tandem triplication on mouse chromosome 4 (Lyon et al., 
1993; Coleman et al., 1998). This results in the overexpression of a chimeric protein 
in neurons, which consists of the first 70 amino acids o f the multi-ubiquitination 
factor, Ufd2 (ubiquitin fusion degradation protein 2a), fused to the entire coding 
sequence of D4Colele/Nmnatl (nicotinamide mononucleotide adenylyltransferasel). 
In addition, the cellular retinoid-binding protein, Rbp7 is also overexpressed in Wlds 
mice but appears not to be expressed in the nervous system (Conforti et al., 2 0 0 0 ; 
Mack et al., 2001). Both the Nmnatl and Ube4b (Ufd2) portions of the Wlds protein 
can protect against axonal degeneration to an extent. Yet, when expressed as separate
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s •molecules together they are insufficient to replicate the effect of Wld , suggesting a 
more complex explanation for the action of Wlds (Zhai et al., 2003; Araki et al., 2004; 
Coleman, 2005; Wang et al., 2005; MacDonald et al., 2006; Conforti et al., 2007). A 
complete understanding of the Wlds mechanism of action is likely to provide insight 
into normal axonal degeneration. At present, how Wlds interacts with other known 
mechanisms of axonal degeneration, such as Ca2+ elevation and calpain activation is 
unknown (Coleman, 2005).
1.6.2 The differences between demyelination in the PNS and the CNS.
Whereas axon degeneration happens within the same timescale in the CNS as in 
the PNS, the clearance of myelin debris is usually completed within 7-14 days in the 
mammalian PNS whereas myelin debris remains for months after injury in the 
mammalian CNS (Stoll et al., 1989a, 1989b; Vargas and Barres, 2007). Furthermore, 
in addition to this there are a number of key differences in the nature of the events that 
occur during Wallerian degeneration between the CNS and the PNS. The majority of 
these differences may be attributed to the contrasting responses of the myelinating 
cells of the PNS, the Schwann cell, and the CNS, the oligodendrocyte to injury 
(Vargas and Barres, 2007). Briefly, in the PNS, Schwann cells both participate in the 
removal of myelin debris and proliferate in response to nerve injury. They are joined 
by hematogenous macrophages, which assist in myelin phagocytosis and removal 
(Hirata and Kawabuchi, 2002). These events are accompanied by the break down of 
the blood nerve barrier along the entire length of the nerve, which allows serum 
components to come into contact with nervous tissue. In the CNS, the 
oligodendrocyte is unable to clear myelin and axonal debris and instead of 
proliferating becomes either apoptotic or atrophic (Ludwin, 1990a, 1990b; Barres et
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al., 1993). Additionally, resident CNS microglia only phagocytose small amounts of 
myelin debris and hematogenous macrophage influx is restricted to only the site of 
injury, possibly due to the fact the blood brain barrier only breaks down at the site of 
injury (Vargas and Barres, 2007).
1.6.3 Schwann cell demyelination.
Within minutes of nerve injury there is a retraction of paranodal myelin and a 
dilation of the Schmidt-Lanterman Incisures (SLIs), even at sites distal to the injury 
region (Williams and Hall, 1971). In teased fibre preparations of degenerating rat 
phrenic nerves, myelin sheaths begin to break up into myelin ovoids around 20 hours 
post injury for the thinnest fibres and 32 hours post injury for the thickest fibres. 
Within a given internode, myelin ovoid formation is seen to originate in the 
perinuclear cytoplasm and then move from internode to internode along a 
proximodistal gradient from the injury site (Lubinska, 1977). Electron microscopic 
analysis has demonstrated that myelin fibre fragmentation appeared to begin at sites 
adjacent to the SLIs (Ghabriel and Allt, 1979). It was proposed that the initial dilation 
of the SLIs could be a mechanical response due to the loss of tension in the nerve 
fibre as a result of injury or a biochemical response by the Schwann cell (Young, 
1945; Williams and Hall, 1971). In addition, nodal widening and paranodal 
demyelination are known to occur within minutes at sites adjacent to nerve 
compression injuries, suggesting that mechanical forces may also be involved in their 
formation after nerve transection or crush (Dyck et al., 1990). Dilation of the SLIs 
would allow for apposition and fusion of opposing myelin membranes around a 
collapsing axon thus forming the closed end of a myelin ovoid (Williams and Hall, 
1971; Ghabriel and Allt, 1979). These observations provide convincing evidence that
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the Schwann cell initiates demyelination. Indeed, Stoll and colleagues reminded us 
that Cajal initially described the series of early changes in the Schwann cell and, 
significantly, that these events preceded the appearance of haematogenous phagocytic 
cells (Stoll et al., 1989b; Ramon y Cajal, 1928).
How Schwann cells process myelin after ovoid formation is not well 
understood. Many ideas have been proposed, based on findings from in vitro studies, 
but so far there has been a critical lack of in vivo evidence for many of these 
hypotheses. Experiments inside Millipore chambers by Beuche and Friede, in which 
segments of sciatic nerve were transplanted into the peritoneal cavity, to prevent 
infiltration of blood-born phagocytes, suggested that Schwann cells play no part in 
myelin digestion and instead divide away from or ‘reject’ their myelin sheaths 
(Beuche and Friede, 1984). Degeneration observed in sciatic nerve explant cultures 
also showed Schwann cells dividing away from their myelin sheaths and secreting 
myelin into the endoneurial space (Crang and Blakemore, 1986). In contrast, 
reduction of macrophage infiltration into injured peripheral nerves by whole body 
irradiation prior to surgery demonstrated that myelin removal proceeded normally for 
the first 5 days after injury and then proceeded at a slower rate after 5 days. This 
suggested that the main contribution to myelin removal by blood-born macrophages 
happens after 5 days and that another cell type, potentially the Schwann cell, was 
responsible for myelin removal before this time point (Perry et al., 1995). This idea is 
supported by observations from Schwann cell/DRG coculture models of Wallerian 
degeneration. In this system, after DRG axons have been severed, most Schwann cells 
are able to remove myelin debris in the absence of macrophages. Only Schwann cells 
associated with very large myelin sheaths appear incapable of removing all their 
myelin, suggesting that macrophages may assist with the removal of large myelin
55
sheaths (Fernandez-Valle et al., 1995). This idea is consistent with the conclusions 
from the early in vivo observations by Cajal and then the later findings by Stoll and 
colleagues (Stoll et al., 1989b; Cajal et al., 1928).
Electron microscopic analysis shows us that Schwann cells contain whorls of 
myelin debris and fat and are therefore capable of processing degenerating myelin 
(Stoll et al., 1989b; Reichert et al., 1994). In addition, Schwann cells show increased 
numbers of dense end-stage lysosomal bodies, seen in close association to myelin 
whorls in the cytoplasm, and demonstrate considerable acid phosphatase reactivity 
after nerve injury, characteristic of heightened degradative enzyme activity (Holtzman 
and Novikoff, 1965; Bigbee et al., 1987; Stoll et al., 1989b; Wang et al., 2004). An 
enzyme that is upregulated by Schwann cells after nerve injury is phospholipase A2 
(PLA2) and blocking its action pharmacologically can delay myelin degeneration 
(Paul and Gregson, 1992; De et al., 2003). One of the ways PLA2 might contribute to 
myelin degeneration is by production of lysophosphatidylcholine (LPC), which can 
act as a detergent to cause myelin breakdown (Hall and Gregson, 1971). Matrix 
metalloproteinases (MMPs) may also have an important role to play in myelin 
degeneration. MMPs, 2, 7, 9 and 12 are all upregulated by Schwann cells after nerve 
injury (Hughes et al., 2002; Krekoski et al., 2002) and an MMP-9 knockout mouse 
shows delayed demyelination after sciatic nerve injury (Shubayev et al., 2006). 
Importantly, further experiments will be required to demonstrate whether the effects 
observed in injured nerves by inhibiting PLA2 and MMP-9 are Schwann cell 
autonomous since macrophages also express these proteins.
Although Schwann cells are seen to contain myelin debris after nerve injury, 
how it ends up inside the Schwann cell still remains unknown. Many authors have 
proposed phagocytosis of myelin debris as a solution. Certainly, Schwann cells are
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capable of phagocytosing myelin debris. Cultured Schwann cells treated with 
exogenous myelin membranes contained MBP positive phagosomes, indicating 
uptake and processing of myelin. Additionally, this process could be blocked with 
ammonium chloride, a lysosomal inhibitor (Bigbee et al., 1987). Furthermore, a 
galactose-specific lectin, MAC2, was identified as a potential mediator of myelin 
phagocytosis by Schwann cells. MAC2 is upregulated by Schwann cells after nerve 
injury and blocking the MAC2 receptor using the competitive inhibitors galactose and 
lactose slowed myelin degeneration in an in vitro nerve segment degeneration assay 
(Reichert et al., 1994). Alternatively, Schwann cells might internalise and digest their 
myelin membranes by an endosomal/ autophagic mechanism. The numerous myelin 
digestion vacuoles seen within Schwann cells appear to be bounded by a single 
membrane that derives from the myelin itself, suggesting that ‘myelin may not be 
phagocytosed in the usual manner’ (Holtzman and Novikoff, 1965). Evidently, the 
lack of any observation of myelin expulsion and subsequent phagocytosis by 
Schwann cells, in the many studies of peripheral nerve demyelination since the time 
of Cajal, suggests that phagocytosis may not be a common process for Schwann cell 
demyelination. It remains to be tested whether Schwann cells operate using an 
autophagic-like mechanism to demyelinate.
1.6.4 Injury induced Schwann cell proliferation.
In the uninjured adult nerve, Schwann cell proliferation is minimal but is 
rapidly induced after injury (Abercrombie and Johnson, 1946; Thomas, 1948). This 
proliferation is highest in nerves containing a majority of large myelinated fibres, 
peaking around 3 days after injury in mice, and lowest in nerves containing only 
unmyelinated fibres (Thomas, 1948; Abercrombie et al., 1959; Bradley and Asbury,
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1970; Romine et al., 1976). Injury induced Schwann cell proliferation moves along a 
proximo-distal gradient, with the rate of proliferation for the distal nerve peaking 
roughly a day later than for the region closest to the injury site (Friede and Johnstone, 
1967; Oaklander et al., 1987).
There is an apparent difference in proliferative behaviour to injury of 
myelinating Schwann cells compared to non-myelinating Schwann cells. Whereas 
myelinating Schwann cells all along the distal stump of an injured nerve proliferate, a 
crush of the unmyelinated cervical sympathetic trunk revealed that non-myelinating 
Schwann cells only proliferate at the injury site but not in the distal nerve (Romine et 
al., 1976). However non-myelinating Schwann cells do demonstrate a much higher 
rate of proliferation distally in a mixed nerve, like the Sciatic nerve (Romine et al., 
1976; Clemence et al., 1989). Similarly, Schwann cell/DRG co-culture experiments 
have shown that only the Schwann cells that have elaborated a myelin sheath 
proliferate after the neurites have been transected. Non-myelinating Schwann cells 
were only induced to proliferate when directly injured in the presence of degenerating 
neurites (Salzer and Bunge, 1980). Furthermore, the presence of Schwann cells 
undergoing demyelination is sufficient to induce non-myelinating Schwann cells of 
neighbouring intact unmyelinated fibres to proliferate (Griffin et al., 1990; Murinson 
et al., 2005), suggesting that the presence of degenerating myelin may be a 
proliferative stimulus for all Schwann cells.
The idea that degenerating myelin may contain the stimulus for proliferation 
after injury has been partially tested by treating Schwann cells in culture with myelin 
membranes. A subset of Schwann cells will proliferate in response to endocytosis and 
lysosomal processing of the myelin membranes (Yoshino et al., 1984; Meador- 
Woodruff et al., 1985). Macrophage processing of myelin membranes can also
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produce a soluble mitogenic factor for cultured Schwann cells (Baichwal et al., 1988). 
Furthermore, the fact that non-myelinating Schwann cells of uninjured unmyelinated 
axons undergo mitosis in response to neighbouring myelinated fibre degeneration 
suggests the existence of a diffusible mitogen, possibly released from myelin 
(Murinson et al., 2005).
An alternative hypothesis for injury induced Schwann cell proliferation is that 
the level of proliferation is related to cell-to-cell interactions within a basal lamina 
tube after myelin removal. Large myelinated nerves have low initial cell densities but 
high rates of proliferation after injury whereas nerves containing unmyeliated fibres 
have high initial cell densities and low levels of proliferation (Joseph et al., 1950). It 
has been suggested that in myelinated fibres, after myelin removal, loss of cell to cell 
contact could be the stimulus for Schwann cells to proliferate, as with other forms of 
epithelial cell (Crang and Blakemore, 1986). Thus, there is a possibility that both 
diffusible and direct cell-to-cell signals may be important in this process.
The intracellular mechanisms that control injury-induced Schwann cell 
proliferation are largely unknown but are likely to be related to mechanisms of 
proliferation that occur in culture in response to growth factors (Harrisingh and Lloyd,
2004). It has been shown that cyclin D1 expression is upregulated by Schwann cells 
after nerve injury and is required for their full mitogenic response (Kim et al., 2000; 
Atanasoski et al., 2001; Yang et al., 2008). In addition, cyclin-dependent kinase 4 
(cdk4) but not cdk2 or cdk6 null mice show reduced proliferation after nerve 
transection (Atanasoski et al., 2008) and furthermore, nerve transection also leads to 
the reduction in levels of the cell cycle inhibitor p27 in Schwann cells (Shen et al., 
2008).
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It is important to note that Schwann cell proliferation in transected nerves takes 
place in the absence of re-growing axons, unlike after nerve crush. Thus, Schwann 
cell proliferation after nerve crush during axonal regeneration may have different 
mechanisms to Schwann cell proliferation in transected nerves. In support of this, 
developmental ‘axon induced’ Schwann cell proliferation appears to be differently 
controlled in comparison to mitosis after nerve cut since embryonic cell division is 
normal in the cyclin D1 and cdk4 knockout mice (Kim et al., 2000; Atanasoski et al., 
2001; Atanasoski et al., 2008; Yang et al., 2008; see section 1.1.3.1).
1.6.5 Role of macrophages in myelin clearance during peripheral nerve injury.
Although Schwann cells are involved in the clearance of myelin after nerve 
injury, they require assistance from heamatogenous macrophages to complete myelin 
removal. Crucially, macrophage entry is minimal after nerve injury in the CNS, which 
may be one of the main reasons why myelin clearance is so slow (Stoll et al., 1989a; 
Vargas and Barres, 2007).
Macrophages begin to enter the peripheral nerve from the bloodstream at the 
lesion site and then enter distal segments of the degenerating nerve from 3 to 4 days 
after injury, with numbers peaking after two weeks (Olsson and Sjostrand, 1969; 
Monaco et al., 1992; Mueller et al., 2003). Prevention of macrophage entry into 
degenerating peripheral nerve, by placement into Millipore diffusion chambers in the 
peritoneal cavity of mice (Beuche and Friede, 1984; Dahlin, 1995), intra-peritoneal 
(IP) injection of silica dust (Beuche and Friede, 1986), whole body irradiation (Perry 
et al., 1995) or treatment with liposomes loaded with clodronate (Briick et al., 1996; 
Liu et al., 2000) can delay myelin clearance. In addition, the peripheral nerve also 
contains a resident population of macrophages, which proliferate after nerve injury
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and also participate in removal of myelin debris (Monaco et al., 1992; Hirata et al., 
1999; Mueller et al., 2001; Mueller et al., 2003).
1.6.5.1 Mechanism of recruitment of haematogenous macrophages during nerve 
injury.
It is widely believed that the disruption of the Schwann cell axon interface leads 
to macrophage recruitment, since influx does not happen after nerve injury in the 
Wlds mouse (Lunn et al., 1989; Briick et al., 1995). This belief is further supported by 
the observation that during LPC-induced demyelination, macrophages do enter the 
Wlds nerve even though the axons remain intact (Hall, 1993). In addition, conditioned 
medium from denervated Schwann cells induces macrophage chemotactic activity in 
culture (Tofaris et al., 2 0 0 2 ).
Upon nerve injury Schwann cells upregulate production of a number of 
cytokines and chemokines, some of which have been shown to act as chemoattractant 
signals for macrophages. The chemokines, macrophage chemoattractant protein-1 
(MCP-1) and macrophage inflammatory protein-la (M IP-la) and the cytokine 
interleukin-lp (IL-ip), are expressed by Schwann cells within 24 hours of nerve 
injury (Toews et al., 1998; Taskinen and Roytta, 2000; Shamash et al., 2002; Perrin et 
al., 2005; Cheepudomwit et al., 2008). The use of blocking antibodies to MCP-1, 
M IP -la  and IL -lp  reduces both macrophage infiltration and activation after nerve 
transection, implicating all three in macrophage recruitment during peripheral nerve 
injury (Perrin et al., 2005). Furthermore, injured peripheral nerves from CCR2 (a 
MCP-1 receptor) knockout mice recruited a reduced number of macrophages and 
showed delayed myelin clearance (Siebert et al., 2 0 0 0 ).
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Additionally, mice lacking the cytokines tumor necrosis alpha (TNFa) or 
leukaemia inhibitory factor (LIF) show reduced macrophage recruitment after 
peripheral nerve injury (Liefner et al., 2000; Sugiura et al., 2000; Shubayev et al.,
2006). LIF  mRNA is induced predominantly in Schwann cells after nerve injury and 
is chemotactic for macrophages. Thus it may directly induce macrophage influx, 
although it may also act indirectly through induction of MCP-1 (Banner and 
Patterson, 1994; Sugiura et al., 2000; Tofaris et al., 2002). In the case of TNFa, it is 
produced by Schwann cells, fibroblasts and also by macrophages after injury although 
it is not required for macrophage activation (Wagner and Myers, 1996; Liefner et al., 
2000; Shamash et al., 2002). It can act as a chemoattractant for macrophages but may 
also act to recruit macrophages indirectly by upregulating expression of chemokines 
such as MCP-1 and other factors such as MMP-9 (Wang et al., 1990; Subang and 
Richardson, 2001; Shubayev et al., 2006). MMP-9 is upregulated by Schwann cells 
and macrophages after nerve injury and MMP-9 knockout mouse nerves show 
reduced macrophage infiltration after injury, though it is currently unknown how 
MMP-9 contributes to macrophage recruitment (Shubayev et al., 2006). Another 
molecule, pancreatitis-associated protein-III (PAP-III), has recently been shown to be 
a chemoattractant signal for macrophages (Namikawa et al., 2006). PAP-III is mainly 
released from Schwann cells after nerve injury and overexpression or knockdown of 
PAP-III in vivo, using adenoviruses, can increase or retard macrophage recruitment 
into crushed sciatic nerves (Namikawa et al., 2005; Namikawa et al., 2006).
Although most studies analyse Schwann cell inflammatory gene expression 
from a mixed nerve, like the sciatic, a recent investigation has highlighted the 
possibility that myelinating Schwann cells and non-myelinating Schwann cells may 
react differently to nerve injury, in terms of cytokine and chemokine expression. Non­
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myelinating Schwann cells show upregulation o f MCP-1 but not IL -lfi  or LIF  mRNA 
after selective capsaicin induced destruction of unmyelinated C-fibres, unlike 
myelinating Schwann cells after sciatic nerve transection (Cheepudomwit et al., 
2008).
In addition to macrophage chemoattractant signals produced by Schwann cells 
during Wallerian degeneration, complement components from the bloodstream also 
help to recruit macrophages. Blocking complement activation in vitro and in vivo, 
using complement protein 3 (C3) deficient serum, blocking antibodies to complement 
receptor 3 (CR3) or cobra venom can impair both the recruitment of macrophages and 
their phagocytic ability and thus delay myelin clearance (Lunn et al., 1989; Bruck and 
Friede, 1990; Bruck and Friede, 1991; Dailey et al., 1998). The use of complement 
protein 6  (C6 ) deficient rats demonstrated a requirement for C6  and formation of the 
membrane attack complex (MAC, a complex of complement proteins C5b-9) in 
macrophage recruitment and phagocytic activation after nerve injury, since in these 
rats demyelination was delayed (Ramaglia et al., 2007). The classical pathway of the 
complement system is activated after nerve injury and inhibiting its activation 
prevents activation of downstream complement proteins and retards myelin clearance 
during nerve injury (Vargas and Barres, 2007). The classical pathway can be activated 
by the binding of C lq  to non-self epitopes, either directly or via antibodies. 
Interestingly, production of autoantibodies to degenerating myelin may be involved in 
macrophage recruitment and activation as both are delayed in B-cell deficient mice 
(Vargas and Barres, 2007).
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1.6.6 Schwann cell activation versus dedifferentiation?
Some researchers refer to Schwann cells dedifferentiating after nerve injury, due 
to the loss of expression of myelin specific genes and the upregulation of a number of 
immature genes. Other researchers prefer to describe Schwann cells as becoming 
activated after nerve injury due to their expression of cytokines and growth factors. 
However, in this thesis, the term ‘Schwann cell activation’ refers to the general 
phenotype of the Schwann cell after nerve injury, whereas ‘Schwann cell 
dedifferentiation’ will only be used in reference to the upregulation of genes 
expressed by Schwann cells after nerve injury that were previously expressed during 
embryonic development (see Fig. 1.1, 1.2 and Chapter 4).
1.6.7 How do Schwann cells become activated during Wallerian degeneration?
As previously described, Schwann cells react during Wallerian degeneration 
with a large number of changes, this argues for a molecular mechanism of Schwann 
cell activation, rather than a passive response to nerve injury due to loss of axonal 
myelin inducing signals (Decker et al., 2006). Furthermore, the fact that a number of 
toxins and pathogens can actively induce Schwann cells to demyelinate prior to axon 
degeneration points to a potential pre-existing molecular pathway for demyelination 
that may be ‘hijacked’ by pathogens, in the case of PNS diseases such as, Guillain- 
Barre syndrome and leprosy (Hall and Gregson, 1971; Tapinos et al., 2006; Lee et al., 
2007).
1.6.7.1 Does the loss of the axon trigger activation of Schwann cells?
Upon nerve transection in the Wlds mouse, Schwann cells fail to respond to the 
injury. However, when Wlds Schwann cells ensheath a wild-type axon they react
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normally upon transection of the axon (Lunn et al., 1989; Glass et al., 1993). This 
suggests that Schwann cells only become activated upon loss of axonal contact. As 
mentioned earlier, Krox-20 is an axonally induced Schwann cell transcription factor 
that controls myelination (Topilko et al., 1994; lessen and Mirsky, 2005). After nerve 
injury, expression of Krox-20 disappears from the majority of myelinating Schwann 
cells within 3 days of the insult (Topilko et al., 1997). Simultaneously, Schwann cells 
down-regulate synthesis of myelin lipids and proteins (White et al., 1989; Trapp et al ., 
1988). A recent study, using a tamoxifen inducible Cre recombinase, ablated Krox-20 
from adult myelinating Schwann cells. This demonstrated that the loss o f Krox-20 
from myelinating Schwann cells was sufficient to induce rapid demyelination in the 
absence of axonal degeneration (Decker et al., 2006). As the authors of this study 
suggested, the rapidity of the induction of the demyelination argues for an active 
programme of Schwann cell demyelination and one that is normally repressed by the 
presence of Krox-20 (Decker et al., 2006). An example of how Krox-20 may suppress 
a ‘demyelination programme’ is demonstrated by the fact that enforced Krox-20 
expression in cultured Schwann cells can downregulate the expression of factors 
potentially involved in regulating the phenotype of denervated Schwann cells, such as 
c-Jun, Sox-2 and components of the Notch pathway (De Felipe et al., 1994; Stewart, 
1995; Shy et al., 1996; Parkinson et al., 2004; Le et al., 2005; Parkinson et al., 2008; 
A. Woodhoo, unpublished observations). Furthermore, there are greatly increased 
levels of c-Jun, Sox-2 and the activated Notch intracellular domain (NICD) in Krox- 
20 null nerves (Parkinson et al., 2004; Le et al., 2005a; A. Woodhoo, unpublished 
observations). These results, together, imply that the down-regulation of Krox-20 in 
myelinating Schwann cells after loss of axonal contact could lead to the upregulation
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of a ‘normally suppressed’ demyelination program, involving factors such as c-Jun, 
Sox-2 and the Notch pathway.
1.6.7.2 The role of ligand receptor signalling systems.
Another way that Schwann cells might sense nerve injury is through activation 
of extracellular receptors. This might occur through release of a ligand from the 
degenerating axon or potentially through autocrine loops induced within the Schwann 
cell by loss of axonal contact. One ligand-receptor signalling system that has been 
studied in some depth in the context of Wallerian degeneration is the NRGl/erbB 
system (see section 1.5.2). Upon sciatic nerve injury, expression of erbB2 and erbB3 
are upregulated by Schwann cells (Cohen et al., 1992; Carroll et al., 1997), erbB2 is 
tyrosine phosphorylated and the downstream kinase, Src is activated (Kwon et al., 
1997; Zhao et al., 2003; Guertin et al., 2005). Furthermore, the mRNA for NRG1 type 
II (glial growth factor, GGF) is induced as early as 3 days after injury and 
immunohistochemistry using a pan-neuregulin antibody showed that neuregulin 
protein colocalised with SlOOp, suggesting Schwann cells as a possible source of 
GGF during Wallerian degeneration (Carroll et al., 1997). A more recent study has 
shown that erbB2 is actually phosphorylated within minutes of nerve injury at nodal 
and paranodal regions (Guertin et al., 2005).
These observations indicate that the NRGl/erbB signalling system may be 
involved in the initiation of some of the events of Wallerian degeneration such as 
demyelination. In support of this, addition of high concentrations of GGF to 
myelinating Schwann cell/DRG cocultures can induce demyelination (Zanazzi et al., 
2001). Also, blocking erbB2 activation in a coculture model of Wallerian 
degeneration or after nerve transection can delay demyelination and reduce injury
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induced Schwann cell proliferation (Guertin et al., 2005). Furthermore, 
mycobacterium leprae can induce demyelination by binding to and activating erbB2 
and chemically blocking erbB2 activation can reduce m.Leprae-induced 
demyelination in vitro and in vivo (Tapinos et al., 2006). Furthermore, constitutive 
erbB2 activation in terminal Schwann cells at neuromuscular junctions induces a 
phenotypic response characteristic of denervation, including process extension and 
proliferation (Hayworth et al., 2006). However, conditional ablation of erbB2 in 
Schwann cells using a tamoxifen inducible PLP-CreERT2 allele demonstrated that 
erbB2 was dispensable for most of the events during Wallerian degeneration, 
especially proliferation (Atanasoski et al., 2006). At present, it is difficult to reconcile 
these results with all the above findings unless other receptor signalling pathways are 
involved in the Schwann cell reaction to nerve injury.
Other ligand/receptor signalling pathways that have been implicated in the 
Schwann cell reaction to injury are the transforming growth factor f3 (TGF|3) 
signalling pathway, the Notch signalling pathway, fibroblast growth factors (FGFs), 
the toll-like receptors 2 and 3 (TLR2 and 3), platelet derived growth factor-BB 
(PDGF-BB) and parathyroid hormone related peptide (PTHrP) (Oya et al., 2002; Lee 
et al., 2006; Jungnickel et al., 2006; D ’Antonio et al., 2006b; Macica et al., 2006; A. 
Woodhoo, unpublished observations). The TGF|3 signalling pathway has been 
strongly linked with the Schwann cell response to Wallerian degeneration, since 
TGFpi mRNA is upregulated after injury (Scherer and Salzer, 2001). Nevertheless, 
mice with a Schwann cell conditional mutation within the TGFp receptor II 
(TGFpRII), which is considered to impair all TGFp signalling, showed normal myelin 
clearance and Schwann cell proliferation after injury, suggesting that TGF|31
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signalling does not have a major involvement in these events (D’Antonio et al., 
2006b).
Denervated Schwann cells upregulate expression of FGF-2 and FGF-5 after 
nerve injury and both isoforms can activate FGF receptors 1 and 2, which are also 
expressed by Schwann cells (Liu et al, 1995; Meisinger and Grothe, 1997; Scarlato et 
al., 2001). Although FGF-2 addition can inhibit the differentiation of cultured 
Schwann cells, unlike NRG1, it does not induce demyelination when added to 
Schwann cell/DRG myelinating cocultures (Morgan et al., 1994; Zanazzi et al., 2001). 
Transgenic overexpression of FGF-2 in mice increases Schwann cell proliferation 
after nerve injury whereas FGF-2 knockout animals show faster rates of Wallerian 
degeneration close to the injury site (Jungnickel et al., 2004; Jungnickel et al., 2006). 
The results suggest that FGF signalling can modulate the early Schwann cell response 
to injury, though further experimentation is needed to identify its exact role.
The Notch signalling pathway is activated during Wallerian degeneration, as 
seen by the increased presence of the cleaved intracellular domain of the Notch 
receptor (NICD) in sciatic nerve extracts from transected nerves. Furthermore 
transgenic mice over expressing NICD specifically in Schwann cells demonstrate 
faster myelin clearance after nerve injury. In addition, mice, where RBP-J/Su(H)(a. 
transcription factor which is necessary for Notch signalling) or the Notch 1 receptor 
have been conditionally ablated specifically in Schwann cells, show slower myelin 
clearance after injury. These results together implicate the Notch signalling pathway 
in modulating the Schwann cell response after injury (A. Woodhoo, unpublished 
observations).
TLRs bind necrotic cell-derived material thereby activating innate immune cells 
(for review see Akira and Takeda, 2004). In the case of Schwann cells, TLR2 and 3
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were shown to mediate inflammatory gene expression, such as MCP-1 and inducible 
nitric oxide synthase (iNOS), by Schwann cells, in response to treatment with necrotic 
neuronal cell extracts (Lee et al., 2006). Furthermore, mice deficient in either TLR2 
or TLR4 show reduced macrophage infiltration and delayed myelin clearance after 
nerve injury (Boivin et al., 2007). Although the identity of the ligand binding to Toll 
receptors after nerve injury is unknown, these studies offer an interesting prospect in 
understanding how Schwann cells may directly sense nerve damage, particularly at 
the site of injury.
1.6.7.3 Do Schwann cells become hypoxic after nerve injury?
Peripheral nerve ischemia can result in myelin degradation and axonal loss 
(Schmelzer et al., 1989; Myers et al., 1991; Myers et al., 1993; Schratzberger et al., 
2000). During ischemia cells become hypoxic and react by trying to restore oxygen 
homeostasis by upregulation of specific genes, such as iNOS (Rocha, 2007). In the 
case of iNOS expression, the relative contribution by Schwann cells and macrophages 
in the degenerating peripheral nerve is still uncertain (Gonzalez-Hernandez et al., 
1999; Levy et al., 2001; Conti et al., 2004). Nevertheless, sciatic nerve injury in iNOS 
knockout mice demonstrated a robust delay in myelin sheath degradation, suggesting 
iNOS has an important role to play during Wallerian degeneration (Levy et al., 2001).
Most of the genes regulated during hypoxia are under the control of members 
from the hypoxia inducible transcription factor (HIF) family (Rocha, 2007). 
Interestingly, a number of these genes are upregulated by Schwann cells after 
peripheral nerve injury, such as, heme oxygenase (H0-1), the transferrin receptor, 
vascular endothelial growth factor (VEGF) and erythropoietin (Epo) (Raivich et al., 
1991a; Hirata et al., 2000; Levy et al., 2001; Scarlato et al., 2003; Keswani et al.,
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2004; Li et al., 2005). The hypoxia regulated subunit of HJF, H IF -la , is upregulated 
in the Sciatic nerves of diabetic rats and is expressed along with Epo and the Epo 
receptor (EpoR) in vestibular schwannomas (Chavez et al., 2005; Diensthuber et al.,
2007). It will be of great interest for future studies to investigate whether expression 
of H IF -la  is induced in Schwann cells after nerve injury and to elucidate the roles of 
the many hypoxia responsive genes that are regulated during Wallerian degeneration.
1.6.7.4 Downstream intracellular signalling cascades.
Whatever the signals are that are responsible for the activation of Schwann cells 
after peripheral nerve injury it is becoming clear that they are, at least partially, 
transduced via intracellular signalling cascades. The mitogen-activated protein kinase 
pathway (MAPK) has recently been implicated in controlling Schwann cell 
dedifferentiation. The MAPK pathway consists of the Ras-Raf-MEK-ERK 
(Extracellular signal regulated kinase) signalling cascade. ERK1/2 is rapidly 
phosphorylated and activated after nerve injury and immunostaining shows that the 
majority of phosphorylated ERK1/2 is contained within Schwann cells (Harrisingh et 
al., 2004; Guertin et al., 2005). Strong activation of the MAPK pathway can block 
Schwann cell differentiation in culture (Harrisingh et al., 2004; Ogata et al., 2004). 
Furthermore, induction of sustained MAPK activation in Schwann cells in a Schwann 
cell/DRG coculture system induces demyelination (Harrisingh et al., 2004). Recent 
evidence has also shown that phosphatidic acid (PA) induced demyelination in 
Schwann cell/DRG cocultures required activation of the MAPK pathway (Nadra et 
al., 2008).
In addition to the MAPK pathway, the c-Jun N-terminal kinase (JNK) and p38- 
mitogen activated protein kinase (p38MAPK) are also rapidly phosphorylated and
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activated after peripheral nerve injury (Myers et al., 2003; Parkinson et al., 2008; A. 
Bhaskaran, unpublished observations). The JNK and p38MAPK pathways have been 
implicated in the control of inflammatory gene expression, including TN Fa and 
iNOS, in Schwann cells (Myers et al., 2003; Lee et al., 2006; Lee et al., 2007). 
Moreover, in the presence of either a JNK or a p38MAPK inhibitor, Schwann cells 
show significantly less myelin degeneration in a dissociated Schwann cell 
demyelination assay or in whole sciatic nerve segments allowed to degenerate in 
culture in the absence of haematogenous macrophages (A. Bhaskaran, unpublished 
observations). In summary, the MAPK, JNK and p38MAPK pathways may all be 
important regulators of Schwann cell demyelination and activation after nerve injury.
1.6.7.5 Is there evidence for a transcriptional program of Schwann cell activation 
after nerve injury?
After nerve injury, Schwann cells upregulate a number of transcription factors, 
many of which are also expressed by, albeit at lower levels, immature Schwann cells 
and non-myelinating Schwann cells (Scherer and Salzer, 2001). Schwann cells have 
been shown to upregulate Egr-1 (Krox-24), Oct- 6  (SCIP/Pou3fl/Tst-l), Sox-2 and 
three members of the AP-1 family of transcription factors, c-Jun, c-fos and Activating 
transcription factor 3 (ATF3) after nerve injury (De Felipe and Hunt, 1994; Scherer et 
al., 1994a; Liu et al., 1995; Stewart et al., 1995; Shy et al., 1996; Topilko et al., 1997; 
Soares et al., 2001; Hunt et al., 2004; Le et al., 2005a). The up-regulation of Oct- 6  
after nerve transection is not thought to have a major role in the events during 
Wallerian degeneration as its exact expression does not correlate with the fall in Po 
mRNA or the induction of Schwann cell proliferation (Scherer et al., 1994). Egr-1 
expression after nerve injury may be responsible for the upregulation of the low
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affinity neurotrophin receptor (p75NTR) by denervated Schwann cells since it was 
recently shown that Egrl and Egr3 could upregulate expression of p75 N1R in 
Schwann cells (Gao et al., 2007). The role of Sox-2 in Schwann cells after nerve 
injury is unknown, although it could potentially have a role in proliferation because a 
Sox-2 expressing lentivirus augmented NRG-1 induced Schwann cell DNA synthesis 
in culture (Le et al., 2005a).
1.6.8 How do Schwann cells promote axonal regeneration?
Studies of peripheral nerve regeneration in the Wlds mouse have shown that in 
the absence of Wallerian degeneration, both sensory and motor fibre regeneration is 
severely compromised (Lunn et al., 1989; Brown et al., 1992; Chen and Bisby, 1993a; 
Chen and Bisby, 1993b; Brown et al., 1994). This suggests that the cellular and 
molecular changes that the distal stump undergoes after nerve injury are vital for 
adequate nerve regeneration. In support of this, normal uninjured adult peripheral 
nerves are not able to promote the growth of either motor or sensory axons (Langley 
and Anderson, 1904; Brown et al., 1991; Bedi et al., 1992).
The fast removal of myelin debris in the PNS is likely to be an important factor 
leading to successful peripheral nerve regeneration (Vargas and Barres, 2007). In the 
CNS, constitutive inhibitors of axonal regeneration such as Nogo, MAG and 
oligodendrocyte myelin glycoprotein (Omgp) are expressed in myelin (Filbin, 2003). 
Some of these proteins are also present in PNS myelin and over-expression of Nogo- 
A (which is not normally expressed in PNS myelin) in Schwann cells significantly 
impairs PNS axon regeneration (Pot et al., 2002). This suggests that PNS axons can 
respond to the same growth inhibitory signals as CNS axons, leading weight to the
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argument that fast removal of myelin debris is needed in order to promote successful 
axonal regeneration.
After nerve injury, the Schwann cells and their basal lamina remain in the distal 
stump forming the bands of Biingner (Scherer and Salzer, 2001). The importance of 
these Schwann cell tubes was highlighted by an elegant study where the authors 
traced individual axons over time as they grew through the distal stump and into the 
neuromuscular junction of the sternocleidomastoid muscle. When the Schwann cell 
tubes remained intact after nerve crush, 96% of axons retraced their original paths and 
innervated their original endplate. However, when the Schwann cell tubes were 
disrupted through nerve transection, only about 1 0 % of axons innervated the correct 
endplate (Nguyen et al., 2002). It was suggested that the main reason for this disparity 
was due to axons choosing the wrong basal lamina tube at the site of transection, as 
Cajal observed, but also because axon growth was delayed after nerve cut so that 
axons made branching mistakes in the distal stump of the nerve (Cajal, 1928; Nguyen 
et al, 2 0 0 2 ).
A number of peripheral nerve regeneration studies have reported axons 
regrowing along the inner aspect of the basal lamina tubes (Barton, 1962; Nathaniel 
and Pearse, 1963; Ide et al., 1983; Scherer and Easter, 1984; Schwab and Thoenen, 
1985, Martini and Schachner, 1988). This raised the question of whether the basal 
lamina in the absence of Schwann cells was sufficient to promote axonal regeneration. 
Indeed, axons do extend neurites into sections of sciatic nerve in which Schwann cells 
have been eradicated by repeated cycles of freeze-thawing (Ide et al., 1983; Schwab 
and Thoenen, 1985). However, growth of neurites is markedly reduced into acellular 
peripheral nerve grafts when compared with cellular grafts (Hall, 1986), and re­
growing axons are always seen in contact with living cells, such as Schwann cells or
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other axons but never exclusively with the basal lamina (Martini and Schachner, 
1988). Furthermore, Schwann cells are among some of the best substrates for neurite 
growth in culture (Fallon, 1985; Tomaselli et al., 1986). Other research has shown 
that axons extend in tandem with Schwann cells processes projected from the cut end 
of a nerve. Furthermore, the axon regrowth is faster when Schwann cells are allowed 
to extend their processes before the axons start to regrow (Son and Thompson, 1995; 
Son et al., 1996). These findings suggest that Schwann cell processes may actually 
guide regenerating axons. Thus it appears likely that the presence of Schwann cells, 
their processes and an intact basal lamina are all required for successful peripheral 
nerve regeneration.
Little is known about the intracellular signalling that is required by Schwann 
cells to promote axonal regeneration, although mice deficient in glial fibrillary acidic 
protein (GFAP) show a regenerative deficit after nerve crush (Triolo et al., 2006). 
Most of the recent research has focused on the extracellular molecular signals that 
target axons, many of which are derived from Schwann cells, and are required for 
adequate nerve regeneration. These factors fall into two main categories, ECM and 
CAMs and neurotrophic factors. These two topics are briefly reviewed here but for a 
more detailed account see Scherer and Salzer, (2001); Boyd and Gordon, (2003a); 
Pizzi and Crowe, (2007); Raivich and Makwana, (2007).
1.6.8.1 Candidate ECM components and CAMs that promote regeneration.
To date the most important ECM component secreted by Schwann cells that is 
known to contribute to axonal regeneration is laminin; potentially laminin 2  and 8  
(Cornbrooks et al., 1983; Tomaselli et al., 1986; Chen and Strickland, 2003). In vitro, 
antibodies to a laminin-heparan sulphate proteoglycan complex strongly inhibit the
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growth of ciliary ganglion neurons on Schwann cell derived ECM substrates 
(Tomaselli et al., 1986). In vivo, conditional ablation of the laminin yl chain using ere 
recombinase under the control of the CAM kinase II promoter reduced the number of 
regenerating motorneurons, 21 days after sciatic nerve crush (Chen and Strickland, 
2003). However, since this promoter is active in neurons in addition to Schwann cells 
it is difficult to interpret the findings in this study. Potentially, the integrin receptor 
a 7 pi could be involved in Schwann cell signalling during nerve regeneration as it is 
expressed by Schwann cells as well as by regrowing axons (Werner et al., 2000; 
Previtali et al., 2003c). Furthermore, mice lacking 017-integrin demonstrate delayed 
peripheral nerve regeneration after injury (Werner et al., 2000). Another ECM 
component, produced by Schwann cells, Reelin, also plays some role in nerve 
regeneration. Reeler mice, which are deficient in Reelin, have a 30% reduction in 
axonal growth rates at 2 and 4 days after crush but show normal numbers of 
motorneurons regenerating at 21 days after crush (Panteri et al., 2006; Lorenzetto et 
al., 2008). Other ECM molecules associated with the Schwann cell basal lamina that 
may be involved in peripheral nerve regeneration are, fibronectin, tenascin C, 
hyaluronic acid, F-spondin and heparan sulpfate and chondroitin sulfate proteoglycans 
(HSPGs and CSPGs) (Martini et al., 1990; Wang et al., 1992; Tona et al., 1993; 
Braunewell et al., 1995; Burstyn-Cohen 1998).
In addition to promoting peripheral nerve regeneration, some ECM components 
such as CSPGs have been suggested to act as inhibitory signals (Muir et al., 1989; 
Zuo et al., 1998). Degradation of CSPGs in various models of peripheral nerve injury 
promotes axonal elongation (Krekosi et al., 2002; Zuo et al., 2002; Groves et al., 
2005). Furthermore it has been proposed that MMPs, expressed by Schwann cells and 
macrophages after nerve injury, may be involved in the degradation of these
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inhibitory CSPGs and thus contribute to efficient axonal regeneration (Ferguson and 
Muir, 2000; Krekosi et al., 2002).
There are a number of CAMs that have been implicated in promoting peripheral 
nerve regeneration. The Ca2+-independent CAMs, neural-cell adhesion molecule 
(NCAM), LI and close homolgue of LI (CHL1) and the Ca2+-dependent CAM, N- 
cadherin are all upregulated by Schwann cells in the distal stump of injured nerves 
(Daniloff et al., 1986; Martini and Schachner, 1988; Padilla et al., 1999; Zhang et al., 
2000a). Furthermore, LI and N-cadherin, but not NCAM, have been shown to 
mediate a large proportion of the neurite growth promoting effects of Schwann cells 
in culture, through use of blocking antibodies (Bixby et al., 1988; Seilheimer and 
Schachner, 1988). In addition, two novel CAMs, ninjurinl and 2, which are capable 
of homophilic adhesion and are upregulated by Schwann cells and DRG neurons after 
nerve injury both promote neurite elongation of DRG neurons in vitro (Araki and 
Milbrandt, 1996; Araki and Milbrandt, 2000).
Interactions between cell adhesion molecules expressed on regrowing neurons 
and Schwann cells are certain to be involved in successful peripheral nerve 
regeneration. However, another level of complexity can be added to these 
interactions, as it appears that carbohydrate modifications on these proteins can alter 
the regenerative properties of axons. The carbohydrate epitope that is recognised by 
the HNK1/L2 antibody and is expressed on CAMs such as, NCAM and L I, regulates 
the outgrowth of chick motor axons on cryosections of rodent ventral root (Martini et 
al., 1992). Furthermore, the polysialic acid moiety on NCAM (PSA-NCAM) 
expressed by motor neurons has been shown to be required for generation of adequate 
collateral sprouts and ultimately for selective targeting of motor neurons to their 
original targets in the periphery (Franz et al., 2005).
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1.6.8.2 Schwann cells produce neurotrophic factors for regenerating sensory and 
motor neurons.
After peripheral nerve injury Schwann cells upregulate production of a number 
of potential trophic factors for regenerating peripheral neurons. Many of these factors 
such as nerve growth factor (NGF), brain-derived growth factor (BDNF), glial- 
derived growth factor (GDNF), neurotrophin-3 (NT-3) and NT-4/5 have well 
established roles in survival of specific populations of neurons during development 
(Huang and Reichardt, 2001). However, because null mutations in many of these 
genes lead to embryonic lethality it has been difficult to investigate their specific roles 
in adult peripheral nerve regeneration (Huang and Reichardt, 2001).
1.6.8.2.1 The neurotrophins.
NGF, a member of the neurotrophin family, promotes the survival and differentiation 
of neural crest-derived sensory and sympathetic neurons during development (Levi- 
Montalcini and Angeletti, 1968). After nerve injury, Schwann cells massively 
upregulate their production of NGF and DRG neurons continue to express the NGF 
receptors trkA and p75NTR, however the amount of NGF retrogradely transported by 
regenerating neurons is actually reduced compared to uninjured neurons (Heumann et 
al., 1987; Raivich et al., 1991b; Sebert and Shooter, 1993). Furthermore, the role of 
NGF during peripheral nerve regeneration is unclear. Although exogenous NGF can 
prevent permanent axotomy-induced death of some sensory neurons other reports 
suggest endogenous NGF is not required for sensory neuron regeneration, though it 
may be required for collateral sprouting (Diamond et al., 1987; Diamond et al., 1992a; 
Diamond et al., 1992b; Rush et al., 1995; Ljungberg et al., 1999).
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Other members of the neurotrophin family are BDNF, NT-3 and NT-4/5. After nerve 
injury, Schwann cells slowly upregulate the expression of BDNF  and NT-4/5 mRNA, 
with BDNF  levels peaking at 4 weeks after injury, but NT-3 mRNA is initially 
downregulated before returning to control levels (Meyer et al., 1992; Funakoshi et al., 
1993; Zhang et al., 2000b). After nerve injury, the BDNF and NT4/5 high affinity 
receptor, trkB, is expressed in the spinal cord and the DRG whereas the NT-3 
receptor, trkC, is downregulated in the spinal cord (Funakoshi et al., 1993; Sebert and 
Shooter, 1993; Foster et al., 1994; Fernandes et al., 1998). The regeneration of motor 
axons is reduced in trkB (the high affinity receptor for BDNF) heterozygous null 
mouse sciatic nerves (Boyd and Gordon, 2001). Also, use of a blocking antibody to 
BDNF reduced the axon growth rate and strongly reduced the number of myelinated 
axons in the distal nerve after crush injury (Zhang et al., 2000b). Treatment of injured 
sciatic nerves with NT-4/5 enhanced axonal regeneration and, in addition, growth of 
axons through grafts of sciatic nerve from NT-4/5 null mice is reduced in comparison 
to wild-type grafts (Yin et al., 2001; Simon et al., 2003; English et al., 2005). 
Furthermore, creation of transgenic mice that express pan-neurotrophin-1, which can 
activate all neurotrophin receptors, demonstrated considerably faster motor and 
sensory function recovery, measured by compound action potentials and reinnervation 
of target tissues (Funakoshi et al., 1998). All of these studies show that either 
reduction in or overactivation of neurotrophin signalling can modulate the rate of 
axonal regrowth during peripheral nerve regeneration.
1.6.8.2.2 The neuropoietic cytokines.
Another family of neurotrophic factors, expressed by Schwann cells that play a 
role in peripheral nerve regeneration are the neuropoietic cytokines, which include
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factors such as ciliary neurotrophic factor (CNTF), LIF and IL - 6  (Bauer et al., 2007). 
CNTF mRNA is expressed in myelinating Schwann cells but is downregulated after 
nerve injury (Friedman et al., 1992; Sendtner et al., 1992; Ito et al., 1998). 
Exogenously applied CNTF can rescue motor neurons from degeneration after facial 
nerve axotomy in neonatal mice and disruption of the CNTF gene in mice causes a 
progressive loss of motor neurons and weakening of peripheral muscles (Sendtner et 
al., 1990; Masu et al., 1993). After nerve injury, even though CNTF mRNA 
decreases, it is thought to be released by damaged myelinating Schwann cells as a 
lesion factor and contribute to motor neuron survival (Sendtner et al., 1997).
IL-6 mRNA and protein is rapidly expressed by Schwann cells but is also 
detected in the CNS, after peripheral nerve injury (Kiefer et al., 1993; Bolin et al., 
1995; Kurek et al., 1996; Hirota et al., 1996; Ito et al., 1998). Early studies showed 
that a blocking antibody to IL - 6  reduced motor axon regeneration whereas a 
transgenic mouse over-expressing IL - 6  and the IL - 6  receptor enhanced motor axon 
regeneration (Hirota et al., 1996). IL-6 knockout mice show a modest decrease in 
speed of motor axon regrowth in the lesioned facial nerve and reduced functional 
recovery after sciatic nerve injury (Zhong et al., 1999; Inserra et al., 2000; Galiano et 
al., 2001). In addition, sensory axon regeneration also appears to be impaired in IL-6  
knockout mice, judged by reduced sensory compound action potential (Zhong et al., 
1999). However, in all of these studies it is uncertain whether the consequences of IL- 
6 removal are due to its role in CNS inflammation or due to local effects on axon 
growth within the PNS and thus further investigation is required (Klein et al., 1997; 
Galiano et al., 2001; Raivich and Makwana, 2007).
LIF, as already discussed, can mediate inflammatory responses after nerve 
injury. However, LIF also has significant effects on sensory axon regeneration as it is
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taken up and retrogradely transported by sensory neurons after nerve injury 
(Thompson et al., 1997). Investigation of LIF  null mice demonstrates that LIF is 
capable of promoting axonal elongation of regenerating small diameter sensory axons 
and preventing axotomy induced neurochemical changes, such as the loss of 
calcitonin gene-related peptide (CGRP) immunoreactivity, in this neuronal population 
(Cafferty et al., 2 0 0 1 ).
1.6.8.2.3 Other neurotrophic factors: GDNF, IGFs and pleiotropin.
GDNF is a member of a sub-family of the TGF|3 superfamily (Lin et al., 1993). 
After nerve injury, Schwann cells in the distal stump upregulate GDNF mRNA 
(Trupp et al., 1995; Naveilhan et al., 1997). Exogenously applied GDNF can enhance 
sensory axon regeneration and can reverse the axotomy-induced changes in small 
diameter IB4 positive C-fibres (Naveilhan et al., 1997; Bennet et al., 1998). In 
addition, GDNF enhances motor axon regeneration after acute and chronic axotomy 
(Chen et al., 2001; Boyd and Gordon, 2003b). A role for GDNF in motor and sensory 
nerve regeneration is supported by the fact that motor neurons upregulate the GDNF 
receptors, G FR al and RET and sensory neurons upregulate G FR al and GFRa3 after 
nerve injury (Naveilhan et al., 1997; Burazin and Gundlack, 1998; Tsujino et al., 
1999; Bennet et al., 2000). Interestingly, the majority of large diameter sensory 
neurons appear to express G FR al whereas many small diameter sensory neurons 
express GFRa3 after injury, suggesting that the GFRa3 ligand, artemin, may play a 
role in nerve regeneration too (Bennett et al., 2000).
The insulin like growth factors, IGF-I and II are upregulated by Schwann cells 
after nerve injury, although macrophages also express IGF-I (Pu et al., 1995; Cheng et 
al., 1996; Meier et al., 1999). Addition of exogenous IGF-II or use of IGF blocking
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antibodies can modulate the distance of motor axon regrowth and both IGF-I and II 
can improve sensory axon regeneration in a diabetic rat model (Near et al., 1992; Ishii 
and Lupien, 1995). However, since IGFs promote the survival and differentiation of 
Schwann cells (Gavrilovic et al., 1995; Stewart et al., 1996; Meier et al., 1999), it is 
uncertain whether IGFs are acting predominately on neurons, Schwann cells or both 
cell types during peripheral nerve regeneration.
Recently, a novel neurotrophic factor, pleiotrophin (PTN) has been shown to 
play a role in peripheral nerve regeneration. PTN  mRNA is upregulated in the distal 
stump of the injured sciatic nerve, most likely in Schwann cells, with expression 
peaking at 7 days. In vitro PTN promotes the extension of spinal motor neurons and 
in vivo, exogenous PTN enhances regeneration after sciatic nerve cut. Additionally, 
PTN can rescue neonatal motorneurons from death after facial nerve transection (Mi 
etal., 2007).
1.6.8.3 Do Schwann cells from motor and sensory nerve fibres express different 
phenotypes during regeneration?
The first evidence that Schwann cells in motor and sensory nerves might 
possess distinct phenotypes came from the discovery that only Schwann cells in 
contact with motor axons express the L2/HNK-1 carbohydrate epitope (Martini et al., 
1988). Furthermore, expression of L2/HNK-1 is lost after denervation and only 
induced again when motor but not sensory, axons reinnervate their original motor 
Schwann cells (Martini et al., 1994). Furthermore, Schwann cells that were previously 
innervated by sensory axons do not have the ability to express L2/HNK-1 when motor 
neurons are forced to innervate them (Martini et al., 1994). Thus Schwann cells
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appear to retain some ‘memory’ of what type of axon they were originally innervated 
by.
More recent investigation has demonstrated that Schwann cells of the dorsal 
(sensory) and ventral (motor) roots upregulate different combinations of growth 
factors after nerve injury. Whereas Schwann cells in the dorsal roots upregulate NGF, 
BDNF, GDNF and IGF-I and II, Schwann cells in the ventral roots upregulate PTN 
and GDNF (Hoke et al., 2006). Thus, these results suggest that Schwann cells adopt 
distinct sensory and motor phenotypes during regeneration.
1.6.8.4 Do Schwann cells control reformation of the blood nerve barrier (BNB) 
during remyelination?
1.6.8.4.1 BNB breakdown after injury.
During peripheral nerve injury the blood-nerve barrier (BNB) breaks down, 
possibly through induction of MMPs by endothelial cells and Schwann cells (George 
et al., 1995; Hughes et al., 2002). This allows components from the bloodstream such 
as fibrinogen, complement and haematogenous macrophages to enter the degenerating 
peripheral nerve. Fibrinogen is converted to fibrin via the clotting cascade and 
clearance of fibrin from the nerve is correlated with remyelination and nerve repair 
(Akassoglou et al., 2002). Fibrin is degraded by the serine protease plasmin, which is 
in turn activated by plasminogen activators (Akassoglou and Strickland, 2002). In the 
absence of tissue plasminogen activator (tPA) there is increased deposition of fibrin 
and increased nerve damage and demyelination and slower functional recovery after 
nerve injury (Akassoglou et al., 2000; Siconolfi and Seeds, 2001). Additionally, fibrin 
inhibits Schwann cell myelin differentiation in culture and fibrin knockout mice 
remyelinate faster after nerve crush (Akassoglou et al., 2 0 0 2 ). Thus it appears that
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blood-borne components, as well as promoting nerve repair, can sometimes have 
deleterious effects.
1.6.8.4.2 Schwann cell remyelination and BNB reformation.
Schwann cell remyelination occurs in very much the same way as the process of 
myelination during development (Scherer and Salzer, 2001; Jessen and Mirsky,
2005). Interestingly, BNB reformation appears to correlate better with remyelination 
than with axonal regeneration, per se, suggesting that the process of remyelination 
might be important for BNB restoration (Bouldin et al., 1991). One potential myelin 
regulated Schwann cell signal that could instruct the reformation of the BNB is Desert 
Hedgehog (DHH) (Bajestan et al., 2006; Sharghi-Namini et al., 2006). DHH is 
normally expressed by myelinating Schwann cells and is downregulated after nerve 
injury (Bajestan et al., 2006). After nerve crush, DHH is re-expressed by myelinating 
Schwann cells between 14-28 days after nerve injury, a time-point that correlates well 
with remyelination and the beginning of BNB restoration (Bouldin et al., 1991; 
Scherer and Salzer, 2001; Bajestan et al., 2006). In addition, it has recently been 
shown that DHH is a direct target for the myelin-related transcription factor Krox-20, 
which would explain DHH’s re-expression around the time of remyelination (Le et 
al., 2005b; Jang et al., 2006). Further evidence to suggest that DHH mediates BNB 
restoration comes from analysis of DHH  null nerves, which have a permeable BNB 
and show macrophage and neutrophil infiltration (Sharghi-Namini et al., 2006). Upon, 
sciatic nerve transection, DHH  null nerves demonstrate faster myelin clearance, 
potentially due to an already permeable BNB (Bajestan et al., 2006; Sharghi-Namini 
et al., 2006). Thus, it is possible that myelinating Schwann cells could instruct BNB 
reformation through DHH during peripheral nerve remyelination.
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1.7 Non-syndromic inherited motor and sensory neuropathies.
Non-syndromic inherited peripheral neuropathies are traditionally known as 
Charcot-Marie-Tooth disease (CMT) or hereditary motor and sensory neuropathy 
(HMSN). They are classified in groups depending on forearm nerve conductance 
velocities (NCVs), nerve pathology, age of onset and severity and pattern of 
inheritance. Briefly, patients presenting with CMT1 (HMSNI) generally have NCVs 
<38m/s, with age of onset in the first or second decade of life. CMT1 is referred to as 
a demyelinating neuropathy since nerve biopsies from patients often show segmental 
demyelination and remyelination, in addition to onion bulbs (supernumerary Schwann 
cells arranged concentrically around an improperly remyelinated axon) and axonal 
loss. CMT2 (HMSNII) is characterised by NCVs >38m/s, has a later onset than 
CMT1 and is associated predominantly with alteration and loss of axons. CMT3 
(HMSNIII) includes more severe demylinating or dysmyelinating neuropathies with 
an early childhood onset. These include Dejerine-Sottas syndrome (DSS) and 
congenital hypomyelinating neuropathy (CHN). CMT4 is a collection of genetically 
heterogeneous autosomal recessive neuropathies, the majority of which are caused by 
defects in axonally expressed genes although some are due to Schwann cell defects. In 
addition, there is also a relatively mild condition called hereditary neuropathy with 
liability to pressure palsy (HNPP), which is classified as a recurrent focal neuropathy 
(Wrabetz et al., 2001; Suter and Scherer, 2003; Berger et al., 2006).
There is remarkable allelic heterogeneity underlying the CMT diseases. CMT is 
caused by mutations in genes in Schwann cells or peripheral neurons. Mutations in 
different genes often cause a similar form of the disease and moreover, different 
mutations in the same gene can lead to different forms of CMT (Suter and Scherer, 
2003). To add further complexity, some forms of CMT2, that present with axonal
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pathology, have actually been shown to be caused by a Schwann cell mutation 
demonstrating the intricacy of the axo-glial relationship in the PNS and the difficulty 
facing researchers and clinicians in understanding the pathology of CMT diseases 
(Wrabetz et al., 2001). I will briefly summarise the mutations and potential 
mechanisms of the main genes involved in causing CMT neuropathies in Schwann 
cells.
1.7.1 Mutations in the PMP22 gene.
The majority of mutations causing CMT and HNPP are found in the PMP22 
gene. A deletion on chromosome 17 that includes the PMP22 gene leads to HNPP. 
Whereas the most common form of inherited neuropathy, CMT1 A, is usually caused 
by the heterozygous inheritance of a duplication that includes PMP22. The molecular 
basis of these diseases is due to two highly homologous sequences flanking the 
PMP22 gene, which can lead to unequal crossing over during meiosis and the 
inheritance of a duplicated or a deleted allele (Lupski and Chance, 2005). How these 
mutations lead to neuropathies is not completely understood although it is believed 
that gene dosage is important since rodents with increasing PMP22 gene dosages 
develop more severe CMT 1-like neuropathies (Huxley et al., 1996, 1998; Sereda et 
al., 1996; Magyar et al., 1996). In addition to duplications and deletions, there are 
more than 40 different point mutations described in the PMP22 gene, which often 
lead to more severe phenotypes in patients (Suter and Scherer, 2003). Many of these 
point mutations are thought to produce a toxic gain of function or dominant-negative 
effect. This notion is supported by evidence that mice that are heterozygous for the 
naturally occurring PMP22 point mutations Trembler (Tr) and Trembler-J (Tr-J) 
produce a more severe neuropathy than PMP22+I' mice (Adlkofer et al., 1997).
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Mechanisms that may play a role in the development of these phenotypes include 
retention of mutant PMP22 proteins within the cell and increased association with the 
molecular chaperone calnexin (Tobler et al., 1999; Dickson et al., 2002). In addition 
mutant PMP22 may accumulate in aggresomes within cells leading to dysfunction 
(Notterpek et al., 1999; Ryan et al., 2002). Furthermore the ability of wild-type 
PMP22 to associate with a 4 p6 integrin, P0 or influence proliferation may in part 
underlie some of the defects in Schwann cells caused by mutant forms of PMP22 
(Berger et al., 2006; See section 1.4).
1.7.2 Mutations in the Po gene.
There are around 1 0 0  different mutations in the Po gene that lead to inherited 
peripheral neuropathies. The majority of these mutations are inherited in an autosomal 
dominant pattern and cause diseases of radically variable phenotypes, ranging from 
CMT1 to DSS and CHN and even CMT2, with predominantly axonal pathology 
(Wrabetz et al., 2001). The majority of these mutations produce more severe 
phenotypes than haploinsufficiency for Po, which causes a relatively mild CMT IB 
phenotype in both man and mice (Wrabetz et al., 2001; Martini et al., 1995a). Thus, 
many believe that most mutations in the Po gene must produce dominant negative or 
gain of function effects. In support of this, recent mouse models of two Po mutations, 
S63C, which causes DSS and S63del which causes CMT IB where shown to have 
separate gain of function effects on Schwann cells. Whereas the Po S63del caused a 
packaging defect in the myelin sheath, Po S63C was retained within the endoplasmic 
reticulum and caused an unfolded protein response (UPR)(Wrabetz et al., 2006). 
Further work then actually demonstrated that ablation of the transcription factor
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CHOP that mediates part of the UPR could ameliorate the phenotype in the P0 S63C 
mouse (Pennuto et al., 2008).
1.7.3 Mutations in GJB1 (Connexin32).
More than 240 different mutations in G JB l, which encodes connexin 32, lead to 
CMTIX. Mutations have been reported in every domain of Cx32, in addition to the 
promoter and the 3’ untranslated region. There are also mutations that lead to deletion 
of the entire gene. The clinical phenotypes of the many CMTIX mutations are more 
homogenous, though point mutations sometimes lead to a more severe phenotype 
(some including CNS involvement) than gene deletion suggesting potential dominant 
negative or gain of function effects (Suter and Scherer, 2003). Mice lacking Cx32 
develop a peripheral neuropathy although this appeared not to be correlated with 
disruption of the radial pathway for diffusion through the SLIs, to which Cx32 is 
thought to contribute (Balice-Gordon et al., 1998; Anzini et al., 1997; Scherer et al., 
1998). Furthermore, evidence suggests that some of the more severe point mutations 
lead to disruption in trafficking of Cx32 within the cell, which may lead to dominant 
negative effects on other connexins (Kleopa et al., 2002; Yum et al., 2002; Suter and 
Scherer, 2003).
1.7.4 Mutations in periaxin  gene.
Recessive mutations in the periaxin gene lead to CMT4F, which is characterised 
by a DSS like phenotype. Unlike other inherited demyelinating neuropathies sensory 
loss and ataxia are more common features of CMT4F. CMT4F is thought to be caused 
by loss of periaxin function (Boerkoel et al., 2001; Guilbot et al., 2001). Mice lacking 
the periaxin gene are initially relatively normal but develop a severe demyelinating
87
neuropathy around 6 weeks after birth characterised by tomacula (hypermyelination) 
and infoldings of intemodal myelin. Mice have reduced motor and sensory 
mechanoreceptor NCVs and develop reflex behaviours associated with allodynia and 
hyperalgesia (Gillespie et al., 2000). How loss of function of periaxin leads to 
demyelinating neuropathies is not completely understood although it may be due to 
disruption of the dystroglycan-DRP2 complex (Sherman et al., 2001). Disruption of 
this complex leads to defects in Schwann cell internodal extension during nerve 
elongation postnataly and reduced NCVs (Court et al., 2004).
1.7.5 Mutations in EGR2 gene.
Mutations in EGR2 lead to development of peripheral neuropathies of varying 
severity including CMT1, DSS and CHN. The majority of mutations are found in the 
DNA binding domain and are inherited autosomal dominantly. These mutations are 
believed to act by a dominant negative or gain of function mechanism (Warner et al., 
1998; Nagarajan et al., 2001; LeBlanc et al., 2007; Szigeti et al., 2007; see Chapter 5). 
Additionally, recessive mutations in the NAB binding domain of EGR2 cause severe 
peripheral neuropathies in humans and mice potentially due to the fact that these 
mutations lead to loss of Egr2:Nabl/2 interactions and the dysregulation of Egr2 
target genes (Warner et al., 1998; Le et al., 2005b; Szigeti et al., 2007; Demazieres et 
al., 2008; see section 1.5.4.1).
1.7.6 Mutations in Myotubularin-related genes (MTMR).
Recessive mutations in MTMR2 and MTMR13/SBF2 lead to CMT4B1 and 
CMT4B2 respectively (Bolino et al., 2000; Azzedine et al., 2003; Senderek et al., 
2003). These diseases are characterised by a demyelinating neuropathy with myelin
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outfoldings, which have been replicated in mice lacking MTMR2 suggesting the 
disease is caused by a loss of function (Bolino et al., 2004; Bonneick et al., 2005). 
MTMRs are present in neurons and Schwann cells and are phosphoinositide lipid 3- 
phosphatases that are thought to regulate endocytosis (Previtali et al., 2003b; Berger 
et al., 2006), although development of CMT4B like phenotypes in mice is due to loss 
of MTMR2 in Schwann cells and not axons (Bolis et al., 2005).
1.7.7 Other mutations associated with Schwann cells causing CMT.
Autosomal recessive mutations in frabin cause CMT4H, a demyelinating 
neuropathy also characterized by myelin outfoldings (Delague et al., 2007; Stendel et 
al., 2007). Frabin is a Rho GDP/GTP exchange factor, specific for cdc42. Since cdc42 
is important for Schwann cell proliferation, axonal sorting and myelination 
(Benninger et al., 2007), it is believed that frabin mutations would lead to impairment 
of cdc42 activity in Schwann cells (Stendel et al., 2007). Mutations in a small integral 
membrane protein of the lysosome/late endosome (SIMPLE) lead to the dominant 
demyelinating neuropathy CMT 1C. Since myelinating Schwann cells express high 
levels of SIMPLE the disease is believed to be caused by a Schwann cell defect 
although the exact mechanism is very unclear. Additionally mutations in N-myc 
downstream-regulated gene 1 (NDRG1) lead to recessive CMT4D, dynamin 2 
mutations are associated with dominant-intermediate CMT IB and recessive mutations 
in ganglioside-induced differentiation associated protein 1 (GDAP1) cause various 
demyelinating, intermediate and axonal forms of CMT (for review see, Suter and 
Scherer, 2003; Berger et al., 2006).
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AIMS
The aim of this thesis was first to investigate the role of cyclic AMP, NRGl and 
the CREB family of transcription factors in mouse Schwann cell myelin 
differentiation (Chapter 3). I then wanted to investigate the role of the transcription 
factor, c-Jun in Schwann cells, in vivo, particularly during peripheral nerve injury and 
regeneration (Chapter 4). Finally, I wanted to characterise the functional properties in 
Schwann cells of a mutant transcription factor, mutant Egr2 (S382R/D383Y) that is 
known to cause congenital hypomyelinating neuropathy in humans (Chapter 5).
90
CHAPTER 2: Materials and Methods
2.1 List of reagents
2.1.1 Reagents for tissue culture
Transferrin, selenium, putrescine, triiodothyronine (T3), thyroxine (T4), 
progesterone, dexamethasone, bovine serum albumin (BSA), insulin, cytosine 
arabinoside (Ara C), poly-D-lysine (PDL), poly-L-lysine (PLL), laminin, dimethyl 
sulphoxide (DMSO), bromodeoxyuridine (BrdU) and 2'-0-dibutyryladenosine 3':5'- 
cyclicAMP (dbcAMP) were obtained from Sigma (Poole, UK). 8-pCPT-2-0-Me- 
cAMP and 6-Bnz-cAMP were purchased from BIOLOG (Bremen, Germany). 
Collagenase was obtained from Worthington (Lome Laboratories, Reading, UK). 
Dulbecco’s modified Eagles medium (DMEM), Minimum Essential Medium (MEM), 
Ham’s F-12 medium, L-15 medium, horse serum (HS) and glutamine were from 
Invitrogen Ltd (Paisley, UK). Trypsin and penicillin/streptomycin was obtained from 
PAA (UK). Foetal calf serum (FCS) was purchased from Perbio (UK). Tissue culture 
Petri dishes, 24 well plates and centrifuge tubes were obtained from VWR (UK) and 
forskolin was from Calbiochem (CA, USA). Round 13 mm coverslips were from 
BDH (Lutterworth, UK). TGFp-1 and NRGP-1 were obtained from R & D Systems 
(Minneapolis, MN, USA).
2.1.2 Reagents for molecular biology
Taq DNA-polymerase, dNTPs, 1KB plus DNA ladder and Agarose were from 
Invitrogen Ltd (Paisley, UK). EDTA disodium salt, ethidium bromide, Sodium 
Citrate, phenyl methyl sulphonyl fluoride (PMSF) and bromophenol blue were from 
Sigma (Poole, UK). Hybond-N nitrocellulose membrane was from Amersham
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Pharmacia Biotech (UK). Absolute ethanol, isopropanol, methanol, sodium dodecyl 
sulphate (SDS), sodium chloride (NaCl) and glycerol were from BDH Lab. Supplies 
(Poole, UK). Kaleidoscope pre-stained standards were from Biorad (CA, USA). 
TUNEL label and enzyme were from Roche Diagnostics (Germany). Phenol- 
chloroform was from Fluka Chemicals Ltd. (Buchs, Switzerland).
2.1.3 Reagents for immunolabelling
Paraformaldehyde was obtained from Fluka Chemicals Ltd. (Buchs, 
Switzerland). Triton X-100, lysine and Hoechst dye H33258 were from Sigma (Poole, 
UK). Citifluor was from Citifluor Ltd. (London, UK). HC1 and glycerol were 
purchased from BDH (Lutterworth, UK).
2.1.4 Reagents for histology and Electron Microscopy
Glutaraldehyde, Agar 100 Resin, methyl nadic anhydride (MNA), dodecenyl 
succinic anhydride (DDSA), N-benzyldimethylamine (BDMA), Tissue Tek OCT 
compound and rubber coffin moulds were from Agar Scientific (UK). DPX mountant 
and 13mm coverslips were from Merck Biosciences (Germany), frosted and 
Superfrost Plus microscope slides were from BDH (Lutterworth, UK).
2.2 List of Antibodies
2.2.1 List of Primary antibodies
p-galactosidase: Mouse monoclonal antibody was purchased from Sigma (UK) and 
used at a concentration of 1:500 for immunocytochemistry (ICC). 
fi-tubulin: Mouse monoclonal antibody was purchased from Sigma (UK) and used at 
a concentration of 1:1000 for western blotting (WB).
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Bromodeoxyuridine: Mouse monoclonal antibody was purchased from Roche 
Diagnostics (UK) and used at a concentration of 1:200 for ICC.
Bromodeoxyuridine: biotinylated mouse monoclonal antibody was purchased from 
Zymed (CA, USA) and used at a concentration of 1:50 for immunohistochemistry 
(IHC).
c-Jun: Mouse monoclonal antibody was purchased from BD Transduction 
Laboratories (UK) and used at a concentration of 1:500 for ICC and 1:2500 for WB. 
c-Jun: Rabbit polyclonal antibody was purchased from Santa Cruz Biotechnology 
(USA) and used at a concentration of 1:500 for IHC and 1:2500 for WB.
Cre recombinase: Rabbit polyclonal antibody was purchased from Novagen (Merck 
Biosciences, Germany) and used at a concentration of 1:10000 for ICC.
Cdk2: Rabbit polyclonal antibody was purchased from Santa Cruz Biotechnology 
(USA) and used at a concentration of 1:100 for ICC.
Cyclin D l:  Mouse monoclonal antibody was purchased from Santa Cruz 
Biotechnology (USA) and used at a concentration of 1:100 for ICC and 1:500 for 
WB.
ERK1/2 (native): Mouse monoclonal antibody was purchased from Sigma (UK) and 
used at a concentration of 1:2500 for WB.
F4/80: Rat polycloncal antibody was purchased from AbD Serotec (UK) and used at a 
concentration of 1:50 for ICC.
Gal-C: The Gal-C hybridoma cell line was a generous gift from Dr B. Ranscht (Max- 
Plank Institute, Germany) (Ranscht et al, 1982), and the mouse monoclonal 
supernatant was used at a 1:5 dilution for ICC.
GAPDH: Mouse monoclonal antibody was purchased from Abeam Ltd. (Cambridge, 
UK) and used at a concentration of 1:1000 for WB.
93
GFP: Rabbit polyclonal antibody was purchased from Invitrogen and used at a 
concentration of 1:1000 for ICC and 1:5000 for WB.
Krox-20: Rabbit polyclonal antibody purchased from Covance (USA) and used at a 
concentration of 1:250 for ICC and 1:2500 for WB.
LI (324): Rat monoclonal antibody (clone 324) was a gift from Dr R. Martini 
(Martini et al., 1994) and was used in hybridoma form for ICC and IHC.
L I (ASCS4): Mouse monoclonal antibody (clone ASCS4) was a gift from Dr. P. 
Patterson (Caltech, USA). This antibody was used in the form of a hybridoma 
supernatant and diluted 1:1 with MEM-H 10% FCS for ICC.
L-periaxin: Rabbit polyclonal antibody was a gift from Prof. P.J. Brophy (University 
of Edinburgh, Scotland, UK) (Gillespie et al., 1994) and was used at a concentration 
of 1:8000 for ICC and 1:15000 for WB.
Myelin basic protein: Mouse monoclonal antibody was purchased from Sternberger 
Monoclonals Inc. (Covance, USA) and used at a concentration of 1:1000 for ICC. 
NAB2: Polyclonal antibody (IC4) was a gift from Dr. Judith Johnson (Kirsch et al.,
1996). This antibody was used in the form of a hybridoma supernatant (neat). 
N-cadherin: Rabbit polyclonal antibody was purchased from Abeam Ltd.
(Cambridge, UK) and was used at a concentration of 1:500 for IHC and ICC.
NCAM: Rabbit polyclonal antibody was a gift from Dr G. Rougon (Rougon and 
Marshak, 1986) and used at a concentration of 1:500 for IHC and ICC.
04: The 0 4  hybridoma cell line was a generous gift from Dr. I. Sommer (Sommer and 
Schachner, 1981), and the mouse monoclonal supernatant was used at a 1:5 dilution 
for ICC.
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0X7: 0X 7 hybridoma cell line secreting IgM recognizing rat Thy 1.1 was from the
European Collection of Animal Cell Cultures (DERA, Wiltshire, UK) and was used
for negative immunopanning in order to purify rat Schwann cell cultures.
p27: Rabbit polyclonal antibody was purchased from Santa Cruz Biotechnology
(USA) and used at a concentration of 1:100 for ICC and 1:500 for WB.
p75NTR: Rabbit polyclonal antibody was purchased from Upstate (Virginia, USA) and
used at a concentration of 1:200 for IHC and ICC.
p-AKT: Rabbit polyclonal antibody specific to the phosphorylated form (Thr308) of 
Akt was from Cell Signalling Tech (Hertfordshire, UK) and used at a concentration of 
1:500 for WB.
p-ERK 1/2: Mouse monoclonal antibody was purchased from Sigma (UK) and used at 
a concentration of 1:5000 for WB.
Protein zero (Po): Mouse monoclonal antibody obtained from Austexx (Austria), used 
at a concentration of 1:500 for ICC and IHC and 1:2500 for WB.
Protein zero (P0): Rabbit polyclonal antibody against rat Po was generated and 
characterized in the laboratory by Louise Morgan (Morgan et al., 1994). The antibody 
was used at a dilution of 1:1000 for ICC.
SlOOfi: Rabbit polyclonal antibody against cow S100p was purchased from Dako 
Immunoglobulins (Dakopatts, Copenhagen, Denmark) and used at a final dilution of 
1:1000 for IHC.
Sox2: Rabbit polyclonal antibody was purchased from Chemicon (CA, USA) and 
used at a concentration of 1:500 for ICC and IHC and 1:2500 for WB.
T24: T24 hybridoma cell line secreting antibodies recognizing mouse Thyl (pan- 
Thyl) was a gift from Dr L. Lopez and was used for negative immunopanning in 
order to purify mouse Schwann cell cultures.
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TuJl: Rabbit polyclonal antibody against (3-tubulin III was purchased from Covance 
(USA) and used at a final concentration of 1:5000 for IHC.
2.2.2 List of Secondary antibodies
Biotinylated anti-mouse Ig, streptavidin-Cy3 and streptavidin-FITC were 
purchased from Amersham International pic. Rhodamine-conjugated goat anti-mouse 
Ig was purchased from MP Biomedicals (Cappel). Cy3-conjugated donkey anti-rabbit 
Ig and Cy3-conjugated donkey anti-mouse IG were purchased from Jackson 
Immunoresearch Laboratories, Inc (USA). Goat anti-rabbit and mouse horse radish 
peroxidase-conjugated antibodies were obtained from Promega Inc. Anti-mouse and 
anti-rabbit Cy5-conjugated secondary antibodies were purchased them from 
Biological Detection Systems, Inc. Goat anti-mouse IgG (Fab specific) was purchased 
from Sigma.
2.3 Tissue culture techniques
2.3.1 Substratum coating of coverslips and dishes
Poly-D-lysine (PDL) or poly-L-lysine (PLL): Round 13mm glass coverslips were 
baked in an oven for 4 hours at 140°C and were coated with 20pg/ml PDL in ultra 
pure water (UPH2 O) or 20pg/ml PLL in UPH2O for 4 hours at room temperature (RT). 
Coverslips were then washed 3 times, for 15 minutes each time, in sterilised water and 
dried overnight in a class I tissue culture hood before being stored sterile and 
desiccated (in presence of silica gel) at RT.
Tissue culture dishes (35mm and 60mm) were coated with PDL (20pg/ml) or PLL 
(20pg/ml) for 4 hours at RT. The solution was removed and the dishes were air-dried 
without washing.
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Laminin: A 15pl drop of laminin, diluted in DMEM (20pg/ml) was placed centrally 
on each coverslip and incubated at 37°C for at least 30 minutes. Excess laminin 
solution was removed after incubation and cells were immediately plated 
Alternatively, laminin in DMEM (lOpg/ml) was added to dishes and left for 30 
minutes to lhour prior to plating of cells.
2.3.2 Medium components
Defined supplemented medium (DM): This medium is a modification of the medium 
of Bottenstein and Sato (1979). A 1:1 mixture of DMEM (containing 1000mg/l 
glucose) and Ham’s F12 medium was enhanced with bovine serum albumin 
(0.3mg/ml), putrescine (16pg/ml), transferrin (lOOpg/ml), thyroxine (400ng/ml), 
progesterone (60ng/ml), dexamethasone (38ng/ml), glutamine (ImM), penicillin (100 
U/ml) and streptomycin (100 U/ml), triiodothyronine (lO.lng/ml) and selenium 
(160ng/ml) and insulin (10‘6M). This medium is referred to as DM in the text.
DMEM: DMEM containing 1000mg/l glucose, pyridoxine and sodium pyruvate was 
used for Schwann cell cultures, whereas DMEM containing 4500mg/l glucose, 
pyridoxine and sodium pyruvate was used for HEK293 cell cultures. Both forms of 
DMEM were supplemented with penicillin (100 U/ml) and streptomycin (100 U/ml) 
before use.
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2.3.3 Cell cultures
2.3.3.1 Serum purified rat and mouse Schwann cells
Methods for purifying neonatal rat and mouse Schwann cells were based on 
methods by Brockes et al., (1979) and Stevens et al., (1998) respectively. Using 
aseptic techniques, the sciatic nerves and brachial plexuses of postnatal day 3 
Sprague-Dawley rats or post-natal day 2 (P2) ICR or C57BL/6 mice, killed by 
decapitation, were dissected out and placed in sterile L-15 medium on ice. The 
epineurial sheaths and any superfluous connective tissue were removed and the de­
sheathed nerves were transferred to a sterile 35mm tissue culture dish containing of 
0.25% trypsin and of 0.4% collagenase. They were incubated at 37°C, 5% CO2 and 
95% air for 35minutes, after which the nerves were triturated gently until fully 
dissociated (using first a blue 1ml and then a yellow 200pl Gilson pipette tip). Then 
the enzyme reaction was halted with the addition of 2-3ml of DMEM containing 10% 
FCS for rat cultures or 5% HS for mouse cultures. The cell suspension was transferred 
into a 15ml centrifuge tube and spun for 10 minutes at lOOOrpm and 4°C. Maintaining 
sterile conditions, the supernatant was removed using a suction pump and the pellet 
was resuspended in 2ml DMEM containing 10% FCS (rat) or 5% HS (mouse) and 
Ara C (10'5M). Ara C is an anti-mitotic and will kill contaminating fibroblasts that 
have been stimulated to divide by addition of the serum. For rat cultures the cell 
suspension was transferred onto a PDL and laminin coated tissue culture dish whereas 
a PLL/ laminin coated dish was used for mouse cultures. The cells were then 
incubated for at least 3 days at 37°C and 5%CC>2 until the majority of fibroblasts have 
been eliminated leaving highly pure cultures of Schwann cells.
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2.3.3.2 Immunopanning of Schwann cells
Purification of rat or mouse Schwann cells was also performed by reverse 
immunopanning using an antibody that recognises Thy 1.1, which is expressed on 
fibroblasts but not Schwann cells (Dong et al., 1999). Freshly isolated or serum- 
purified Schwann cells from Sprague-Dawley rats were placed in DM on a 90 mm 
Petri dish, coated with anti-mouse IgG and mouse anti-rat Thy 1.1 and incubated at 
37°C, 5% CO2 for 30 min. Every 10 min the cells were removed from the incubator 
and agitated by gentle shaking. The cell suspension obtained was devoid of almost all 
fibroblasts as they had bound to the Thy 1.1 specific antibodies coating the dish. The 
cells were then centrifuged at lOOOrpm for 10 min at 4°C and the resulting pellet was 
resuspended in the appropriate medium. For mouse Schwann cells, a 90 mm Petri dish 
was coated with anti-rat IgG and rat anti-mouse Thy 1.1.
2.3.3.3 Expanding Schwann cells
For western blot analysis it was necessary to expand rat or mouse Schwann cell 
cultures in order to extract sufficient quantities of protein. Schwann cells were 
previously serum-purified and immunopanned before being replated on several 
PDL/laminin or PLL/laminin coated dishes in medium containing DM, 0.5% FCS or 
HS, NRG-1 (lOng/ml) and 2pM forskolin. NRG-1 in the presence of low 
concentrations of forskolin is highly mitogenic for rat and mouse Schwann cells and 
induced them to proliferate until confluent. Cells were then placed in DM without 
mitogenic factors for 12 hours until experimental reagents were added.
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2.3.4 Adenoviral constructs and preparation
Adenoviruses expressing either full length Egr2, mutant Egr2 (S382R, D383Y) 
or the appropriate empty vector were obtained as a gift from Dr J. Milbrandt 
(Nagarajan et al., 2001) and these were made in the laboratory of Dr M. Ehrengruber 
(Ehregruber et al., 2000). Wild-type Egr2 (Chavrier et al., 1988) or mutant Egr2 
(S382R, D383Y) was inserted into the El regions of Ad5PacIsGFP to yield AdGFP 
Egr2 or AdGFP mutant Egr2. Ad5PacIsGFP was prepared by ligating an expression 
cassette, CMV-sGFP-SV40pA, into the Pacl site (in the E3 deletion) of Ad5PacI as 
described (Ehrengruber et al., 1998). The adenovirus expressing full length Egr2 is 
referred to as wild-type Egr2 in the text and its matched control adenovirus expressing 
the empty vector plasmid, is referred to as GFP control. Both viruses also express 
GFP after infection of cells.
The adenovirus expressing VP16-CREB, a fusion protein between Herpes Simplex 
Virus VP 16 (aa 363-490) and CREB (aa 88-341) (Barco et al., 2002) and GFP control 
adenovirus were a gift from Dr M.T. Filbin (Gao et al., 2004). The adenovirus was 
constructed using the Tet-Off system from Clontech and inserted by homologous 
recombination into pAdeasy-1 (He et al., 1998). The VP16-CREB adenovirus and its 
corresponding empty vector control both express GFP after infection.
The adenovirus expressing A-CREB (a dominant negative inhibitor of CREB formed 
by fusing an acidic amphiphatic extension onto the CREB leucine zipper domain) 
(Ahn et al., 1998) and control adenovirus were a gift from Dr J. Uney (Warburton et 
al., 2005). The adenoviruses were generated by cloning cDNAs for A-CREB  and 
EGFP, individually, into the multiple cloning site of the plasmid pXCXCMV 
(Harding et al., 1998). Recombinant E l deleted adenoviral constructs were then
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generated by homologous recombination in HEK 293 cells. The A-CREB adenovirus 
and its corresponding empty vector control both express GFP after infection.
The adenovirus expressing Cre recombinase was obtained as a gift from Dr A. 
Behrens and was made in the laboratory of Dr A. Berns (Akagi et al., 1997). The 
Hindlll fragment of PBS 185 containing the Cre recombinase open reading frame, 
under the control of the human CMV immediate early promoter and the 
metallothionein I polyadenylation signal was inserted into the H indlll site of 
pdElspIA. This was then co-transfected with pJM17 into 293 cells and adenovirus 
was obtained via plaque purification (Akagi et al., 1997).
Adenoviral supernatants were prepared and titred as described previously 
(Parkinson et al., 2001). Briefly, confluent HEK 293 cells were infected with 
adenovirus and once cells began to show cytopathic effects (rounding up and 
detachment from the culture dish, usually after 2 days) the cell supernatant was 
collected and purified with the vivapure AdenoPACK 500 (Sartorius AG, UK) 
according to manufacturer’s protocol. The viruses were then titred by infection of 
serum-purified Schwann cells with different volumes of virus. The volume which 
resulted in an infection rate of >95% (as seen by expression of GFP) and no 
cytopathic death was chosen. For western blotting, extracts were probed with an 
antibody to GFP, to ensure equal levels of infection between conditions. Please note 
that after each viral preparation, the amount of virus used was always titred.
2.3.4.1 Adenoviral infections
Expanded rat or mouse Schwann cells grown on PDL/laminin or PLL/laminin 
dishes and serum purified rat or mouse Schwann cells plated onto PDL/laminin or 
PLL/laminin coated coverslips (5000 cells/coverslip) were infected by adenoviral
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preparations in medium containing DM, 0.5% FCS or HS and 2pM forskolin. After 
24 hours the medium was changed to DM and 0.5% FCS or HS. Infected cultures 
were treated in various ways and fixed at different times for ICC or proteins were 
extracted for analysis by western blot.
2.3.5 Retroviral constructs and preparation
Using PCR, the cDNA for wild-type Krox-20 was engineered with a myc tag 
(Evan et al., 1985) at the 5’ end. This was cloned into the retroviral vector 
pBABEpuro (Morgenstem and Land, 1990) and the GP + E ecotropic packaging cell 
line (Morgenstem and Land, 1990), grown in DMEM/10%FCS, was then transfected 
with lOug of pBABEpuro empty vector or pBABEpuro wild-type Krox-20. Stably 
transfected clones were selected using puromycin (2.5pg/ml), pooled and expanded.
2.3.5.1 Retroviral infections
For retroviral infections, GP + E cells were then transferred to puromycin free 
medium and after 48 hours the supernatant containing the virus was collected, filtered 
and polybrene polycation was added (8pg/ml). Rat Schwann cell cultures that were 
70% confluent and thus actively proliferating were treated with the retroviral 
supernatant, since the retrovirus will only infect proliferating cells. After 4 hours, 
three quarters of the viral supernatant was removed and replaced with the same 
volume of DMEM, 10% FCS and 4pM Forskolin (expansion medium). The following 
day the expansion medium was changed and after a further 24 hours cells were spilt 
and selected in expansion medium containing puromycin (lp,g/ml). Pools of Schwann 
cells with strong expression of the retrovims were used for experiments.
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2.3.6 Myelin differentiation Assays
cAMP/NRGl induction experiments in mouse Schwann cells: Serum-purified mouse 
Schwann cells were plated on PLL/laminin coated coverslips (5000 cells/coverslip) in 
medium containing DM treated with NRG1 (20ng/ml), dbcAMP (ImM), dbcAMP 
(ImM) and NRG1 (20ng/ml) or left unstimulated (Control) for between 48 and 120 
hours before fixation and analysis by ICC.
2.3.7 Demyelination Assay
Nerve segment demyelination assay: I removed equal 6mm length segments from the 
tibial nerve measured from the sciatic notch from adult male mice (2-4 months old) 
and placed them floating in a 35mm tissue culture dish containing DMEM and 5%HS 
at 37°C for 6 days. Nerves were then fixed and processed for EM analysis (see section 
2.12.1). Only the middle 2mm of each nerve segment was analysed in order to 
standardise the observations between conditions. For details on quantification of this 
experiment see section 2.14.
Dissociated cell demyelination assay: Sciatic nerves were dissected from P8 animals, 
dissociated in trypsin and collagense and then plated on laminin coated coverslips, at 
a concentration of a 1000 cells per coverslip, in DM, 0.5% HS and AraC (10'5M). 
Cells were cultured for a maximum of 10 days with half the medium replaced every 3 
days. At 3 hours, 3, 5, 7 and 10 days after plating cells were then fixed and analysed 
by ICC. Experiments were quantified by sampling 15 fields across each coverslip and 
counting the total number of Po or M BP positive cells, in each field, for each time 
point. Counts were then expressed as a percentage of the counts at the 3 hour time 
point. For upregulation of non-myelin genes, like LI, N-cadherin and p75NTR,
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percentages of positive Schwann cells, recognised by SlOOp immunolabelling, were 
recorded over 15 fields per coverslip for each time point. Two coverslips were 
included for each time point and experiments were repeated a minimum of three 
times.
2.3.8 In vitro BrdU proliferation assay
Bromodeoxyuridine (BrdU), is a uridine derivative that can be incorporated 
specifically into DNA in the place of thymidine when cells undergo DNA synthesis 
(during the S-phase of the cell cycle). Anti-BrdU immunolabelling can then be used to 
identify cells that undergo DNA synthesis.
Mutant Egr2 proliferation assay: Serum-purified rat Schwann cells were infected as 
previously described (Parkinson et al., 2001) with GFP control, Egr2 wild type or 
mutant Egr2 adenoviruses, in DM and 0.5% FCS. Cells were, again, placed in fresh 
medium 24 hours after infection and NRG-1 (20ng/ml) was added after a further 22 
hours. BrdU (10'5M) was added for the last 20 hours of the experiment and cells were 
fixed at 72 hours after infection for analysis by ICC.
NRG-1 proliferation assays: c-junm or c-jun-null mouse Schwann cells (see section 
4.2.6) were plated on PLL/laminin coated coverslips (5000 cells/coverslip) in medium 
containing DM treated with NRG-1 (20ng/ml). BrdU (10'5M) was added for the last 
20 hours of the experiment and cells were fixed after 72 hours of growth factor 
addition for analysis by ICC.
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Cyclic AM P/NRG-1 proliferation assays: Serum-purified mouse Schwann cells were 
plated on PLL/laminin coated coverslips (5000 cells/coverslip) in medium containing 
DM and treated with NRG-1 (20ng/ml) and varying concentrations of dbcAMP 
(lpM-2mM). BrdU (10‘5M) was added for the last 20 hours of the experiment and 
cells were fixed after 72 hours of growth factor addition for analysis by ICC. Results 
shown are pooled from at least three individual experiments.
In order to quantify Schwann cell proliferation, counts were performed, 
recording the number of GFP expressing or hoechst labelled cells that incorporated 
BrdU and then converting this to a percentage. All Schwann cell cultures were greater 
than 95% pure (Schwann cells were identified by a combination of S I00(3 
immunolabelling, the presence of cigar-shaped nuclei and a bi- or tri-polar shape, see 
lessen et al., 1994) and the few fibroblasts in each culture were easily identifiable due 
to their much larger overall size, larger nucleus and flattened shape.
2.3.9 In vitro Cell Death Assay
Immunopanned Schwann cells from a newborn rat were infected as previously 
described (Parkinson et al., 2001) with GFP control, GFP/wild-type Egr2 or 
GFP/mutant Egr2 (S382R, D383Y) adenoviruses, in DM. Cells were placed into fresh 
medium after 24 hours. After 48 hours, cells were then either fixed (time zero 
control), or treated with or without TGFp (5ng/ml) for a further 24 hours and then 
fixed for immunocytochemistry. Results shown are pooled from three individual 
experiments. Cell survival in this assay was measured by recording the number of 
GFP positive Schwann cells at the end of the experiment as a percentage of the 
number of GFP positive Schwann cells that had been plated successfully at the
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beginning of the experiment. Dying cells were identified by Hoechst nuclear 
labelling, as described previously (Parkinson et al., 2001).
2.3.10 Inhibitor experiments
Different inhibitors were used to block specific pathways in our culture system 
as mentioned in the text:
U0126: MEK1/2 blocker (prevents phosphorylation and activation of the MEK1/2 
downstream targets ERK 1/2), obtained from Calbiochem (Nottingham, UK) and used 
at 20pM (Maurel and Salzer, 2000; Harrisingh et al., 2004).
SP600125: a JNK1/2 blocker, obtained from Affiniti Research Products, Ltd and used 
at 30pM (Parkinson et al., 2004).
DJNKJ peptide: a JNK1/2 phosphorylation blocker, obtained as a gift from Dr. H. 
Mehmet (Imperial College London, UK) (Borsello et al., 2003) and used at lOpM 
(Parkinson et al., 2004).
H89: a PKA blocker, obtained from Sigma (UK) and used at lpM  (Kim et al., 1997). 
LY294002: a blocker of the catalytic activity of phosphatidylinositol 3-kinase (PI3-K) 
obtained from Calbiochem (Nottingham, UK) and used at lOpM (Maurel and Salzer, 
2000).
2.4 Molecular Biology Techniques
2.4.1 Western Blotting
Frozen nerve samples or cell lysates were transferred into either a triton based 
lysis buffer (25mM Hepes pH 7.5, 0.1M NaCl, 1% Triton X-100 and proteinase and 
phosphatase inhibitors) or a SDS lysis buffer (25mM Tris-HCL pH 7.4, 95mM NaCl, 
lOmM EDTA, 2% SDS and proteinase and phosphatase inhibitors) and homogenized
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with micropestle homogenizers (Fisher Scientific UK). Proteinase inhibitor cocktail: 
leupeptin (lOpg/ml) and soya bean trypsin inhibitor (10fxg/ml) from Sigma (UK), cx2- 
macroglobulin (O.lU/ml) from Roche Diagnostics (Germany) and ImM 
phenylmethanesulphonyylfluoride (PMSF). Phosphatase inhibitor cocktail: okadaic 
acid (lpM ) from Sigma (UK), sodium fluoride (50mM), sodium orthovanadate 
(ImM), EDTA (5mM), |3-glycerophosphate (10.8mg/ml) and para- 
nitrophenylphosphate (7.4mg/ml). Before protein estimation, SDS extracted samples 
were boiled and centrifuged. Protein concentration was measured by colorimetry, 
using the Biorad protein assay kit (Biorad, USA), according to the manufacturer’s 
instructions. Samples were then treated with 1/5 volume of 5X Laemmli loading 
buffer and stored at -80°C before being separated by SDS-PAGE. Between 5pg and 
50p,g of protein samples were loaded and separated by SDS-PAGE, under denaturing 
conditions, with a mini Protean II gel electrophoresis apparatus (Biorad, USA) 
containing running buffer. Kaleidoscope pre-stained standards molecular weight 
(Biorad, USA) was run alongside samples to enable identification of band sizes. 
Separated proteins were then transferred to a nitrocellulose membrane, Hybond-N, in 
a mini gel tank (Biorad, USA) containing transfer buffer at 4°C. The composition of 
all the reagents used is found in appendix I.
The membrane was incubated in 5% fat free milk powder in tris-buffered saline 
(TBS) for 2hours, in order to block non-specific binding sites. Then, primary 
antibodies were incubated in 5% fat free milk powder in TBS overnight at 4°C on a 
slow rotator (Gallenkamp, UK). Membranes were washed 3X 5 minutes at RT and 
subsequently incubated with horse radish peroxidase (HRP) -conjugated secondary 
antibody diluted in TBS for 1 hour at RT and again washed in TBS 3X 5 minutes. 
Membranes were then treated with a mix of homemade ECL 1 and 2
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chemiluminescent reagents. ECL1 solution was made from 2.5mM luminol, 0.4mM 
coumaric acid, 0.1M Tris (pH 8.5) in distilled water. ECL2 solution was made using 
0.1M Tris (pH 8.5), 0.02% hydrogen peroxide in distilled water. Both solutions were 
kept at 4°C in dark conditions and mixed 1.1 just prior to use. Specific protein 
complexes were then revealed by placing membranes in autoradiography cassettes 
(Appligene, USA) and developed by brief exposure (5 seconds to 10 minutes) to 
Kodak BioMax Mr-1 film in an X-Ograph Compact X2 automatic developer (UK).
2.4.2 Genotyping
DNA extraction. 5mm of tail samples were digested at 55°C overnight in lysis buffer 
(0.01M Tris pH 8.0, 0.05M EDTA pH 8.0, 0.04M NaCl and 1% SDS in UP H20) 
containing 20ng/ml Proteinase K (Sigma, UK). DNA was obtained from this mix 
using a phenol-choloform (Fluka, UK) extraction. The DNA was then precipitated 
using 100% ethanol, washed in 70% ethanol, air dried and then dissolved in UP H20 
in order to use for PCR.
Genotyping by semi-quantitative PCR : PCR reactions were set up for each sample 
using 100-200ng of DNA and run at specific conditions for each primer set and 
performed in a MWG Biothec Primus96 Thermal Cycler or in a Perkin Elmer Gene 
Amp 2400 thermocycler. Typically 50pl reaction volumes containing 20mM Tris- 
HC1, pH 8.4, 50mM KC1, 1.5mM MgCl2, 0.2mM dNTPs, 50pmol of each primer and
2.5 units of Taq DNA-polymerase were used. The reaction conditions, sequence of 
the primers and band sizes generated can be found in the appendix II. Upon 
completion of PCR, one tenth volume of lOx loading buffer (0.5M EDTA, pH 7.5, 
10% SDS, 50% glycerol and 0.25% bromophenol blue) was added to each PCR
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sample and lOpl of each reaction was electrophoresed on 2% agarose gels including 
ethidium bromide in lx  Tris Acetate EDTA (TAE) buffer in a Horizon 58 gel 
apparatus (BRL-Life Technologies, Gaithersburg, MD). In order to determine band 
sizes, samples were run alongside lOpl of lkb DNA ladder diluted in DNA loading 
buffer.
2.4.3 In situ Hybridisation
A digoxigenin-labelled cDNA probe was used to detect Po mRNA induced by 
cyclic AMP and NRG1 in mouse Schwann cell cultures. These cells were fixed in 4% 
paraformaldehyde and washed 3X in RNAse-free PBS (IX). They were then 
incubated with hybridisation buffer containing 2.5ng/ml of the Po probe (Lee et al.,
1997) and left overnight at 65°C in a humidified box containing 2X SSC. The next 
day, the coverslips were rinsed with IX SSC at RT, after which they were washed 
with IX SSC at 65°C for lhour. They were then washed again with IX SSC for 5 min 
at RT, after which they were incubated with buffer B1 containing 10% normal goat 
serum (Sigma, UK) for at least 1 hour. They were incubated overnight with anti-DIG 
antibody (roche diagnostics, USA) overnight at 4°C. The next day, the coverslips 
were washed with buffer B1 3X for 5 min each, after which they were treated with 
buffer B3 for 5 min. Then buffer B4 was added to the coverslips and the plates 
wrapped in aluminium foil and developed according to manufacturer’s protocol. The 
cells were then mounted in aquamount (VWR, UK) and allowed to dry. The 
composition of all reagents used can be found in appendix III.
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2.5 Animals used
c-Jun ‘flo xed ’ mice. Transgenic mice in which loxP sites are present in the 5’ 
untranslated region (UTR) of c-jun and in the 3’ flanking sequence 2.5 kb 
downstream of the translation stop codon. Breeding with a Cre transgenic mouse 
leads to excision of the entire c-jun gene (Behrens et al., 2002). A schematic 
representation of the floxed c-jun allele and deleted c-jun allele, after Cre mediated 
excision, is shown in Figure 4.2, A (Chapter 4). These animals were kindly provided 
by Dr A. Behrens (Cancer Research UK).
PO-Cre mice. Transgenic mice expressing Cre-recombinase under a transgene driven 
by the Po promoter. Strong PO-Cre activity was only detected in the peripheral nerve, 
starting from around E l3.5, with slight activity in the occipital lobe of the cerebral 
cortex, Purkinje cell layer of the cerebellum and in the heart (Feltri et al., 1999a, 
1999b, 2002). These mice were kindly provided by Dr L. Wrabetz and Dr M.L. Feltri 
(San Raffaelle Institute, Italy).
Krox-20 mice: Knockout mice in which a null allele is created in the Krox-20 gene by 
an in-frame insertion of the E. coli lacZ gene (Schneider-Maunoury et al., 1993). 
Heterozygous animals were kindly provided by Dr P. Chamay (Ecole Normale 
Superieur, France).
WLDS mice: C57BL/601aHsd-JF7ds mice carry a spontaneous mutation resulting in a 
85Kb tandem triplication on chromosome 4 (Lyon et al., 1993; Coleman et al., 1998). 
Male animals (2 months old) were purchased from Harlan (UK).
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C57BL/6 mice: Male mice (2 months old) were purchased from Harlan (UK). These 
mice were used as controls for C51YSLI60\?&{s&-Wl(f mice.
ICR mice. Breeding pairs were purchased from Charles River (UK) to generate post­
natal pups.
Sprague-Daw ley rats: Post-natal pups were obtained from the Biological services 
Unit at University College London.
2.6 Peripheral nerve injury experiments
All the experiments in which animals were involved were performed following 
the UK Home Office guidelines.
Short-term sciatic nerve transections: Adult transgenic mice (2-4 months old) were 
anaesthetised with either 2% halothane or 2% isofluorane, and the right sciatic nerve 
was exposed and cut at the level of the sciatic notch. A piece of the proximal stump 
was removed and the remaining proximal stump was diverted to limit the possibility 
of axonal regeneration into the degenerating distal stump. Wounds were sutured with 
3/0 black polyamide monofilament, mersilk (Johnson&Johnson, USA) and skin was 
sealed using vetinerary autoclips (VET-TECH, UK). Three, five or seven days 
following transection, the animals were culled and both the distal stump of the right, 
transected sciatic nerve and the contralateral control nerve were excised. Tissue was 
then processed for WB, IHC and EM (see sections 2.4.1, 2.10 and 2.13.1 
respectively). After IHC and EM processing, the distal stump was cut into 3 segments
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before analysis (0-2mm distal to the cut site, known as the injury region; 2-4mm distal 
to the cut site and 4-6mm distal to the cut site).
Long-term sciatic nerve transections: Adult transgenic mice (2-4 months old) were 
anaesthetised with either 2% halothane or 2% isofluorane, and the right sciatic nerve 
was exposed and cut at mid thigh level. The proximal stump was then ligated and 
sutured into the gluteal muscle using 8/0 black polyamide monofilament, mersilk 
(Johnson&Johnson, USA) to prevent axonal regeneration into the degenerating distal 
stump. Wounds were sutured with 3/0 black polyamide monofilament, mersilk 
(Johnson&Johnson, USA) and skin was sealed using vetinerary autoclips (VET- 
TECH, UK). Seven days after the surgery, skin autoclips were removed. Four weeks 
following transection, the animals were culled and both the distal stump of the right, 
transected sciatic nerve and the contralateral control nerve were excised. Tissue was 
then processed for osmium staining or EM (see sections 2.9 and 2.13.1 respectively).
Sciatic nerve crushes: Adult transgenic mice (2-4 months old) were anaesthetised 
with either 2% halothane or 2% isofluorane, and the right sciatic nerve was exposed 
and crushed using watchmaker’s forceps three times for 10 seconds at the level of the 
sciatic notch. Wounds were sutured with 3/0 black polyamide monofilament, mersilk 
(Johnson & Johnson, USA) and skin was sealed using vetinerary autoclips (VET- 
TECH, UK). Seven days after the surgery, skin autoclips were removed. Ten weeks 
following nerve crush, some animals were anaesthetised and perfused (see section 
2.7). Following this, both right and left dorsal and ventral roots from spinal level L5 
and a 2 centimeters length of the right sciatic and tibial nerve distal to the sciatic
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notch (including crush site) and of the contralateral control nerve were excised. Tissue 
was then processed for EM (see section 2.13 .1).
2.7 Mouse perfusion
For 10 week cut and crush experiments, transgenic mice were terminally 
anaesthetised with a 0.2ml intraperitoneal injection of sodium pentobarbital 
(conc.5pg/ml) and intracardially perfused with 75-100ml of ice cold 4% PF over a 5 
minute period using a peristaltic pump at 4rpm. On completion, sciatic nerves and L5 
dorsal and ventral roots were removed for histology (see section 2.13.1).
2.8 In vivo BrdU proliferation assay
Schwann cell proliferation after nerve cut: 2-4month old mice that had their right 
sciatic nerve transected at the sciatic notch. Wounds were sutured and the mice were 
allowed to recover. Five days after the surgery, these mice were injected 
intraperitoneally with lOOpg BrdU solution per g of body weight and allowed to rest 
without disturbance for two hours. Both the injured and the contralateral uninjured 
sciatic nerves were dissected out and fixed in -20°C methanol for 2 hours and then 
placed in 4% PF overnight. Nerves were then washed in IX PBS for 3X 15 minutes 
before being placed in 20% sucrose overnight. The next day the tissues were 
embedded in OCT compound and stored at -70°C. Frozen sections (10pm thickness) 
were cut using a cryostat (Reichert-Jung, Germany) and double IHC was performed 
on sections for BrdU and SlOOp (Schwann cell specific marker) (see section 2.10).
To quantify the number of BrdU positive Schwann cells in uninjured and 
injured nerves, 5 sample areas (40,000pm2) on at least 3 sections, 50pm apart were 
counted using average confocal projections (see section 2.13.2). The total area
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counted was then calculated and the total number of BrdU positive cells was 
expressed per 1mm2 of nerve. At least 4 separate nerves were counted per condition.
2.9 Osmium staining of sciatic nerves
Sciatic nerves were embedded in OCT compound in rubber coffin moulds and 
stored at -80°C. Sections of 10pm thickness were cut using a cryostat (Reichert-Jung, 
Germany) and collected on Superfrost Plus microscope slides. Before staining, 
sections were air-dried for 30 minutes and then fixed in 4% PF for 10 minutes, 
washed twice with IX PBS and then incubated with 2% osmium solution in the dark 
overnight at RT. The next day the sections were drained and washed 3 times in PBS 
and mounted using Citifluor antifade mountant and sealed with nail varnish.
2.10 Immunohistochemistry (IHC)
Sciatic nerves were embedded in OCT compound in rubber coffin moulds and 
stored at -80°C. Sections of 10pm thickness were cut using a cryostat (Reichert-Jung, 
Germany) and collected on Superfrost Plus microscope slides. Before 
immunolabelling, sections were air-dried for 30 minutes and then treated with 
different fixatives and blocking solutions depending on the primary antibody used. 
For N-cadherin IHC , sections were fixed in 4% PF for 10 minutes, blocked in 0.1% 
triton X-100, 1% BSA in PBS for 1 hour at RT, then primary antibody, diluted in 
blocking solution, was applied o/n at 4°C.
For L I (324) IHC, sections were fixed in 4% PF for 10 minutes, then primary 
antibody was applied o/n at 4°C. For p75NTR and NCAM IHC, sections were fixed in 
2% PF for 5 minutes, then primary antibodies, diluted in MEM-Hepes 10% calf 
serum, were applied o/n at 4°C.
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For Krox-20 IHC, sections were fixed in 4% PF for 10 minutes, blocked in 0.5% 
triton X-100 in antibody diluting solution (ADS, PBS containing 10% calf serum, 
0.1% lysine and 0.02% sodium azide) for 30 minutes at RT and then primary
antibodies, diluted in blocking solution, were applied o/n at 4°C.
For polyclonal P 0 IHC, sections were fixed in 2M HC1 for 10 minutes, neutralized 
with 0 .1M sodium borate for 7 minutes, blocked with ADS for 2 hours at RT and then 
primary antibody, diluted in ADS, was applied o/n at 4°C.
For polyclonal c-Jun IHC , sections were fixed in 4% PF for 10 minutes, blocked in 
0.2% triton X-100 in ADS for 30 minutes at RT and then primary antibodies, diluted 
in blocking solution, were applied o/n at 4°C.
For TnJI IHC, sections were fixed in 4% PF for 10 minutes and then primary
antibody, diluted in ADS was applied o/n at 4°C.
For BrdU IHC, sections were fixed in 2M HC1 for 20 minutes at 50°C, neutralized 
with 0.1M sodium borate for 7 minutes and primary antibody, diluted in 0.1% triton 
X-100 in PBS, was applied o/n at 4°C.
For SlOOfl/BrdU IHC, sections were treated with -20°C methanol for 10 minutes, 
permeabilised with 0.2% triton X-100 in PBS for 30 minutes at RT, blocked in 3% 
bovine gelatin (Sigma, UK) in PBS for 30 minutes at 37°C and then incubated with 
primary polyclonal antibody to S100p, diluted in ADS was applied o/n at 4°C. The 
next day sections were incubated with secondary antibody for 30 minutes at RT, 
treated with -20°C methanol for 10 minutes, treated with 2M HC1 for 20 minutes at 
50°C, neutralized with 0.1M sodium borate for 7 minutes and primary antibody, 
diluted in 0.1% triton X-100 in PBS, was applied o/n at 4°C.
115
For the dilutions of different primary and secondary antibodies, please see section 2.2. 
All secondary antibodies were diluted in ADS and applied for 30 minutes at RT. 
Between each step, slides were washed 3 times with PBS for 5 minutes each and 
slides were mounted using Citifluor antifade mountant and sealed with nail varnish. In 
order to ensure that secondary antibodies did not cause any non-specific background 
staining, primary antibodies were excluded from a single sample in each experiment.
2.11 Immunocytochemistry (ICC)
For ICC, cells were fixed in different fixatives and blocked in different 
solutions depending on the primary antibody used.
For monoclonal c-Jun, Sox-2, Krox-20, p27, cdk2, /3-galactosidase, Cyclin D l and  
Cre-recombinase ICC , cells were fixed in 4% PF for 10 minutes, blocked in 0.2% 
triton X-100 in ADS for 30 minutes at RT and then primary antibodies, diluted in 
blocking solution, were applied o/n at 4°C.
For L-periaxin ICC, cells were were fixed in 4% PF for 10 minutes, blocked in 0.2% 
triton X-100 in ADS for 30 minutes at RT and then primary antibody, diluted in ADS, 
was applied o/n at 4°C.
For MBP ICC, cells were fixed in 2% PF for 10 minutes, permeabilised in ice cold 
methanol for 10 minutes, treated with 0.2% triton X-100 in ADS for 30 mins at RT 
and then primary antibody, diluted in ADS, was applied for 2 hours at RT.
For monoclonal PoICC, cells were fixed in 4% PF for 10 minutes, permeabilised in 
ice cold methanol for 10 minutes, blocked in ADS for 30 minutes and then primary 
antibody, diluted in ADS, was applied o/n at 4°C.
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For polyclonal P 0 ICC, cells were fixed in 2M HC1 for 10 minutes, neutralized in 
0.1M sodium borate for 7 minutes, blocked in ADS for 2 hours and then primary 
antibody, diluted in ADS, was applied o/n at 4°C.
For BrdU ICC, cells were fixed in 2M HC1 for 10 minutes, neutralized in 0.1M 
sodium borate for 7 minutes and then primary antibody, diluted in 0.1% triton X-100 
in PBS, was applied for 1 hour at RT.
For N-cadherin ICC, cells were fixed in 4% PF for 10 minutes, blocked in 0.1% triton 
X-100, 1% BSA in PBS for 1 hour at RT, then primary antibody, diluted in blocking 
solution, was applied o/n at 4°C.
For L I (324) ICC, cells were fixed in 4% PF for 10 minutes, then primary antibody 
was applied o/n at 4°C.
For L I (ASCS4), cells were fixed in 2% PF for 5 minutes, then primary antibody, 
diluted in MEM-Hepes 10% calf serum, was applied for 1 hour at RT.
For NCAM and p75NTR ICC, cells were fixed in 2% PF for 5 minutes, then primary 
antibody, diluted in MEM-Hepes 10% calf serum, was applied o/n at 4°C.
For 0 4  and Gal-C, primary antibodies were added to unfixed cells for 1 hr and then 
incubated with relevant secondary antibodies, after which they were post-fixed with 
4% PF for 10 minutes.
S100f3ICC was done in conjunction with MBP, N-cadherin, L I (324) and p75NTR 
ICC. In the case of MBP ICC, primary antibodies were added at the same time, in 
ADS o/n at 4°C. For all other labelling, S I00(3ICC was carried out after N-cadherin, 
L I (324) and p75NTR ICC. The cells were post fixed in 4% PF for 10 minutes, 
permeabilised with ice cold methanol for 10 minutes, blocked with 0.2% triton X-100 
for 30 minutes and primary antibodies, diluted in the blocking solution, were applied 
o/n at 4°C.
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All secondary antibodies were diluted in ADS and applied for 30 minutes at RT. 
For LI (ASCS4) a three layer system was employed, using a biotinylated secondary 
antibody, applied for 30 minutes at RT and a tertiary antibody to strepavidin, applied 
for 15 minutes at RT. Both antibodies were diluted in ADS. Between each step, cells 
were washed 6 times with PBS and coverslips were mounted using Citifluor antifade 
mountant and sealed with nail varnish. In order to ensure that secondary antibodies 
did not cause any non-specific background staining, primary antibodies were 
excluded from a single sample in each experiment.
2.12 In vivo cell death assay
Apoptotic cells were identified by in situ labeling of DNA fragmentation, using 
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling 
(TUNEL). For TUNEL labelling, sections were fixed in 4% PF for 10 minutes, treated 
with permeabilisation solution (0.1% triton X-100, 0.1% Na citrate in PBS) for 2 
minutes at 4°C, incubated with 50pl reaction mix (5pi TUNEL enzyme and 45pi 
TUNEL mix) for 1 hour at 37°C in dark and then stained with hoechst in ADS for 5 
minutes at RT. For positive controls sections were incubated with DNase I (Sigma, 
UK) (30U/ml in 50mM Tris-HCL, pH 7.5, lmg/ml BSA) for 10 minutes at RT prior 
to incubation with TUNEL mix. A negative control was also included which involved 
incubating sections with TUNEL mix without enzyme.
To quantify the number of TUNEL positive cells in uninjured and injured 
nerves, 5 sample areas (40,000pm2) on at least 3 sections, 50pm apart were counted 
(see section 2.12.2). The total area counted was then calculated and the total number 
of TUNEL positive cells was expressed per 1mm2 of nerve. At least 4 separate nerves 
were counted per condition.
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2.13 Microscopy
2.13.1 Electron Microscopy
The Injured sciatic nerve, contralateral control nerve and L5 dorsal and ventral 
roots from mutant mice were fixed in situ for 15 minutes, using freshly prepared 2% 
glutaraldehyde in 0.1M sodium phosphate buffer, pH 7.4. Nerves were then dissected 
out from the animals and placed in fixative overnight at 4°C. The next day, the tissue 
was washed three times for 15 minutes in 0.1M phosphate buffer, pH 7.4 and then 
stained with 1% osmium tetroxide in 0.2M phosphate buffer for 1.5 hours. The 
samples were then washed twice, for 15 minutes, in UPH2 O before being dehydrated 
as follows; 25% ethanol for 5 minutes; 50% ethanol for 5 minutes; 70% ethanol for 5 
minutes; 90% ethanol for 10 minutes; 100% ethanol, 4X 10 minutes; propylene oxide, 
3X 10 minutes. The nerves were then incubated in a 1:1 mixture of propylene oxide 
and resin (12g agar resin, 8g DDSA, 5g MNA and 16 drops of BDMA) for 1 hour, 
after which, nerves were placed in resin alone overnight at RT. The following 
morning, the resin was replaced with fresh resin and 8 hours after this tissue samples 
were placed in rubber coffin moulds containing resin and thermo-cured at 65°C 
overnight. Semi-thin and ultra-thin sections were both cut using an Ultracut E 
ultramicrotome (Leica, Germany). Handmade glass knives were used to cut semi-thin 
sections, which were collected on microscope slides and then stained with 0.1% 
toluidine blue in ethanol. Ultra-thin sections were cut by Mr M. Turmaine 
(Department of cell and developmental biology, Universty College London) using a 
diamond knife (Diatome, USA) and collected on copper grids (Agar scientific) or 
films (made by M. Turmaine). Sections were stained for 15 minutes in lead citrate 
solution, washed in UPH2 O, dried and viewed using a Jeol lOpO electron microscope 
(Japan).
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2.13.2 Fluorescent microscopy
Immunofluorescent cells or sections were visualised using either a Nikon 
Optiphot-2 or a Nikon Eclipse E800 fluorescent microscope. Images were captured 
using a digital camera (model: DXM1200, Nikon) and ACT-1 acquisition software 
(Nikon). Confocal microscopy was performed using a Leica DMRE fluorescence 
microscope with a SP1 confocal head and Leica confocal software. The average 
confocal projection of 15 sections over a distance of 10pm was used in all 
experiments. All images were imported into Adobe Photoshop version 8.0.
2.14 Quantification of observations in semithin and ultrathin sections
Thickness o f  myelin sheath (G-ratio): Between 15 and 20 photographs were taken of 
tranverse ultrathin sections of the tibial nerve at the mid-thigh level (5mm from sciatic 
notch) in control and experimental conditions at x2500 magnification. Images were 
imported into Image J (NIH, USA) in order to measure the axon diameter and 
diameter of the axon plus myelin sheath. Using Microsoft Excel, from these 
measurements the g-ratio for each myelinated fibre (axon diameter divided by 
diameter of the axon and myelin sheath) was calculated.
Numbers o f  myelinated axons in the uninjured adult mouse and after nerve crush: 
Photographs of semithin sections of the tibial nerve stained with toluidine blue were 
taken at x 100 magnification. Images were imported into Photoshop, a montage of the 
whole nerve was made and the total number of myelinated axons in the tibial nerve 
(5mm distal to the sciatic notch) was made.
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Numbers o f  intact myelin sheaths after nerve cut: Ultrathin sections of samples were 
cut and placed on copper grids and viewed by EM. Counts of intact compact myelin 
sheaths with either a collapsed or swollen axon were made for every complete grid 
square (64pm2) for the entire tibial nerve at x2500 magnification for 3 (1mm from 
sciatic notch), 5 and 7 (5mm from sciatic notch) days after sciatic nerve transection. 
The total number of sheaths counted and the total area sampled were then calculated. 
The area of the nerve was then measured by importing a x l50  magnification photo of 
the tibial nerve into Image J (NIH, USA). Using this information the total number of 
intact myelin sheaths could be calculated for the entire tibial nerve.
Numbers o f  Remak fibres and unmyelinated axons in the adult mouse sciatic nerve 
and after nerve crush: Ultrathin sections of samples were cut and placed on copper 
grids and viewed by EM. Counts of Remak fibres and number of axons per Remak 
fibre were made for every complete grid square (64pm2) for the entire tibial nerve 
(5mm distal to the sciatic notch) at x2500 magnification. The total number of Remak 
fibres and unmyelinated axons counted and the total area sampled was then 
calculated. The area of the nerve was then measured by importing a xl50 
magnification photo of the tibial nerve into Image J (NIH, USA). Using this 
information the total number of Remak fibres and unmyelinated axons could be 
calculated for the entire tibial nerve.
Numbers o f  Schwann cell nuclei: Ultrathin sections of samples were cut and placed on 
copper grids and viewed by EM. Counts of Schwann cell nuclei (identified by nuclei 
containing peripheral heterochromatin within a cell containing a basal lamina, 
macrophages, fibroblasts, mast cells and endothelial cells were all identifiable and
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discounted) were made for every complete grid square (64pm2) for the entire tibial 
nerve (5mm distal to sciatic notch) at x2500 magnification, 4 and 10 weeks after 
sciatic nerve transection. The total number of Schwann cell nuclei counted and the 
total area sampled were then calculated. The area of the nerve was then measured by 
importing a xl50 magnification photo of the tibial nerve into Image J (NIH, USA). 
Using this information the total number of Schwann cell nuclei could be calculated 
for the entire tibial nerve.
Numbers o f  myelinated axons in the dorsal and ventral roots: Photographs of 
semithin sections of the right and left L5 dorsal and ventral roots stained with 
Toluidine Blue were taken at xlOO magnification. Images were imported into 
Photoshop, a montage of the each whole root was made and the total number of 
myelinated axons was counted.
2.15 Functional testing for animal regeneration experiments
All the experiments in which animals were involved were performed following 
the UK Home Office guidelines.
The presence of a toe-spreading reflex was recorded after mice were lifted 
gently by the tail (Gutmann et al., 1942; Siconolfi and Seeds, 2001). Mice 
demonstrating full extension of the hind limb and full extension and abduction of all 
five toes so that clear space can be seen between each toe were given a toe-spreading 
reflex score of 2. Whereas, mice showing a partial toe spreading reflex, such as 
improper hind limb extension or only abduction and extension of some but not all five 
toes were given a toe-spreading reflex score of 1. Mice showing no abduction of all 5 
toes, in response to being lifted by their tail, were given a score of 0.
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Recovery of pressure and pain sensitivity was tested on mice, by pinching the 
most distal part of the lateral three toes, which derive sensation from the sciatic nerve, 
on both uninjured and injured limbs, with a number 5 forceps. Hind limb withdrawal 
and/or vocalization were recorded as positive responses, demonstrating functional 
sensory regeneration after injury (Siconolfi and Seeds, 2001).
2.16 Statistical analysis
All data are presented as arithmetic mean ± standard deviation (SD). Unless 
otherwise stated (either in the main text or figure legends) statistical significance was 
estimated by the Student’s t test using Microsoft Excel program (Microsoft UK, UK). 
Other statistical tests, including one-way and two-way analysis of variance (ANOVA) 
and the non-parametric Mann-Whitney U test were performed using the software 
package Prism version 5 (GraphPad).
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CHAPTER 3: P-neuregulin-1 and cyclic-AMP synergise to induce 
myelin differentiation in mouse Schwann cells.
3.1 INTRODUCTION
The generation of myelinating Schwann cells from immature Schwann cells 
appears to be controlled from signals from the axon (lessen and Mirsky, 2005; see 
Chapter 1). One axonally derived molecule that has shown to be important in 
regulating the process of myelination in Schwann cells is NRG1 (Nave and Salzer, 
2006; see Chapter 1). However, cultured Schwann cells are not induced to express 
myelin genes by exogenously applied NRG1, in either a soluble or a membrane bound 
form, and instead proliferate, suggesting that other signals are likely to play a role in 
myelin differentiation, potentially modulating NRG1 signalling (Taveggia et al., 
2005).
Once such signal that is known to modulate NRG1 signalling in Schwann cells 
is cyclic AMP. Addition of cyclic AMP analogues or the adenylate cyclase activator, 
forskolin, to Schwann cell cultures can boost proliferation stimulated by NRG1 and 
prolongs activation of the MAPK and PI3K pathways (Raff et al., 1978; Levi et al., 
1995; Kim et al., 1997; Rahmatullah et al., 1998; Monje et al., 2006). In addition 
intracellular cyclic AMP elevation is a prerequisite for most growth factors, such as 
PDGF and FGFs, to induce rat Schwann cell proliferation (Chen et al., 1991; Stewart 
et al., 1991; Kim et al., 2001). Cyclic AMP elevation has also been shown to act as a 
differentiation factor for cultured rat Schwann cells, upregulating genes such as 
galactocerebroside (galC), 04 antigen, E-cadherin, periaxin, Krox-20, Po and MBP 
(Sobue and Pleasure, 1984; Lemke and Chao, 1988; Mirsky et al., 1990; Morgan et 
al., 1991; Parkinson et al., 2003; Crawford et al., 2008) and downregulating genes 
expressed on immature Schwann cells, like, p75NTR, NCAM, N-cadherin, GFAP,
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growth-associated protein-43 (GAP-43), c-Jun and Sox-2 (Jessen et al., 1987b; 
Mokuno et al., 1988; Morgan et al., 1991; Scherer et al., 1994b; Parkinson et al., 
2004, 2008; Crawford et al., 2008). Importantly, the capacity to induce Schwann cell 
differentiation by cyclic AMP elevation is independent from its role in assisting 
growth factor or serum induced proliferation (Morgan et al., 1991).
Cyclic AMP effectors include protein kinase A (PKA), cyclic nucleotide-gated 
cation channels and a family of guanine nucleotide exchange factors (GEFs) (Fig. 
3.1). In cultured rat Schwann cells, myelin differentiation induced by contact with 
neurons or by cyclic AMP elevation requires PKA activity (Howe and McCarthy, 
2000; Yoon et al., 2008). Furthermore, the peak of PKA activity in the sciatic nerve 
occurs around the time when myelination begins (Yoon et al., 2008).
In this study, I wanted to investigate possible interactions between NRG1 and 
cyclic AMP signalling pathways in Schwann cell differentiation. However, one caveat 
with this proposal is that all the evidence showing the importance of the NRGl/erbB 
signalling pathway in myelin differentiation has come from experiments in mice 
whereas the majority of cyclic AMP studies have been carried out using rat Schwann 
cells. For this reason, I opted to establish a technique for readily culturing mouse 
Schwann cells (Stevens et al., 1998; see Chapter 2), in order to investigate whether 
the two factors played a role in myelin differentiation in Schwann cells from the same 
species.
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Figure 3.1: Overview of cyclic AMP signalling.
Ligand binding to G-protein coupled receptors activates adenylyl cyclases and 
generates a pool of cyclic AMP, the concentration and distribution of which is 
regulated by phosphodiesterases. Cyclic AMP binds to and activates dissociation of 
the PKA heterotetramer, the catalytic domains (C) migrate to the nuclear 
compartment and phosphorylate the transcription factor CREB on S eri33, which 
promotes CREB dependent transcription. In addition to numerous other targets, PKA 
activation can also positively and negatively regulate the Raf/MEK/ERK pathway 
depending on the context (Stork and Schmitt, 2002). Cyclic AMP can also bind and 
active the guanine exchange factors, epacl and 2, which carry out their downstream 
effects through Rapl, a small GTPase (Bos, 2003). Adapted from Tasken and 
Aandahl, (2004).
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3.2 RESULTS
3.2.1 Cyclic AMP has concentration dependent effects in the presence of NRG1 
in mouse Schwann cells.
Previous studies have demonstrated a concentration dependent action of cyclic- 
AMP analogues on Schwann cell proliferation and differentiation. In these 
investigations, it was found that relatively low concentrations of cyclic AMP 
analogues were sufficient to induce Schwann cell proliferation whereas 
concentrations 10-fold higher induce maximal expression of the early differentiation 
marker, gal-C (Sobue et al., 1986; Yamada et al., 1995). However, both of these 
studies used calf serum in their experiments and cyclic AMP is unable to promote 
proliferation in the absence of serum or growth factors (Stewart et al., 1991; Morgan 
et al., 1991). Therefore, I decided to investigate the effects of cyclic AMP and NRG1 
signalling on mouse Schwann cell proliferation and differentiation, in serum free 
conditions. Briefly, mouse Schwann cells were plated a density of 5000 cells per 
coverslip in DM. Cells were then treated with a constant concentration of NRG1 
(20ng/ml) and a varying concentration of the cyclic AMP analogue, dbcAMP, ranging 
from lpM  to 2mM for a 72 hour period. Some cells were pulsed with BrdU for the 
last 24 hours of the experiment and then fixed and labelled with an antibody against 
BrdU, whereas other cells were fixed and labelled with an antibody detecting Krox- 
20 .
I found that a concentration of lOOpM dbcAMP achieved the maximal 
elevation of NRG 1 induced Schwann cell BrdU incorporation, from 41.6 +/-4.4% 
BrdU positive cells in NRG1 alone to 77.2 +/-1% in the presence of IOOjliM dbcAMP 
and NRG1 (n=6)(p<0.001). However concentrations of dbcAMP above lOOpM began 
to reduce Schwann cell BrDU incorporation with the result that, ImM dbcAMP had
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no effect on NRG1 induced Schwann cell DNA synthesis and a concentration of 2mM 
dbcAMP actually inhibited proliferation induced by NRG1 (n=4)(p<0.001)(Fig. 3.2, 
A). In contrast, under these conditions in the presence of NRG1, only high 
concentrations of dbcAMP (<500pM) were able to induce significant levels of Krox- 
20 protein expression in mouse Schwann cells, with maximal induction occurring at 
ImM dbcAMP where 49.3 +/-5.8% of Schwann cells expressed Krox-20 
(n=5)(p<0.001)(Fig.3.2, B). Thus, these experiments confirm that the cyclic AMP 
analogue, dbcAMP, demonstrates similar concentration dependent effects on mouse 
Schwann cell proliferation and differentiation, in the presence of NRG1 as previous 
reports showed with cyclic AMP analogues in the presence of serum in rat Schwann 
cells (Sobue et al., 1986).
3.2.2 Only a combination of cyclic AMP and NRG1 is sufficient to induce Krox- 
20 expression in mouse Schwann cells.
Cyclic AMP elevation alone, in the absence of serum or growth factors, is 
sufficient to induce myelin gene expression in cultured rat Schwann cells (Morgan et 
al., 1991; Parkinson et al., 2003). Thus, it was important to discern whether cyclic 
AMP was able to induce myelin gene expression in mouse Schwann cells. To test 
this, expanded mouse Schwann cells were treated with either NRG1 (20ng/ml) alone, 
dbcAMP (ImM) alone, a combination of NRG1 (20ng/ml) and dbcAMP (ImM ) or 
left in just DM for 72 hours. After this, protein was extracted from the cells and 
analysed by Western blotting. Surprisingly, I found that ImM dbcAMP treatment was 
insufficient to induce Krox-20 expression in mouse Schwann cells, as was NRG1 
treatment. However, a combination of both ImM dbcAMP and NRG1 demonstrated a
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robust induction of Krox-20 protein, confirming results from the previous 
experiments (Fig.3.2, C).
In order to substantiate this finding, I used Schwann cells from mice that were 
heterozygous for a Krox-20/lacZ chimaeric gene (referred to as Krox-20 ~) 
(Schneider-Maunoury et al., 1993). In these mice, expression of the lacZ gene reflects 
the normal expression pattern of the Krox-20 gene (Topilko et al., 1994; Murphy et 
al., 1996). Krox-20+/~ Schwann cells were serum purified, plated in DM and HI and 
treated with the same conditions as in the above experiment for 72 hours. Cells were 
then fixed and stained with an antibody to (3-galactosidase ((3-gal), the lac-Z  gene 
product. Schwann cells maintained in DM or NRG1 expressed virtually no (3-gal and 
only 2.2 +/-1.3% of Schwann cells expressed (3-gal in response to ImM dbcAMP 
treatment. However, 43.5 +/-3.2% of Schwann cells treated with a combination of 
both ImM dbcAMP and NRG1 displayed strong (3-gal expression 
(n=4)(p<0.001)(Fig.3.2, D-H). Thus it appears that either dbcAMP or NRG1 
treatment alone are incapable of inducing significant levels of Krox-20 and that both 
are required in combination in order to induce strong Krox-20 expression in cultured 
mouse Schwann cells.
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Figure 3.2: A combination of cyclic AMP and NRG1 induces Krox-20 in mouse 
Schwann cells.
(A) Effects of varying concentrations of dbcAMP (0-2mM) on NRG1 induced 
Schwann cell BrdU incorporation. For these experiments mouse Schwann cells were 
kept in a constant concentration of NRG1 (20ng/ml) for 72 hours. The concentration 
of dbcAMP (x-axis) is plotted on a log scale. Error bars show the standard deviation 
of the mean. Statistical analysis was measured by one-way ANOVA with Tukey’s 
Multiple Comparison test.
(B) Effects of varying concentrations of dbcAMP (0-2mM) in the presence of NRG1 
(20ng/ml) on Schwann cell Krox-20 expression after 72 hours treatment. The 
concentration of dbcAMP (x-axis) is plotted on a log scale. Error bars show the 
standard deviation of the mean. Statistical analysis was measured by one-way 
ANOVA with Tukey’s Multiple Comparison test. Note how the optimal 
concentrations for dbcAMP for the enhancement of NRG1 induced proliferation (A) 
were an order of magnitude lower than the optimal concentrations for Krox-20 
induction (B).
(C) Western blot showing Krox-20 expression by expanded mouse Schwann cells 
after 72 hour treatment with NRG1 (20ng/ml) alone, dbcAMP (ImM ) alone, dbcAMP 
(ImM ) and NRG1 (20ng/ml) or cells were left unstimulated (Control), p-tubulin was 
used as a loading control. Molecular weight (MW) of proteins is illustrated in kDs. 
(D-G) Schwann cells from mice that were heterozygous for a Krox-20/lacZ chimaeric 
gene were cultured and treated with NRG1 (20ng/ml) alone, dbcAMP (ImM ) alone, 
dbcAMP (ImM) and NRG1 (20ng/ml) or left unstimulated (Control) for 72 hours. 
Arrowheads demonstrate (3-gal positive Schwann cells. Cells are co-labelled with 
hoescht nuclear dye (Ho). Scale bar, 50pm.
(H) The percentage of Schwann cells that express |3-gal in response to NRG1 
(20ng/ml) alone, dbcAMP (ImM) alone, dbcAMP (ImM ) and NRG1 (20ng/ml) 
treatment or after left unstimulated (Control) for 72 hours. Error bars show the 
standard deviation of the mean.
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3.2.3 Cyclic AMP and NRG1 synergistically induce high levels of Po mRNA and 
protein in mouse Schwann cells.
Since a com bination of dbcAMP and NRG1 can induce expression of Krox-20 
in mouse Schwann cells, I wanted to test whether this treatment could also induce 
strong expression o f the myelin protein Po, which is characteristic of myelin 
differentiation. Serum purified mouse Schwann cells were again incubated with 
NRG1 (20ng/ml) alone, dbcAMP (ImM) alone, a combination of NRG1 (20ng/ml) 
and dbcAMP (Im M ) o r  left in just DM. Some cells were left for 72 hours and then 
fixed and probed for Po  mRNA expression whereas other cells were left for 120 hours 
before being fixed and assayed for Po protein expression by immunocytochemistry. 
After 72 hours, Schw ann cells treated with either dbcAMP or NRG1 demonstrated 
slightly elevated levels o f Po mRNA but only cells that received the combination of 
the two factors expressed high levels of Po mRNA (Fig.3.3, A-D). Additionally after 
120 hours of dbcA M P/N R G l treatment, 18.2 +/-3% of Schwann cells expressed a 
high level of Po pro te in , characteristic of a myelin differentiated cell (Jessen and 
Mirsky, 2005), w hereas these cells were very rarely seen in unstimulated cultures 
(n=4)(p<0.01)(Fig.3.3, E  andF).
As mentioned in Chapter 1, Po is a direct transcriptional target of Krox-20 and 
in the absence of K ro x -2 0 , P 0 gene expression is not upregulated by Schwann cells at 
the beginning of m yelination (Topilko et al., 1994; LeBlanc et al., 2006). Therefore, I 
wanted to test whether the  Po induction by dbcAMP/NRGl treatment relied on the 
expression of Krox-20. T o  investigate this I stimulated Schwann cells from control or 
Krox-20'' mice (Schneider-M aunoury et al., 1993), with dbcAMP (ImM ) and NRG1 
(20ng/ml) for 96 hours an d  then fixed and stained the cells with antibodies to P0 and 
Krox-20. No Krox-20' ' Schwann cells expressed significant levels of P0 or Krox-20
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protein in response to dbcAMP/NRGl (Fig.3.3, G-K), demonstrating that 
dbcAMP/NRGl Po upregulation requires prior induction of Krox-20.
Interestingly, 22.1 +/-D.4% of control Schwann cells expressed high levels of Po 
after 96 hours, suggesting that no more Schwann cells are recruited to express Po 
protein between 96 and 120 hours after dbcAMP/NRGl stimulation (Fig.3.3, F and 
K). However, Schwann cells treated for 120 hours with dbcAMP/NRGl do appear 
much flatter and appear to express a greater amount of Po (Fig.3.3, E) than cells 
stimulated for only 96 hours (Fig.3.3, G). In summary, these experiments show that 
prolonged treatment of mouse Schwann cells with a combination of ImM dbcAMP 
and NRG1 leads to strong induction of Po mRNA and protein and that this induction 
is dependent on the upregulation of the transcription factor Krox-20.
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Figure 3.3: A combined cyclic AMP and NRG1 signal induce PO mRNA and 
protein expression in mouse Schwann cells.
(A-D) Expression of Po mRNA in serum purified mouse Schwann cells either after 
treatment with NRG1 (20ng/ml), dbcAMP (ImM), dbcAMP (ImM ) and NRG1 
(20ng/ml) or left unstimulated (Control) for 72 hours. Arrowheads show Schwann 
cells expressing high levels of Po mRNA after the combined treatment of dbcAMP 
andN RG l. Scale bar, 50pm.
(E) Immunocytochemistry for P0 in serum purified mouse Schwann cells treated with 
dbcAMP (ImM) and NRG1 (20ng/ml) for 120 hours. Notice the significant flattening 
of the Po positive cells (denoted by arrowheads) compared to the normal spindle 
shaped morphology seen in panel (G). Cells are co-labelled with hoescht nuclear dye 
(Ho). Scale bar, 50pm.
(F) The percentage of Schwann cells that express high levels of Po protein after 
dbcAMP (ImM ) and NRG1 (20ng/ml) treatment or left unstimulated for 120 hours. 
Error bars show the standard deviation of the mean.
(G-J) Serum purified Schwann cells from control (G and I) and Krox-20/_ mice (H 
and J) were treated with dbcAMP (ImM) and NRG1 (20ng/ml) for 72 hours and 
assayed for Po (G and H) and Krox-20 protein expression (I and J). Arrowheads mark 
Po positive Schwann cells from control mice. Cells are co-labelled with hoescht 
nuclear dye (Ho). Scale bar, 50pm.
(K) The percentage of Po positive Schwann cells in control and Krox-20' ' cultures 
after 96 hours of dbcAMP (ImM) and NRG1 (20ng/ml) treatment. Error bars show 
the standard deviation of the mean.
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3.2.4 Cyclic AMP treatment alone promotes an ‘early differentiated’ phenotype 
in mouse Schwann cells.
The previous experiments have shown that cyclic AMP alone does not 
upregulate expression of the myelin related genes, Krox-20 and Po, in mouse Schwann 
cells, unlike in rat Schwann cells (Morgan et al., 1991; Parkinson et al., 2003). 
However, as mentioned earlier, cyclic AMP can also induce expression of 
differentiation markers in cultured rat Schwann cells that appear on Schwann cells, in 
vivo, just prior to myelination, such as gal-C, 04 and periaxin (lessen et al., 1985; 
Sobue and Pleasure, 1984; Mirsky et al., 1990; Morgan et al., 1991; Parkinson et al., 
2003). Therefore, I tested mouse Schwann cells for the expression of these three 
markers after a 72 hour induction with the conditions used in the previous 
experiments. Interestingly, ImM dbcAMP treatment alone could induce 24.2 +1-3.1% 
of gal-C positive cells (n=5)(p<0.001)(Fig.3.4, C and E) and 54.5 +1-6.6% of 04 
positive cells (n=5)(p<0.0001)(Fig.3.4, H and J). In addition, Western blotting of 
protein extracts from expanded mouse Schwann cells treated with ImM dbcAMP for 
72 hours demonstrated a low level of peraxin induction unlike unstimulated cells 
which did not show periaxin expression (Fig.3.4, K). However, in all three cases 
addition of NRG1 could further boost the induction of these genes by dbcAMP in 
mouse Schwann cells. The percentage of Schwann cells that expressed gal-C and 04, 
in the presence of both dbcAMP and NRG1, increased to 65.5 +/-8.7% 
(n=5)(p<0.001)(Fig.3.4, D and E) and 76.2 +1-1.9% (n=5)(p<0.01)(Fig.3.4, I and J) 
respectively. Furthermore, Western blotting demonstrated a large increase in the 
amount of periaxin protein induced by dbcAMP and NRG1 combined compared to 
dbcAMP alone (Fig.3.4, K).
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In addition, to investigating genes that could potentially be induced by cyclic 
AMP, I also tested whether cyclic AMP was sufficient to downregulate inhibitors of 
Schwann cell myelin differentiation, such as c-Jun and Sox-2, in mouse Schwann 
cells as it can in rat Schwann cells (Le et al., 2005a; Parkinson et al., 2008; see 
Chapter 4). Western blotting demonstrated that treatment of mouse Schwann cells 
with ImM dbcAMP for 72hours was sufficient to strongly inhibit protein expression 
of both c-Jun and Sox-2 by cultured mouse Schwann cells (Fig.3.4, K). Furthermore, 
although NRG1 on its own appeared to enhance Sox-2 expression, Schwann cells 
maintained little c-Jun or Sox-2 expression after treatment with the combination of 
both dbcAMP and NRG1 (Fig.3.4, K).
Thus, cyclic AMP alone can induce expression of the early markers of 
Schwann cell differentiation, gal-C, 04 and periaxin on cultured mouse Schwann 
cells. Furthermore, cyclic AMP is sufficient to downregulate the inhibitors of myelin 
differentiation, c-Jun and Sox-2. However, although cyclic AMP treatment can induce 
early differentiation of mouse Schwann cells, it must be noted that, only when cyclic 
AMP is used in combination with NRG1 can high levels of gal-C, 04 and periaxin be 
induced on mouse Schwann cells.
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Figure 3.4: Cyclic AMP can induce partial differentiation of mouse Schwann 
cells.
(A-D) Immunocytochemistry for gal-C on serum purified mouse Schwann cells 
treated with NRG1 (20ng/ml) alone, dbcAMP (ImM) alone, dbcAMP (ImM ) and 
NRG1 (20ng/ml) or left unstimulated (Control) for 72 hours. Arrowheads demonstrate 
gal-C positive Schwann cells in both dbcAMP alone (C) and dbcAMP and NRG1 (D) 
conditions. Notice that generally Schwann cells treated with dbcAMP and NRG1 
express a higher level of gal-C compared with Schwann cells treated with dbcAMP 
alone. Cells are co-labelled with hoescht nuclear dye (Ho). Scale bar, 50pm.
(E) Percentage of Schwann cells that express gal-C after treatment with NRG1 
(20ng/ml) alone, dbcAMP (ImM) alone, dbcAMP (Im M ) and NRG1 (20ng/ml) or 
left unstimulated (Control) for 72 hours. Error bars show the standard deviation of the 
mean.
(F-I) Immunocytochemistry for 04 on serum purified mouse Schwann cells treated 
with NRG1 (20ng/ml) alone, dbcAMP (ImM) alone, dbcAMP (ImM ) and NRG1 
(20ng/ml) or left unstimulated (Control) for 72 hours. Arrowheads demonstrate 04 
positive Schwann cells in both dbcAMP alone (C) and dbcAMP and NRG1 (D) 
conditions. Cells are co-labelled with hoescht nuclear dye (Ho). Scale bar, 50pm.
(J) Percentage of Schwann cells that express 04 after treatment with NRG1 (20ng/ml) 
alone, dbcAMP (ImM) alone, dbcAMP (ImM ) and NRG1 (20ng/ml) or left 
unstimulated (Control) for 72 hours. Error bars show the standard deviation of the 
mean.
(K) Western blot of expanded mouse Schwann cells treated with NRG1 (20ng/ml) 
alone, dbcAMP (ImM) alone, dbcAMP (ImM) and NRG1 (20ng/ml) or left 
unstimulated (Control) for 72 hours. Blots were probed with antibodies to periaxin, c- 
Jun and Sox-2. (3-tubulin was used as a loading control. Molecular weight (MW) of 
proteins is illustrated in kDs.
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3.2.5 Activation of PKA is sufficient to replicate the effects of cyclic AMP on 
mouse Schwann cells.
In order to determine the downstream effectors of cyclic AMP in mouse 
Schwann cells I used cyclic AMP analogue 6-Bnz-cAMP that only activates PKA or 
the analogue 8-pCPT-2-0-Me-cAMP that selectively activates the guanine exchange 
factors, epacl and 2. Schwann cells were treated with each analogue separately, either 
on its own or in the presence of NRG1. After 72 hours cells were fixed and stained for 
c-Jun, Krox-20 and Po. Like dbcAMP, both ImM 8-pCPT-2-0-Me-cAMP and ImM 
6-Bnz-cAMP alone were unable to induce Krox-20 expression in mouse Schwann 
cells (Fig.3.5, A-D). Furthermore, treatment of Schwann cells with ImM 8-pCPT-2- 
O-Me-cAMP for 72 hours was unable to reduce c-Jun expression, whereas only 26.7 
+1-2.1% of Schwann cells expressed c-Jun after stimulation with ImM 6-Bnz-cAMP, 
compared to 97 +/-0.7% of control Schwann cells (n=3)(p<0.05). The percentage of c- 
Jun positive Schwann cells also remained significantly reduced upon supplement of 
ImM  6-Bnz-cAMP and NRG1 in combination (n=3)(p<0.0001)(Fig.3.5, E). In 
addition, ImM 6-Bnz-cAMP and NRG1 was able to induce 41.6 +/-2.8% of Schwann 
cells to express Krox-20 (n=4)(p<0.0001)(Fig.3.5, G and J) and 8.2 +/-0.3% of 
Schwann cells to express high levels of Po (n=4)(p<0.0001)(Fig.3.5, K). In contrast, 
the combination of ImM 8-pCPT-2-0-Me-cAMP and NRG1 was unable to induce 
significant levels of either Krox-20 or Po protein (Fig.3.5, F and J).
Together, these results demonstrate that activation of PKA is sufficient to 
downregulate c-Jun expression in mouse Schwann cells and in combination with 
NRG1 signalling, PKA activation is able to induce both Krox-20 and Po. These results 
also suggest that the alternative cyclic AMP pathway, utilising epac 1 and 2 is 
unlikely to play a role in these events.
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Figure 3.5: The PKA activator, 6-Bnz-cAMP, mimics the effects of dbcAMP on 
cultured mouse Schwann cells.
(A-D) Immunocytochemistry for c-Jun and Krox-20 on cultured mouse Schwann cells 
after treatment with ImM 8-pCPT-2-0-Me-cAMP (A and C) or ImM 6-Bnz-cAMP 
(B and D) for 72 hours. Arrowheads demonstrate Schwann cells that are negative for 
c-Jun after treatment with 6-Bnz-cAMP. Cells are co-labelled with hoescht nuclear 
dye (Ho). Scale bar, 50pm.
(E) The percentage of mouse Schwann cells that express c-Jun after treatment with 
ImM 8-pCPT-2-O-Me-cAMP alone, ImM 6-Bnz-cAMP alone, ImM 6-Bnz-cAMP 
and 20ng/ml NRG1 or left unstimulated (Control) for 72 hours. Error bars show the 
standard deviation of the mean.
(F-I) Immunocytochemistry for Krox-20 on cultured mouse Schwann cells after 
treatment with ImM 8-pCPT-2-0-Me-cAMP and 20ng/ml NRG1 (F and H) or ImM 
6-Bnz-cAMP and 20ng/ml NRG1 (G and I) fro 72 hours. Arrowheads demonstrate 
Schwann cells that are positive for Krox-20 after treatment with 6-Bnz-cAMP and 
NRG1. Cells are co-labelled with hoescht nuclear dye (Ho). Scale bar, 50pm.
(J) The percentage of mouse Schwann cells that express Krox-20 after treatment with 
either ImM 8-pCPT-2-0-Me-cAMP and 20ng/ml NRG1 or ImM 6-Bnz-cAMP and 
20ng/ml NRG1 for 72 hours. Error bars show the standard deviation of the mean.
(K) Immunocytochemistry for Po on cultured mouse Schwann cells after treatment 
with ImM 6-Bnz-cAMP and 20ng/ml NRGl for 72 hours. Arrowheads show Po 
positive Schwann cells. Cells are co-labelled with hoescht nuclear dye (Ho). Scale 
bar, 50pm.
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3.2.6 Cyclic AMP treatment alters NRG1 activation of the MAPK pathways in 
mouse Schwann cells.
Both the PI3-K pathway and the MAPK pathway have been implicated in 
regulating Schwann cell differentiation (Maurel and Salzer, 2000; Ogata et al., 2004; 
Harrisingh et al., 2004). Furthermore, cyclic AMP elevation has been shown to 
prolong the activation of both the PI3-K and MAPK pathways by NRG1 in human 
Schwann cells (Monje et al., 2006). Therefore, I assessed the expression of 
components of these pathways in expanded mouse Schwann cells after treatment with 
NRG1 (20ng/ml) alone, dbcAMP (ImM) alone or a combination of dbcAMP (ImM ) 
and NRG1 (20ng/ml) for 72 hours, by western blotting. Treatment of mouse Schwann 
cells with NRG1 led to strong sustained activation of both MAPK and PI3-K 
pathways at 72 hours, judged by phosphorylation of ERK 1/2 and Akt, respectively. 
In addition, at the same time point, ImM dbcAMP appears to have little effect on the 
basal level of ERK1/2 and Akt phosphorylation although it does seem to upregulate 
the levels of ERK proteins, particularly ERK2. However, addition of dbcAMP 
reduces the phosphorylation of ERK1/2, 72 hours after NRG1 treatment whereas the 
phosphorylation of Akt seems to remain unchanged (Fig.3.6, A). Importantly, 
measurement of the levels of Akt protein in Schwann cells was not carried out and 
would need to be tested under experimental conditions to corroborate these findings.
In order to test whether activation of either the PI3-K or MAPK pathways are 
required for dbcAMP/NRGl induced Schwann cell differentiation I used chemical 
blockers for these pathways. Briefly, cultured mouse Schwann cells were plated onto 
coverslips in DM, supplemented with U0126, to block ERK activation, LY294002, to 
block PI3-K signalling and DMSO as a control. Some cells were also incubated with 
the PKA inhibtor, H89 as well. After lhour incubation with their respective inhibitors,
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cells were pulsed with a combination of dbcAMP (ImM ) and NRG1 (20ng/ml) for 48 
hours before being fixed and assayed for Krox-20 expression by 
immunocytochemistry. Blocking ERK 1/2 phosphorylation, using the U0126 inhibitor 
completely abolished Krox-20 induction by dbcAMP/NRGl (n=3)(p<0.001). 
Surprisingly, blocking the PI3-kinase pathway, using the LY294002 blocker, led to a
2.3 fold increase in the percentage of Krox-20 positive Schwann cells induced by 
dbcAMP/NRGl compared to the DMSO control (n=3)(p<0.05). Predictably, blocking 
PKA activation, using the H89 inhibitor, led to a 7.1 fold reduction in Krox-20 
expression by mouse Schwann cells in response to dbcAMP/NRGl compared to the 
DMSO control (n=3)(p<0.01)(Fig.3.6, B).
Together, these results demonstrate that cyclic AMP can reduce NRG1 
activation of the MAP kinase pathway but not the PI 3-kinase pathway, yet this 
reduced MAP kinase activation is still necessary for Krox-20 induction. Furthermore, 
PI3-kinase signalling appears to antagonize Krox-20 induction in cultured mouse 
Schwann cells.
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Figure 3.6: MAPK signalling by cyclic AMP and NRG1 in mouse Schwann cells.
(A) Western blot of expanded mouse Schwann cells treated with NRG1 (20ng/ml), 
dbcAMP (ImM), dbcAMP (ImM) and NRG1 (20ng/ml) or left unstimulated 
(Control) for 72 hours. Blots were probed with antibodies to phosphorylated ERK 1/2 
(ERK1, 44kD and ERK2, 42kD), native ERK1/2 and phosphorylated Akt (Thr308). 
GAPDH was used as a loading control. Molecular weight (MW) of proteins is 
illustrated in kDs.
(B) Percentage of Krox-20 positive Schwann induced by a 48 hour treatment of 
dbcAMP (ImM) and NRG1 (20ng/ml) in the presence of U0126 (20pM), LY294002 
(lOpM) and H89 (lpM ). Supplement of DM with DMSO was used as a control. Error 
bars show the standard deviation of the mean.
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3.2.7 The cyclic AMP response element binding protein (CREB) family of 
transcription factors are required for cyclic AMP/NRG 1 induced Schwann cell 
differentiation.
Since activation of PKA appears to replicate the effects o f cyclic AMP on 
mouse Schwann cells (Fig. 3.5), I wanted to investigate which factors downstream of 
PKA were responsible. One set of targets for PKA is the CREB family of 
transcription factors, which it phosphorylates and activates. The main members of the 
CREB family o f transcription factors include, CREB1, cyclic AMP response element 
modulator (CREM) and activating transcription factor 1 (ATF1), which bind as 
dimers to cyclic AMP responsive elements (CREs, 5’-TGACGTCA-3’) in target 
genes (Mayr and Montminy, 2001). CREB1 has previously been identified in 
Schwann cells and their precursors, in vivo and in vitro and is phosphorylated at Ser- 
133 in response to stimuli such as NRG1, axons and ATP treament (Stewart et al., 
1995; Tabernero et al., 1998; Lee et al., 1999; Stevens and Fields, 2000).
In order to test whether the CREB family of transcription factors were required 
for cyclic AMP/NRG 1 induced Schwann cell differentiation I used adenoviruses 
expressing a dominant negative form o f CREB, A-CREB and GFP (Ahn et al., 
1998)(see section 2.3.4 for method of inhibition), and a control virus expressing only 
GFP (CMV control)(Warburton et al., 2005). Serum purified mouse Schwann cells 
were plated and infected with either A-CREB or CMV control viruses in DM, 0.5% 
HS and 2(iiM forskolin for 48 hours (see legend to Fig. 3.7, A). During this time the 
medium was replaced with the same medium after 24 hours. Schwann cells were then 
pulsed with a combination o f dbcAMP (Im M ) and NRG1 (20ng/ml) for a further 48 
hours before cells were fixed and stained for a number o f differentiation markers by 
immunocytochemistry. Expression of A-CREB in mouse Schwann cells significantly
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inhibited dbAM P/NRGl induced Po, with 3.2 +/-2.3% P0 positive cells compared to 
19.5 +/-1.3% Po positive for CMV control infected cells (n=3)(p<0.05)(Fig.3.7, A). In 
addition, A-CREB strongly reduced periaxin induction by dbAM P/NRGl, with only
34.1 +/-8.8% of periaxin positive cells compared to 81.9 +/-7.6% of positive cells 
infected with the CMV control virus (n=4)(p<0.001)(Fig.3.7, B-F). Thus, the CREB 
family o f transcription factors are required for dbcAMP/NRGl induced myelin- 
related gene expression.
To test whether CREB is required for the initiation of the myelin differentiation 
program, I assayed cultured mouse Schwann cells for the expression o f Krox-20 after 
dbcAM P/NRGl treatment in the presence of A-CREB or CMV control adenoviruses. 
Krox-20 expression was strongly inhibited by the presence of A-CREB compared to 
CMV control infected cells, with 3.6 +/-0.6% compared to 55.7 +/-5.3% of Krox-20 
positive cells in their respective conditions (n=4)(p<0.001)(Fig.3.8, A-E). Similarly, 
the A-CREB adenovirus strongly inhibited p-gal expression by 9.3 fold in Krox-20 ' 
Schwann cells induced by dbcAM P/NRGl, 4.1 +/-1.4% versus 38 +/-7.1% for A- 
CREB and CMV control infected cells respectively (n=4)(P<0.01)(Fig.3.8, F-J). Thus, 
the CREB family o f transcription factors is required, at least at the level o f Krox-20 
induction, during dbcAM P/NRGl induced myelin differentiation.
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Figure 3.7: The CREB family of transcription factors is required for Po and 
periaxin induction by cyclic AMP/NRG1.
(A) The percentage o f CMV control and A-CREB adenovirally infected Schwann 
cells expressing Po after a 48 hour induction by dbcAMP (Im M ) and NRG1 
(20ng/ml), preceded by a 48 hour pre-treatment by 2pM  forskolin. Modest pre­
treatment with a cyclic AMP elevating agent prior to cyclic AMP/NRG 1 treatment 
was found to increase the number of myelin differentiating Schwann cells compared 
to induction by cyclic AMP/NRG 1 without any pre-treatment (see section 3.3.3). 
Error bars show the standard deviation of the mean.
(B-E) Cultured mouse Schwann cells immunolabelled for periaxin after infection with 
CMV control (B and D) and A-CREB (C and E) adenoviruses and treatment with 
2pM  forskolin for 48 hours and then dbcAMP (Im M ) and NRG1 (20ng/ml) for a 
further 48hours. Arrows show CMV control infected Schwann cells that are positive 
for GFP and periaxin. Arrowheads demonstrate A-CREB infected Schwann cells that 
are GFP positive but periaxin negative. Cells are co-labelled with hoescht nuclear dye 
(Ho). Scale bar, 50pm.
(F) The percentage of CMV control and A-CREB adenovirally infected Schwann 
cells expressing Po after treatment with 2pM forskolin for 48 hours and then dbcAMP 
(Im M ) and NRG1 (20ng/ml) for a further 48hours. Error bars show the standard 
deviation o f the mean.
149
Figure 3.7
U 16
,° 10
CMV Control A-CREB
CMV Control A-CREB
1  — M ^ j*--- ..
[ w c’ ■, MM^ jL
)f B9 f j ^  1 CMV Control
u
A-CREB
150
Figure 3.8: The CREB family of transcription factors is required for Krox-20 
induction by cyclic AMP/NRG1.
(A-D) Cultured mouse Schwann cells immunolabelled for Krox-20 after infection 
with CMV control (B and D) and A-CREB (C and E) adenoviruses and treatment 
with 2(liM  forskolin for 48 hours and then a combination of dbcAMP (Im M ) and 
NRG1 (20ng/ml) for a further 48hours. Arrows show CMV control infected Schwann 
cells that are positive for GFP and Krox-20 Arrowheads demonstrate A-CREB 
infected Schwann cells that are GFP positive but Krox-20 negative. Cells are co­
labelled with hoescht nuclear dye (Ho). Scale bar, 50pm.
(E) The percentage o f CMV control and A-CREB adenovirally infected Schwann 
cells expressing Krox-20 after treatment with 2pM  forskolin for 48 hours and then 
dbcAMP (Im M ) and N RGl (20ng/ml) for a further 48hours. Error bars show the 
standard deviation of the mean.
(F-I) Cultured mouse K rox-20 ' Schwann cells immunolabelled for (3-gal after 
infection with CMV control (B and D) and A-CREB (C and E) adenoviruses and 
treatment with 2pM  forskolin for 48 hours and then dbcAMP (Im M ) and NRGl 
(20ng/ml) for a further 48hours. Arrows show CMV control infected Schwann cells 
that are positive for GFP and (3-gal. Arrowheads demonstrate A-CREB infected 
Schwann cells that are GFP positive but (3-gal negative. Cells are co-labelled with 
hoescht nuclear dye (Ho). Scale bar, 50pm.
(J) The percentage of CMV control and A-CREB adenovirally infected Krox-20' 
Schwann cells expressing (3-gal after treatment with 2pM  forskolin for 48 hours and 
then dbcAMP (Im M ) and NRGl (20ng/ml) for a further 48hours. Error bars show the 
standard deviation o f the mean.
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3.2.8 Constitutive activation of a CREB-like molecule induces periaxin but does 
not downregulate c-Jun in mouse Schwann cells.
In order to test whether activation of members o f the CREB family of 
transcription factors was sufficient to replicate cyclic AMP/NRG 1 induced myelin 
differentiation, I infected Schwann cells with an adenovirus that expressed a 
constitutively active CREB molecule, VP16-CREB (Barco et al., 2002; Gao et al., 
2004)(see section 2.3.4 for mechanism of action) or a CMV control adenovirus. Both 
viruses co-expressed GFP. In a different protocol to the previous adenoviral 
infections, cultured mouse Schwann cells were infected with CMV control or VP 16- 
CREB adenoviruses in DM, 0.5% HS and 2pM forskolin. After 24 hours, the medium 
was changed to just DM and 0.5% HS. Cells were then left for a further 48 hours until 
fixation and immunocytochemistry was performed.
VP16-CREB expressing Schwann cells did not express any 04, gal-C or P0 (data 
not shown) however, 30.9 +/-4.5% of VP16-CREB expressing Schwann cells 
upregulated periaxin protein (n=4)(p<0.01)(Fig.3.9, A-C). Interestingly, VP16-CREB 
infected cells did appear much flatter than CMV control infected cells, seeming to 
possess many more lamellipodia (Fig.3.9, A and D). Furthermore, unlike dbcAMP 
treatment or PKA activation, constitutive CREB activation in mouse Schwann cells 
failed to reduce c-Jun protein expression, with 98.3 +/-1.4% of VP16-CREB 
expressing Schwann cells also positive for c-Jun (Fig.3.9, D-G).
I postulated that the reason VP16-CREB expressing Schwann cells did not 
express the majority o f myelin differentiation markers was due to the inability to 
downregulate inhibitors o f myelin gene activation, such as c-Jun (Parkinson et al., 
2008; Chapter 4). To test this, I used c-Jun null Schwann cells in which c-Jun was 
deleted by infecting c-Jun^f Schwann cells with an adenovirus expressing ere
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recombinase (see Chapter 4). I then infected control {c-Jun11) or c-Jun null Schwann 
cells with adenoviral VP16-CREB, using the same protocol as described above. 
Deletion of c-Jun lead to a 1.9 fold increase in the percentage o f periaxin positive 
VP16-CREB expressing Schwann cells, to 53.7 +/-8.6% compared to 28 +/-8.2% of 
CMV control infected Schwann cells (n=4)(p<0.05)(Fig.3.9, H-J). However, even in 
the absence o f c-Jun , VP16-CREB was still unable to induce Po expression in mouse 
Schwann cells.
Thus, these results demonstrate that CREB activation is sufficient to induce 
periaxin expression in mouse Schwann cells and that the transcription factor, c-Jun 
antagonizes VP16-CREB induced periaxin expression. However VP16-CREB 
expression is not sufficient to induce expression of other myelin differentiation 
markers, like Po.
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Figure 3.9: Constitutively active CREB can induce periaxin expression in mouse 
Schwann cells.
(A and B) Cultured mouse Schwann cells immunolabelled for periaxin after infection 
with VP16-CREB adenovirus for 72 hours in DM and 0.5% HS (Cells were incubated 
with 2pM  forskolin for only the first 24 hours). Arrows show VP16-CREB infected 
Schwann cells positive for both GFP and periaxin. Cells are co-labelled with hoescht 
nuclear dye (Ho). Scale bar, 50pm.
(C) The percentage o f CMV control and VP16-CREB adenovirally infected Schwann 
cells expressing periaxin after 72 hour infection. Error bars show the standard 
deviation o f the mean.
(D-G) Cultured mouse Schwann cells immunolabelled for c-Jun after infection with 
either CMV control or VP16-CREB adenovirus, for 72 hours in DM and 0.5% HS 
(Cells were incubated with 2pM  forskolin for only the first 24 hours). Arrowheads 
show CMV control or VP16-CREB infected Schwann cells that are positive for GFP 
and c-Jun. Cells are co-labelled with hoescht nuclear dye (Ho). Scale bar, 50pm.
(H-I) c-Jun null Schwann cells immunolabelled for periaxin after infection with 
VP16-CREB adenovirus for 72 hours in DM and 0.5%HS (Cells were incubated with 
2pM  forskolin for only the first 24 hours). Arrows show VP16-CREB infected c-Jun 
null Schwann cells that are positive for GFP and periaxin. Cells are co-labelled with 
hoescht nuclear dye (Ho). Scale bar, 50pm.
(J) The percentage o f control Schwan cells (Control SC, c-Junff) or c-Jun null 
Schwann cells (c-Jun null SC) infected with VP16-CREB adenovirus that express 
periaixn after 72 hour infection. Error bars show the standard deviation o f the mean.
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3.2.9 VP16-CREB can induce Krox-20 expression in rodent Schwann cells.
The promoter region of the Xenopus laevis and murine Krox-20 gene and the 
human KGR2 gene (Krox-20 homologue) contain putative CRE sites (Rangnekar et 
al., 1990; W atanabe et al., 2005; Mayr and Montminy, 2001). Thus, I wanted to test 
whether VP16-CREB expression was sufficient to induce Krox-20 expression in 
rodent Schwann cells. Expression of VP16-CREB for 72 hours induced very weak 
Krox-20 protein in 7.1 +/-2.4% of infected mouse Schwann cells
(n=4)(p<0.05)(Fig.3.10, A, C and E). However, VP16-CREB infection o f rat 
Schwann cells for 72 hours produced 61.3 +/-4.8% Krox-20 positive infected cells 
(n=4)(p<0.001)(Fig.3.10, B, D and E). Although, it must be noted that the level of 
Krox-20 induction by VP16-CREB in rat Schwann cells was significantly weaker 
than normally achieved by ImM dbcAMP treatment for the same length o f time. 
Thus, it appears that constitutively active CREB is sufficient to drive Krox-20 
expression, albeit at a low level and significantly more strongly in rat compared to 
mouse Schwann cells.
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Figure 3.10: Constitutively active CREB can induce expression of Krox-20 in 
rodent Schwann cells.
(A-D) Cultured mouse (mouse SC, A and C) and rat (rat SC, B and D) Schwann cells 
immunolabelled for Krox-20 after infection with VP16-CREB for 72 hours. Arrows 
demonstrate Schwann cells infected with VP16-CREB that are positive for GFP and 
Krox-20. Importantly, photos for Krox-20 immunostaining in mouse and rat Schwann 
cells were taken at the same exposure. Notice the much stronger expression o f Krox- 
20 in rat Schwann cells compared to mouse. Cells are co-labelled with hoescht 
nuclear dye (Ho). Scale bar, 50pm.
(E) Percentage o f mouse (mouse SC) and rat Schwann cells (rat SC) infected with 
either CMV control or VP16-CREB adenoviruses that express Krox-20 protein. Error 
bars show the standard deviation of the mean.
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3.3 DISCUSSION
The identities o f the signals from the axon that potentially instruct a Schwann 
cell to differentiate still remain largely elusive. However, recent studies have 
implicated axonally expressed NRGl type III as such a signal (Michailov et al., 2004; 
Taveggia et al., 2005). Nevertheless, the mechanism by which NRGl might 
potentially activate myelin gene expression in Schwann cells is unknown.
In this study, I have shown that NRGl alone is incapable o f activating 
significant myelin gene expression in cultured mouse Schwann cells, confirming 
previous reports using rat Schwann cells (Taveggia et al., 2005). Furthermore, I have 
demonstrated that cyclic AMP, long known to promote myelin gene expression in 
cultured rat Schwann cells (Morgan et al., 1991; Parkinson et al., 2003), is incapable 
of performing this function in cultured mouse Schwann cells. Thus, using cultured 
mouse Schwann cells as an experimental model, my experiments identify that cyclic 
AMP, acting through protein kinase A can switch the function o f N RG l from 
promoting proliferation to promoting myelin differentiation. In addition, the CREB 
family o f transcription factors are required for cyclic AMP/NRG1 induced myelin 
differentiation. However, activation of CREB is only partially able to induce Schwann 
cell differentiation, suggesting cooperation with other factors.
3.3.1 Cyclic AM P signalling and Schwann cell proliferation.
My findings clearly show that a relatively low concentration o f dbcAMP 
(lOOpM) can augment N R G l induced Schwann cell proliferation in cultured mouse 
Schwann cells. This confirms similar findings in human and rat Schwann cells (Levi 
et al., 1995; Rahmatullah et al., 1998; Monje et al., 2006; Iacovelli et al., 2007). 
Furthermore, as mentioned earlier, in rat Schwann cells most growth factors, such as
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PDGF, actually require cyclic AMP elevating agents to promote proliferation (Chen et 
al , 1991; Stewart et al., 1991), however this may not necessarily be the same for 
mouse Schwann cells (Stevens et al., 2004). Further work on rat Schwann cells 
demonstrated that cyclic AMP elevation induced cyclin D1 expression which was 
required for growth factor induced cell cycle progression past Gi (Kim et al., 2001). 
In addition, modest cyclic AMP elevation was shown to prolong NRGl activation of 
MAPK and PI3-K pathways and blocking both pathways inhibited proliferation 
(Monje et al., 2006). Interestingly, a target of active ERK1/2, S6-Kinase, was shown 
to be strongly phosphorylated in response to low but not high concentrations o f cyclic 
AMP analogues in rat Schwann cells (Mutoh et al., 1998).
The direct downstream effector o f cyclic AMP effects on Schwann cell 
proliferation is likely to be PKA, however, there are conflicting reports o f whether 
PKA is involved in Schwann cell axon induced proliferation (Kim et al., 1997; Howe 
and McCarthy, 2000). Indirect evidence for a role for PKA in Schwann cell 
proliferation comes from the study of an autosomal dominant neoplasia syndrome 
called Carney complex. Here, loss-of-function mutations in the PRKAR1A  gene (PKA 
type 1A regulatory subunit) lead to excessive PKA signalling and development of 
schwannomas in both humans and mice (Kirschner et al., 2000; Stratakis et al., 2001; 
Kirschner et al., 2005).
3.3.2 Cyclic AMP signalling and Schwann cell differentiation.
The fact that cyclic AMP signalling can promote myelin differentiation in both 
cultured rat and mouse Schwann cells, suggests that cyclic AMP or components o f the 
cyclic AMP pathway could be important for Schwann cell myelination, in vivo. 
However, studies have shown that cyclic AMP levels from whole nerve extracts do
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not correlate well with remyelination after sciatic nerve crush (Poduslo et al., 1995). 
However this does not preclude localised subcellular elevations in cyclic AMP being 
important for Schwann cell differentiation (Tasken and Aandahl, 2004). There is 
stronger evidence for a role for PKA in Schwann cell differentiation, since activation 
o f PKA is highest in the sciatic nerve just after birth, when myelination begins and 
blocking PKA inhibits myelination in Schwann cell/DRG cocultures (Howe and 
McCarthy, 2000; Yoon et al., 2008). PKA phosphorylation o f the p65 subunit o f the 
transcription factor Nuclear Factor-xB (NF-kB) is required for cyclic AMP induced 
rat Schwann cell differentiation and also myelination in Schwann cell/DRG cocultures 
(Yoon et al., 2008). In both experimental models NF-kB activation was necessary for 
induction o f the transcription factor Oct-6 (Nickols et al ., 2003; Yoon et al ., 2008).
In my experiments, activation o f PKA, using a PKA specific cyclic AMP 
analogue, appeared to replicate the effects o f cyclic AMP, with and without the 
presence o f N R G l, on mouse Schwann cells. However, downstream of PKA, 
activation o f the CREB family of transcription factors was required but not sufficient 
to induce mouse Schwann cell differentiation. In other experiments, I also found 
VP16-CREB unable to induce Oct-6 expression in mouse Schwann cells (P.Arthur- 
Farraj, data not shown), despite putative CRE sites being present in the Oct-6 
Schwann cell specific enhancer (Mandemakers et al., 2000). In contrast, constitutively 
active p65 can actually induce Oct-6 in rat Schwann cells. Thus, NF-kB activation is 
likely to be another component o f PKA induced Schwann cell differentiation, in 
addition to CREB.
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3.3.3 N RG l and Schwann cell differentiation.
The fact that NRGl alone cannot promote differentiation in cultured Schwann 
cells has prompted many researchers to look for mechanisms by which NRGl 
signalling may be modulated (Nave and Salzer, 2006). One possibility is that the 
different isoforms o f NRGl may have different functions in Schwann cells. To 
support this, overexpression o f NRGl type III on axons leads to PNS 
hypermyelination whereas overexpression of NRGl type I does not (Michailov et al., 
2004). There is also evidence that NRGl may be developmentally processed or 
cleaved by enzymes such as the endopeptidase, B acel, which could alter its signalling 
(Michailov et al., 2004; Willem et al., 2006; Hu et al., 2008). However, results in this 
study suggest that alteration in the levels of cyclic AMP signalling is sufficient to 
switch N RGl into driving myelin differentiation in mouse Schwann cells. 
Furthermore, in all the experiments in this study, the EGF domain from N R G l, which 
is common between all 3 NRGl isoforms, was used to induce mouse Schwann cells. 
This suggests that the particular type of NRGl isoform expressed may not be the most 
important factor in determining the outcome o f N RGl signalling. In other 
experiments in mouse Schwann cells, it was shown that constant cyclic AMP 
signalling was required at the same time as N RGl signalling in order to induce myelin 
differentiation. In addition, pre-treatment of Schwann cells with as little as 2pM  
forskolin or lOOpM dbcAMP for 48 hours prior to high dbcAMP (Im M ) and N RGl 
treatment boosts the number o f differentiating cells compared to cells that were not 
primed with cyclic AMP or cells that were primed with NRGl (K. Wanek and P. 
Arthur-Farraj, data not shown). Thus cyclic AMP appears to be able to modulate the 
cellular environment in mouse Schwann cells in order to allow NRGl to promote 
differentiation. An example o f this is the fact cyclic AMP alone can downregulate the
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expression o f two known inhibitors of myelin differentiation, c-Jun and Sox-2 (Le et 
al., 2005a; Parkinson et al., 2008; Chapter 4).
W hether and potentially how cyclic AMP signalling is activated in Schwann 
cells in development remains to be tested, though it could possibly be through signals 
derived from either the axon or the extracellular matrix. Signals other than NRGl that 
have been identified to play a role in Schwann cell differentiation include BDNF 
signalling through the p75N1R receptor, Lgi4, laminin and integrin signalling, the Rho 
GTPases, Racl and cdc42 and action potential activity dependent signals such as ATP 
and adenosine (Stevens and Fields, 2000; Chan et al., 2001; Cosgaya et al., 2002; 
Feltri et al., 2002; Chen and Strickland, 2003; Yu et al., 2005; Bermingham et al., 
2006; Stevens, 2006; Nodari et al., 2007; Benninger et al., 2007; see section 1.5). O f 
the list above, adenosine is particularly interesting since it has been shown to activate 
cyclic AMP linked A2a receptors on Schwann cells and increase intracellular cyclic 
AMP to a similar level as 20pM forskolin treatment (which has similar effects as 
ImM dbcAMP) in cultured mouse Schwann cells (Stevens et al., 2004). It will be 
interesting to test whether adenosine can cooperate with NRGl signalling in mouse 
Schwann cells to regulate differentiation.
3.3.4 Cyclic AM P modulation of N R G l signalling in Schwann cells.
Cyclic AMP demonstrates concentration dependent effects in response to serum 
or N RG l in both rat and mouse Schwann cells. Low cyclic AMP concentrations 
promote proliferation whereas higher concentrations promote differentiation (Sobue et 
al., 1986; Mutoh et al., 1998; Fig. 3.1 A and B; P. Arthur-Farraj, K.Wanek and D.B. 
Parkinson, data not shown). One study demonstrated that low concentrations o f cyclic 
AMP promoted strong but transient phosphorylation of ERK1/2 pathway whereas
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concentrations 10 fold higher produced a lower but sustained activation o f ERK1/2 in 
rat Schwann cells (Mutoh et al., 1998). This idea o f transient versus sustained 
ERK1/2 activation is known to regulate proliferation and differentiation, respectively 
in other cell types (Marshall et al., 1995). Certainly, my finding that high 
concentrations o f dbcAMP actually reduce NRGl induced phosphorylation of 
ERK1/2 after 72 hours are consistent with this view. Another report demonstrated that 
forskolin addition also reduced MAP kinase activation by GGF (N RG l)(K im  et al., 
1997). In the presence o f high concentrations o f U0126 that presumably cause 
complete inhibition o f ERK1/2 activation, cAMP/NRG 1 is unable to induce myelin 
differentiation in mouse Schwann cells. This suggests that this low ERK1/2 activation 
is required for differentiation. Similarly, blocking ERK1/2 activation in dbcAMP 
treated rat Schwann cells abrogates myelin differentiation (Harrisingh et al., 2004; 
P.Arthur-Farraj, data not shown). It must be noted that blocking the MEK/ERK1/2 
pathway in Schwann cell/DRG cocultures did not affect myelination, although the 
data was not shown (Maurel and Salzer, 2000). Cyclic AMP has also been shown to 
prolong activation o f the PI3-K pathway in human Schwann cells (Monje et al., 
2006), although in my experiments blocking this pathway did not inhibit cyclic 
AMP/NRG induced differentiation and actually increased Krox-20 expression. 
Interestingly, a recent study demonstrated that constitutive over-activation of Akt in 
mouse Schwann cells does not affect myelination (Flores et al., 2008), however it is 
unknown whether Akt phosphorylation is actually required for PNS myelination.
Both cyclic AMP induced proliferation and differentiation appear to require 
PKA activation (Kim et al., 1997; Howe and McCarthy, 2000; Fig.3.5 and Fig.3.6, C), 
suggesting that cyclic AMP modulation of NRGl signalling also requires PKA 
activation. In support o f this activation of the epac pathway, a PKA independent
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cyclic AMP pathway did not appear to cooperate with NRGl to induce Schwann cell 
myelin differentiation (Fig.3.5) or increase proliferation (data not shown, unpublished 
observations). It is not known how PKA activation could lead to two alternative cell 
fates. One simple explanation is that low levels o f activation might promote 
proliferation whereas strong activation might be sufficient for differentiative changes. 
Also, the PKA holoenzymes, I and II have different affinities for cyclic AMP (PKA 
type I having roughly 4 times lower activation thresholds by cyclic AMP than PKA 
type II) and generally PKA type II is often confined to subcellular structures by A- 
Kinase anchoring proteins (AKAPs) whereas PKA type I is though to be located 
mainly in the cytoplasm. Futhermore, PKA and AKAPs can be specifically localised 
in lipid rafts with certain cellular receptors. Thus expression of different PKA 
holoenzymes, AKAPs and both of their subcellular localizations can all lead to the 
generation o f cell and signal specific responses to cyclic AMP (Tasken and Aandahl, 
2004). Clearly, further investigation is required to understand the mechanisms by 
which PKA can interact with growth factor pathways and regulate Schwann cell 
biology.
3.3.5. The role of CREB in Schwann cell biology.
The findings in this study suggest that the CREB family o f transcription factors 
may have a role in regulating Schwann cell differentiation. Active CREB can induce 
periaxin expression in mouse Schwann cells and this is potentially due to the presence 
o f a CRE -360bp from the transcriptional initiation site (Dytrych et al., 1998). 
However, the requirement for CREB in Schwann cell myelin differentiation appears 
to be at the level o f Krox-20 induction, although a potential role in Oct-6 induction 
cannot be ruled out (section 3.3.2). Yet CREB activation was not sufficient for robust
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Krox-20 expression in mouse Schwann cells, even in combination with NRGl (data 
not shown). Thus, CREB is likely to cooperate with other transcription factors such 
as, Oct-6, NF-kB and Sox-10 in inducing Krox-20 in response to cyclic AMP/NRG 1 
in mouse Schwann cells. Significantly, constitutively active CREB was a much more 
potent activator o f Krox-20 expression in rat Schwann cells, which may underlie part 
o f the reason why cyclic AMP elevation alone can induce Krox-20 in rat Schwann 
cells but not in mouse Schwann cells.
CREB has previously been shown to be phosphorylated at Ser-133 in response 
to NRGl treatment of rat Schwann cells, although addition o f 2pM  forskolin and 
N RGl induces a more sustained phosphorylation o f CREB (Tabernero et al., 1998; 
Rahmatullah et al., 1998). It has been postulated that CREB activation may have a 
role in Schwann cell proliferation (Rahmatullah et al., 1998), although A-CREB 
expression does not block NRG-1 or low cyclic AMP/NRG1 induced rat Schwann 
cell proliferation (K.Wanek, unpublished observations). Interestingly, CREB was 
shown to be phosphorylated in cultured Schwann cells after prolonged contact with 
neurite membranes (Lee et al., 1999), however it is not known whether CREB 
phosphorylation in Schwann cells is regulated by axonal contact in vivo.
The use o f the A-CREB inhibitor or the VP 16 fused constitutively active CREB 
molecule does not discriminate between CREB family members such as CREB1, 
ATF1 and CREM, thus it would be necessary to check the expression o f the various 
family members in Schwann cells. A CREB null mutation causes lethality in mice, 
late in embryogenesis (Rudolph et al., 1998), thus conditional inactivation o f CREB 
and potentially other family members would be a useful approach in the future to 
determine its role in Schwann cells.
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In summary this study has demonstrated that high concentrations o f cyclic AMP 
analogues in combination with NRGl signalling induce myelin differentiation in 
cultured mouse Schwann cells, including expression of Krox-20 and Po protein. 
Furthermore, PKA activation is sufficient to combine with NRGl signalling to induce 
Schwann cell differentiation and there is also a requirement for the CREB family of 
transcription factors in cyclic AMP/NRG1 induced Schwann cell differentiation.
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CHAPTER 4: The role of c-Jun in the Schwann cell response to
peripheral nerve injury.
4.1 INTRODUCTION
The success o f nerve regeneration after PNS injury is discussed in more detail 
in Chapter 1. However, the Schwann cell is thought to play a central role in the 
capacity of the PNS to regenerate. In particular, the fact that adult myelinating and 
non-myelinating Schwann cells retain the ability to dedifferentiate after injury and re- 
differentiate during axonal regrowth is thought to be a key step that is required for the 
regeneration process (Jessen and Mirsky, 2005).
The basic-leucine zipper transcription factor, c-Jun, is a member o f the AP-1 
transcription factor family forming dimers with itself or other members, including 
JunB, JunD, fos proteins (c-fos, FosB, Fra-1 and Fra-2) and some ATF/CREB family 
members. Whereas JunJun  and Jun:fos dimers bind AP-1 DNA elements or TREs 
(12-0-Tetradecanoylphorbol-13-acetate (TPA) responsive elements; 5’-TGAC/CTCA- 
3 ’), Jun.ATF dimers preferentially bind cyclic-AMP responsive elements (CRE, 5’- 
TGACGTCA-3’) (Shaulian and Karin, 2001). c-Jun and AP-1 transcriptional activity 
is activated by many signals but in particular by extracellular stress (Shaulian and 
Karin, 2001). Interestingly, in both hepatocytes and peripheral neurons, c-Jun is 
activated by tissue damage and is required for the in vivo regenerative ability o f these 
cell types (Behrens et al., 2002; Raivich et al., 2004). In the peripheral nerve, c-Jun is 
expressed in immature Schwann cells before birth (Stewart, 1995; Parkinson et al., 
2008). After birth, c-Jun is downregulated in Schwann cells that begin to myelinate 
and is therefore not expressed in myelinating Schwann cells in the adult and is only 
expressed at low levels in non-myelinating Schwann cells (Shy et al., 1996; Parkinson 
et al., 2008). However, Schwann cells re-express c-Jun protein during peripheral
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nerve injury or during culture (DeFelipe and Hunt, 1994; Stewart, 1995; Shy et al., 
1996; Soares et al., 2001; Parkinson et al., 2008). Thus c-Jun expression in Schwann 
cells appears to be correlated with the immature or denervated phenotype. To further 
investigate this, I wanted to discern whether c-Jun is in fact an axonally regulated 
factor or is simply activated by injury or cellular stress during peripheral nerve 
transection. Second, I wanted to test whether the dedifferentiation o f Schwann cells 
during nerve injury might actually require a transcriptional program to actively drive 
Schwann cells back to an immature-like state. Thus I sought to investigate the role of 
c-Jun as a potential regulator o f the cellular processes that occur in Schwann cells 
during peripheral nerve injury and regeneration (discussed in more detail in Chapter 
1).
Since mice lacking c-Jun die between E l 2.5 and E l3.5 with defects in cardiac 
morphogenesis and increased apoptosis of hepatoblasts and haematopoietic cells 
analysis o f the peripheral nervous system is not feasible (Hilberg et al., 1993; Johnson 
et al., 1993; Eferl et al., 1999). Therefore, I opted to generate a conditional knockout 
mouse in which c-Jun is specifically deleted in Schwann cells. To achieve this, I 
crossed a mouse carrying a floxed c-Jun gene (Behrens et al., 2002) with a transgenic 
P0 CRE  mouse, where CRE recombinase is expressed under the Schwann cell 
specific Po prom oter (Feltri et al., 1999a, 1999b). Both of these transgenic mice have 
been used previously: the c-Jun floxed mouse has been used to specifically delete c- 
Jun in hepatocytes and neurons (Behrens et al., 2002; Raivich et al., 2004) and the P0 
CRE  mouse has been used to ablate many genes, including (31-integrin, dystroglycan 
and TGFfJRII (Feltri et al., 2002; Saito et al., 2003; D ’Antonio et al., 2006b). In 
addition, c-Jun is located on chromosome 1 whereas the P0 CRE  allele has been 
mapped to chromosome 13 (M. D ’Antonio, personal communication) suggesting that
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the combination o f the c-Jun floxed and PO CRE mice should successfully ablate c- 
Jun in Schwann cells.
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4.2 RESULTS
4.2.1 The tim ing o f axonal degeneration during nerve injury, regulates the 
expression of both c-Jun and Krox-20 in Schwann cells.
Strong c-Jun protein expression in Schwann cells is not only inversely 
correlated with the presence o f axons but also with the expression o f the transcription 
factor Krox-20, that controls myelination both in vitro and in vivo (Shy et al., 1996; 
Parkinson et al., 2004; Parkinson et al., 2008). Thus, in vivo strong c-Jun expression 
can be used as a marker for denervated Schwann cells whereas Krox-20 expression 
denotes axon associated myelinating Schwann cells. To confirm whether this 
reciprocal relationship between Krox-20 and c-Jun is maintained during nerve injury 
in a situation where axons remain intact for prolonged periods of time, we performed 
sciatic nerve transections on control and Wlds transgenic mice. In Wlds mice axons 
remain intact for at least 14 days after nerve injury compared to 24-48 hours in 
control mice (Coleman et al., 2005; see section 1.6.1). Either 7 or 28 days after the 
initial surgery (see section 2.6 for protocol), the distal stumps o f control and Wlds 
mice were collected and processed for sectioning. 10pm thick cryosections o f each 
nerve were then immunolabelled with antibodies for c-Jun or Krox-20.
Confirming previous studies, in control mice, 7 days after sciatic nerve 
transection, axons have degenerated and Schwann cells in the distal stump are 
strongly immunoreactive for c-Jun protein and do not express Krox-20 (Fig. 4.1, A- 
E). Interestingly, Schwann cells in control mice appear to express a lower level o f c- 
Jun 28 days after nerve cut compared to 7 days after nerve injury (Fig. 4.1, K-O). 
However, in Wlds mice 7 days after nerve transection, when axons in the distal stump 
remain intact, Schwann cells do not express c-Jun and, remarkably, still express Krox- 
20 protein (Fig. 4.1, F-J). Only after 28 days post injury in W lds mice, when the
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majority o f axons have degenerated, do Schwann cells in the distal stump upregulate 
c-Jun protein and lose Krox-20 expression (Fig. 4.1, P-T). These results suggest that 
the loss o f Krox-20 and the upregulation of c-Jun expression in Schwann cells along 
the distal stump o f the nerve during injury are dependent on the eventual degeneration 
of the axon rather than the initial insult.
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Figure 4.1: Interruption of axon-Schwann cell interactions in both control and 
W lds mice determines c-Jun and Krox-20 expression after sciatic nerve injury.
(A-E) Schwann cells in the distal stump of control sciatic nerve 7 days after 
transection express high levels of c-Jun (arrowheads) and do not express Krox-20. 
(F-J) Schwann cells in the distal stump of the Wlds sciatic nerve 7 days after 
transection do not express c-Jun and still express Krox-20 protein (arrows).
(K-O) Schwann cells in the distal stump o f control sciatic nerve 28 days after 
transection still express c-Jun (arrowheads), albeit at a lower level, and do not express 
Krox-20.
(P-T) Schwann cells in the distal stump of the Wlds sciatic nerve 28 days after 
transection now express high levels of c-Jun (arrowheads) and have lost expression of 
Krox-20 protein.
(Panels A, F, K and P) Axonal degeneration in each condition was determined by 
morphology in 1pm thick transverse semi-thin sections o f the distal stump o f nerves 
stained with toluidine blue. Note the preservation of intact axons and myelin sheaths 
in W lds sciatic nerve 7 days after transection (F), whereas axons and myelin sheaths 
have degenerated in all other conditions (A,K and P). Scale bars, 20pm.
(Panels, B-E, G-J, L-O and Q-T). 10pm thick longitudinal cryosections o f nerves 
from each condition were immunolabelled with polyclonal antibodies for either c-Jun 
or Krox-20 and co-stained with hoescht nuclear dye (Ho). Scale bars, 20pm.
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4.2.2 Generation of mice conditionally null for c-Jun in Schwann cells.
To further investigate the role that c-Jun plays in Schwann cells during nerve 
injury I decided to conditionally inactivate c-jun in Schwann cells in vivo. To achieve 
this, mice that carried two floxed c-jun alleles (c-jun[i; c-jun floxed mice) were used. 
In the c-Jun floxed mouse, loxP sites are inserted either side o f the c-jun open reading 
frame. In the presence o f cre-recombinase, the DNA between the two loxP sites is 
recombined and c-jun is excised from the genome (Behrens et al., 2002; Fig. 4.2, A).
f/f*Homozygous c-jun mice were crossed with heterozygous transgenic mice that 
express cre-recombinase under the Schwann cell specific promoter of the Po gene (P0 
CRE\ Feltri et al., 1999a, b) in order to obtain mice that lack c-jun in Schwann cells 
{c-jun^j. c-jun ^  mice were born approximately with Mendelian frequencies and were
f/f'
viable, fertile and indistinguishable from control littermates (c-jun ; P 0 CRI<7). I 
confirmed that c-jun had successfully been deleted in sciatic nerve extracts of c-jun vS
f  \  r  r y r
mice and not c-jun mice by PCR (Fig. 4.2, B). In contrast to c-jun mice, very little 
c-Jun protein is expressed in the sciatic nerve o f adult c -ju n ^  mice, 7 days after 
sciatic nerve transection, judged by Western blotting and immunocytochemistry (Fig.
4.2, C-G). Additionally, purified dedifferentiated Schwann cell cultures were made 
from P5 c -ju n ^  and c-junm mice and immunolabelled for c-Jun. Whereas, 94 +/-1.2% 
of cells from c-junm Schwann cell cultures were c-Jun positive, only 4.8 +/-1.3% of 
cells from c -ju n ^  Schwann cell cultures expressed c-Jun (n=4)(p< 1.0*1 O'10).
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Figure 4.2: Conditional ablation of c-jun from Schwann cells.
(A) Schematic representation of the c-jun targeting locus, the c-jun floxed allele ( o  
ju n {) and the c-jun deleted allele (c-junA). The c-jun open reading frame is 
characterized by a rectangle and the thin lines represent the untranslated region o f the 
c-jun locus. The neomycin resistance gene (NeoR) and the thymidine kinase gene (tk) 
are also shown. Adapted from Behrens et al., (2002).
(B) PCR analyis for the deleted c-jun allele (c-junA) from genomic DNA from either 
tail (T) or sciatic nerve (N) of mice from the indicated genotypes. Note that the c- 
ju n A allele is only seen in the nerve from c-junm\ P 0 C RE+ and c-junf' \ Po CRE* 
animals and not the tail where Po CRE  is not expressed (M. D ’Antonio personal 
communication). No PCR product is seen in either the tail or the nerve o f c-junm\ P 0 
C R E  animals. Equal amounts o f DNA were amplified in each reaction. PCR for 
Interleukin-2 (IL-2) ensured DNA integrity.
(C) Western blot o f uninjured (U) and 7 day transected (C) sciatic nerve extracts from 
c-junt f (<c-junm; Po C R E )  and c-jun** (c-junm\ P 0 C RE+). GAPDH is used as a loading 
control.
(D-G) Immunohistochemistry for c-Jun shows c-Jun is barely expressed in Schwann 
cells o f the distal stump 7 days after sciatic nerve cut in c-jun** animals (E and G) in
r/r
comparison to c-jun animals (D and F). Sections are co-labelled with hoescht 
nuclear dye (Ho). Scale bar, 50pm.
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4.2.3 The adult tibial nerve develops normally when Schwann cells lack c-jun .
Although the c-jun™ adult tibial nerve appeared histologically normal (Fig.4.3, 
A and B), I wanted to investigate in more detail whether there were any quantifiable 
differences between the c-junn and the c-jun™ peripheral nerves. Since c-Jun has been 
identified as an inhibitor o f in vitro myelin differentiation (Parkinson et al., 2008), it 
was important to discern whether there were any abnormalities in the myelin sheath 
structure or number in peripheral nerves. The mean measurement of myelin sheath
f/f'thickness by g-ratio for all axonal sizes in c-jun nerves was 0.67 whereas the g-ratio 
was 0.70 for c-jun™ nerves suggesting myelin sheaths may be slightly thinner in the 
absence of c-jun. However, the differences in g-ratio between c-junm and c-jun™ mice 
for each axonal size were not statistically significant (n=3)(p=0.1, Mann-Whitney U 
test)(Fig.4.3, C). Furthermore, there was no statistical difference in total number of
f/fmyelinated axon profiles per tibial nerve, with 2296 + /-115 in the c-jun animal and 
2156 +/-221 in the c-jun™ animal (p=0.7, Mann-Whitney U test) (n=r3)(Fig.4.3, D).
c-Jun is expressed at low levels in non-myelinating Schwann cells in the adult 
rodent PNS (Shy et al., 1996). Therefore, I wanted to examine whether there were any 
differences in non-myelinating Schwann cells or unmyelinated axon number in the 
tibial nerve o f the c-jun™ mouse compared to the c-jun{ { mouse. I found that there was 
no statistically significant alteration in the number o f non-myelinating Schwann cells 
or unmyelinated axons in the tibial nerve, with 614 +/-124 non-myelinating Schwann 
cells in the c-junm mouse compared to 538 +/-49 (n=4) (p=0.6, Mann-Whitney U test) 
in the c-jun™ mouse and 5486 +/-871 and 4614 +/-577 (n=4) )(p=0.2, Mann-Whitney 
U test) for the unmyelinated axons, respectively (Fig.4.3, E and F). Thus the adult 
peripheral develops relatively normally in the absence o f c-jun in Schwann cells.
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Figure 4.3: Normal tibial nerve morphology and axon number in c-jun** mice.
(A and B) Electron micrographs showing no obvious differences in tibial nerve 
morphology between c-junvr and c-jun'* mice. Scale bar, 10pm.
(C) Myelin sheath thickness measured by g-ratio (diameter of axon/ diameter o f axon 
+sheath) for different sizes o f axon in the tibial nerve o f c-junfl[ and c-jun*s mice. The 
mean g-ratio for each axonal size category is shown along with linear regression lines 
for nerves o f c-junm and c-jun** mice. Error bars show the standard deviation of the 
mean. Notice that the g-ratios for c-jun** mice appear slightly higher than for c-junt{ 
animals although the differences in g-ratio for every axonal category were not 
statistically significant using the Mann-Whitney U test.
(D) Total number of myelin sheaths in the tibial nerve at mid thigh level in c-jun1 f and 
c-jun** mice. Error bars show the standard deviation of the mean.
(E) Total number o f non-myelinating Schwann cell profiles (Remak fibres) in 
transverse profile at mid-thigh level in the tibial nerve in c-junM and c-jun** mice. 
Error bars show the standard deviation of the mean.
(F) Total number o f unmyelinated axons in the tibial nerve at mid thigh level in c- 
ju n m and c-jun** mice. Error bars show the standard deviation of the mean.
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4.2.4 The role of c-jun in Schwann cell demyelination
4.2.4.1 Myelin sheath fragmentation is delayed after nerve transection in the 
absence of c-jun.
Within 2 to 3 days after peripheral nerve injury, myelin sheaths begin to break 
up into characteristic ovoid structures (see Chapter 1). This occurs at a similar time to 
the upregulation o f c-Jun protein in Schwann cells of the distal stump (Parkinson et 
al., 2008). I wanted to test whether c-Jun played any role in regulating the rate of 
myelin sheath break up after nerve injury. To do this, I performed sciatic nerve 
transections on c-jun1 f and c-jun** mice. I then sacrificed the mice at either 3, 5 or 7 
days after the surgery and removed a 1 cm length o f the stump distal to the transection 
site. Nerves were then processed for electron microscopy. Ultra-thin sections were cut 
and viewed under a transmission electron microscope (see Chapter 2). On first 
inspection o f the distal stumps, 3 days after nerve transection, at 1mm from the site of 
injury, I saw a remarkable preservation of the myelin sheaths in the c-jun** mice
f'T •compared to the c-jun mice (Fig.4.4, A and B). I counted the total number o f intact 
myelin sheaths remaining in the distal stump, with 217 +/-289 sheaths in c-junf f  mice 
compared to 1064 +/-318 sheaths in c-junAs mice (n=5)(p<0.05)(Fig.4.4, C). At 5 and 
7 days after nerve cut, at 5mm from the site o f injury, there was still a significant 
difference in myelin sheath preservation, with 268 +/-55 compared to 504 +/-101 for 
c-junm and c-junAs mice, 5 days after nerve cut (n=5)(p<0.05), and 75 +/-20 versus 
124 +/-25, 7 days after nerve cut, respectively (n=5)(p<0.05)(Fig.4.4, D). Importantly, 
there is a noticeable drop in the number of intact sheaths in c-junAs mice between 5 
and 7 days (p<0.01) suggesting that the lack of c-jun in Schwann cells only causes a 
delay in myelin sheath fragmentation after nerve cut rather than a complete block 
(Fig.4.4, D).
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In addition I examined whether there was a difference in the rate of myelin 
protein clearance after sciatic nerve transection, in the absence o f c-jun in Schwann 
cells. To test this, I labelled 10pm thick cryosections of 7 day cut sciatic nerves with a 
polyclonal antibody to the myelin protein, P0. Confocal microscopy revealed that 
there was a visibly greater area of the nerve labelled with P0 antibodies in c-jun'* 
compared to c-jun11 mice (n=3)(Fig.4.4, E and F).
Interestingly, the onset of axonal degeneration remains unaffected in c-jun*  
mice, since electron micrographs demonstrate that even though the myelin sheath may 
remain intact the space in between contains only axonal debris (Fig. 4.5, A-D). 
Furthermore, immunostaining for (3-tubulin, 3 days after nerve cut, demonstrates that 
axonal microtubules have fragmented to a similar degree in the c-jun1 f and c-jun*  
animals (Fig. 4.5, E-H). In summary, these results suggest that, while Schwann cell c- 
ju n  may not be necessary for axonal degeneration, it is required for rapid 
demyelination after peripheral nerve injury.
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Figure 4.4: Demyelination after nerve injury is delayed in the absence of c-jun in 
Schwann cells.
(A and B) Electron micrographs o f the distal stump, 1mm from the site o f injury o f c- 
ju n if  and c-jun** animals, 3 days after sciatic nerve transection. Scale bar, 20pm.
(B) Number of remaining intact sheaths per tibial nerve, 3 days after cut at 1mm from 
the site o f injury in c-jun11 and c-jun** animals. Error bars show the standard deviation 
o f the mean. Statistical analysis was performed using the Mann-Whitney U test.
(D) Number o f remaining intact sheaths per tibial nerve, at 5 and 7 days after cut at 
5mm from the site of injury, in c-junm and c-jun** animals. Error bars show the 
standard deviation o f the mean. Statistical analysis was performed using the Mann- 
Whitney U test.
(E and F) Confocal images o f immunohistochemistry for Po in c-junM and c-jun** 
nerves, 7 days after nerve cut, 5mm from the site o f injury. Note that Po staining is 
brighter and covers a greater proportion o f the c-jun** nerve in comparison to the c-
■ f / fju n  nerve.
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Figure 4.5: The onset of axonal degeneration is unaffected by deletion of c-jun in 
Schwann cells.
(A-D) Electron micrographs demonstrating axons in c-junm and c-jun** animals, 
before (uninjured) and 3 days after sciatic nerve cut. Note the loss o f axonal contents 
such as mitochondria and microtubules in both c-junft and c-jun** nerves after injury. 
Scale bar, 2pm.
(E-H) Immunostaining for p-tubulin (T uJl) in c-junm and c-jun** animals, before 
(uninjured) and 3 days after sciatic nerve cut. Note the broken pattern of staining, 3 
days after cut, suggesting microtubules are fragmenting in both c-junm and c-jun*s 
nerves. Scale bar, 50pm.
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4.2.4.2. Myelin sheath fragmentation is delayed even when haematogenous 
macrophages are prevented from entering the degenerating c-jun** nerve.
Macrophages play a significant role in removing degenerating myelin from the 
distal stump o f degenerating nerves. Two populations of macrophages contribute to 
removing myelin debris, the resident and the haematogenous macrophages, with the 
haematogenous group removing the large majority o f myelin, starting from 3 days 
after nerve injury (see section 1.6.5). In order to discount the possibility that the delay 
in demyelination in the c-jun** animals was solely due to an effect on haematogenous 
macrophage function, I observed c-jun1 f and c-jun** nerves degenerate in the absence 
o f invading macrophages. To achieve this, I removed equal length segments (about 
6mm, starting at the sciatic notch) from the tibial nerve from c-junfi and c-jun** 
animals and placed them floating in a 35mm tissue culture dish containing DMEM 
and 5% HS at 37°C for 6 days (see section 2.3.7). After this period, nerves were fixed 
and processed for resin sections and analysed by electron microscopy. Only the 
middle 2mm o f each nerve segment was analysed in order to standardise the 
observations between conditions. I found that there was still a striking preservation of 
myelin sheaths in the c-jun** nerve segement, with 604 +/-110 intact sheaths in 
comparison to 234 +/-62 in the c-junm nerve (n=4)(p<0.05)(Fig.4.6, A-C). These 
results suggest that at least part o f the delay in demyelination observed in the c-jun** 
nerve is not due to a defect in the recruitment of haematogenous macrophages.
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4.2.4.3. Demyelination is delayed in dissociated Schwann cell cultures deficient in 
c-jun.
In order to test whether there was an intrinsic deficit in the ability o f Schwann 
cells to clear myelin debris in the absence of c-jun, I studied demyelination in 
dissociated Schwann cell cultures. Both sciatic nerves were dissected from P8 c-juni{ 
and c-junAs animals, dissociated in trypsin and collagenase and then plated on laminin 
coated coverslips, at a concentration of a 1000 cells per 15pl drop, in DM 
supplemented with 0.5% HS and AraC (10‘5M). Cells were cultured for a maximum 
of 10 days with half the medium replaced every 3 days. Cells were then fixed and 
immunolabelled for the myelin proteins, Po and myelin basic protein (MBP) at 3 
hours, 3, 5, 7 and 10 days after plating. Coverslips were also immunolabelled with an 
antibody against S I00(3, in order to identify Schwann cells (see section 2.3.7).
In the absence o f c-jun , cultured Schwann cells were unable to rapidly clear 
myelin proteins, retaining myelin debris which was immunoreactive to Po and MBP, 
within their cytoplasm (Fig.4.6, D-G). When I quantified the rate o f loss o f either P0 
or MBP protein, it was significantly delayed in c-junAs Schwann cells compared to c-
f / fju n  cells, at all time points studied relative to the 3 hour time point (n=5)(p<0.0001) 
(Fig.4.6, H-I). These cultures contained macrophages that were normally resident in 
uninjured nerves, judged by immunolabelling for the macrophage specific marker, 
F4/80. However there was no difference in macrophage number between genotypes, 3 
days after culturing, with 5.6 +/-1.8% and 5.8 +/-1.7% in ju n m and c-junAs cultures 
respectively. Importantly, no F4/80 positive cells contained any myelin debris at this 
time point, suggesting that these cells were not contributing significantly to the 
removal o f myelin (data not shown). Together these results demonstrate that c-jun is
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necessary for dissociated Schwann cells to quickly remove myelin debris from their 
cytoplasm using a mechanism that does not rely on the function o f macrophages.
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Figure 4.6: Cell autonomous delay in demyelination in c-jun*s Schwann cells.
(A and B) Electron micrographs showing, c-junm and c-jun** tibial nerve segments 
after 6 days in vitro. Scale bar, 5pm.
(C) Number o f intact myelin sheaths remaining in c-jun1'1 and c-jun** tibial nerve 
segments after 6 days in vitro. Error bars show the standard deviation o f the mean. 
Statistical analysis was performed using the Mann-Whitney U test.
(D-G) Dissociated Schwann cells from c-jun1 A and c-jun** P8 nerves, after 5 days in 
culture. Cells are stained with antibodies to the Schwann cell marker, S I00(3 and to 
MBP and also with hoescht nuclear stain (Ho). Arrowheads in E and G demonstrate c- 
ju n  null Schwann cells containing MBP positive myelin debris. Note that c-jun null 
Schwann cells develop a flattened morphology with multiple filopodia whereas c-
f/fju n  Schwann cells have a bipolar shape, characteristic of dedifferentiated Schwann 
cells in culture.
(H) Total number o f MBP positive c-junm and c-junAS Schwann cells over a lOday 
period o f culturing, expressed as a percentage o f the total number o f MBP positive 
cells at the 3 hour time point. Error bars show the standard deviation o f the mean. 
Statistical analysis was performed using two-way ANOVA and the unpaired students 
t-test.
(I) Total number o f Po positive c-junm and c-junAs Schwann cells over a 10 day period 
o f culturing, expressed as a percentage of the total number o f P0 positive cells at the 3 
hour time point. Error bars show the standard deviation of the mean. Statistical 
analysis was performed using two-way ANOVA and the unpaired students t-test.
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4.2.4.4. Clearance of myelin debris is still delayed 28 days after sciatic nerve 
transection in c-junAs animals.
The clearance o f myelin debris from peripheral nerves is thought to be largely 
complete by 14 days after injury (Vargas and Barres, 2007). To determine whether 
myelin debris is eventually cleared from c-jun1* nerves, I performed sciatic nerve cuts 
on both c-junm and c-jun1* animals, where the proximal stump was sutured into the 
gluteal muscles to prevent axonal regeneration into the distal stump (see section 2.6). 
Distal stumps from both sets of animals were then analysed, 28 days after the original 
surgery, a time point when myelin debris removal should be complete. Remarkably, 
28 days after sciatic nerve transection, the distal stump o f the c-jun** mouse still 
maintained a white opaque appearance whereas the distal stump of the c-junm animal 
had become translucent (n=5)(Fig.4.7, A and B), suggesting that, in the absence o f c- 
ju n , myelin lipid clearance may still be delayed at this time point.
To assess the remaining amount o f myelin lipid in the distal stumps o f both 
genotypes, I stained 10pm thick cryosections of both sets o f nerves with 2% osmium, 
a lipid stain (Wigglesworth, 1957; Hayes et al., 1963). Whereas uninjured nerves from 
c-junm and c-jun** animals stained heavily with osmium (Fig. 4.7, C and D), the 28
f fday cut c-jun nerve showed very little osmium stain, demonstrating that clearance of 
myelin lipids was complete (Fig.4.7, E). In contrast, the 28 day cut c-jun** nerve 
demonstrated considerable osmium stain (Fig.4.7, F). I then quantified the percentage
• fyrof nerve area stained with osmium relative to the uninjured nerves. In the c-jun 
distal stump only 1.1 +/-0.6% of the original nerve area contained myelin lipid 
compared to 17.4 +/-1.1% in the jun*s nerve, 28 days after injury
(n=3)(p<0.001)(Fig.4.7, G). Thus myelin lipid clearance is still delayed at 28 days 
after nerve cut in the absence of c-jun in Schwann cells.
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In addition, I analysed the nerve ultrastructure o f the c-jun[i and c-junAs distal 
stumps, at 28 days after transection, by electron microscopy, to ascertain which cell 
types contained remaining myelin debris. In the c-junm mouse, the majority of the 
distal stump contained large deposits of collagen and little myelin debris confirming 
the previous results. Discreet myelin whorls were often seen in macrophages but 
Schwann cells were always completely devoid of any myelin debris (Fig.4.7, H and 
J). The histology o f the c-junAs nerve, 28 days after transection, was radically 
different. First, the nerve contained a lot of myelin debris and lipid droplets, the 
majority of which appeared to be inside grossly enlarged macrophages. In addition, 
Schwann cells, identified by their basal lamina, also often contained lipid droplets,
f/f
which was in complete contrast to Schwann cells in the c-jun nerve. Furthermore, 
characteristic structures, known as the Bands of Bungner that contain multiple
f / fSchwann cell processes inside a single basal lamina tube are seen in the c-jun distal 
stump, but do not develop normally in the c-jun** nerve. Instead, a single Schwann 
cell process is seen in continuous association with the basal lamina (Fig. 4.7, H-K). In 
summary, these observations demonstrate that Schwann cells without c-jun are still 
impaired in processing myelin debris 28 days after nerve transection. c-Jun also 
appears to be important for Schwann cell morphology and correct formation o f the 
Bands o f Bungner. Moreover, macrophages in the c-jun** nerve appear to be unable to 
properly clear degenerating myelin once they have phagocytosed it, suggesting 
possible altered signalling between Schwann cells and macrophages in the c-jun** 
mouse.
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Figure 4.7: Delayed clearance of myelin debris by Schwann cells and
macrophages, 28 days after transection in the c-junAs sciatic nerve.
(A and B) Photographs of the distal stumps (black arrows), 28 days after sciatic nerve 
transection (cut), o f c-jun1,1 and c-jun** animals. Note that the control nerve (arrow) is 
translucent whereas the c-jun** nerve (arrow) remains opaque.
(C-F) 10pm thick cryosections, stained with 2% osmium, o f uninjured nerves in 
transverse section (C and D) and distal stumps, 28 days after nerve transection, in 
longitudinal section (E and F), from c-jun[( and c-jun** animals respectively. Scale 
bar, 50pm. Note the increased osmium stain in the c-jun** cut nerve compared with
f / fthe c-jun nerve.
(G) Percentage o f area stained by osmium in the c-junm and c-jun** 28 day cut nerves, 
relative to c-jun*f and c-jun** uninjured nerves. Error bars show the standard deviation 
o f the mean. Statistical significance was determined using the Mann-Whitney U test.
f / f(H and I) Electron micrographs demonstrating the overall histology of the c-jun and 
c-jun** nerve 28 days after sciatic nerve transection. Black arrowheads identify 
macrophages in both conditions. Note the enlarged size of the macrophages in the c- 
ju n ** nerve. Macrophages in the jun** nerve also appear to contain a more 
heterogeneous array of degenerating myelin profiles as well as many lipid droplets, in
f / f  •comparison to macrophages in the c-jun distal stump. Scale bar, 5pm.
(J and K) Electron micrographs showing the structure o f Schwann cells in the distal 
stump o f c-junm and c-jun** nerves 28 days after sciatic nerve transection. The red 
arrow demonstrates a Schwann cell containing a large lipid droplet in the c-jun** 
nerve. The black arrow shows the morphology of Schwann cells, identified by their 
basal lamina, 28 days after nerve cut in the c-junM and c-jun** distal stumps. Note how 
in the c-junm nerve multiple cell processes are found with collagen within one basal 
lamina tube (Bands o f Bungner; see also inset in J, small black arrowheads denote the 
basal lamina), whereas in the c-jun** nerve a single continuous cell process often with 
an asteroid morphology is seen adhering to the basal lamina (see also inset in K, small 
black arrowheads denote the basal lamina). Scale bar, 2pm (scale bar for inset figures, 
0.5pm).
195
28 days post cut 
Schwann cells Macrophages 28 days post cut
28 days post cut Uninjured
o
% Osmium 
stained area
o  t* o  o  o? o
Figure 
4.7
4.2.5. c-Jun is an inhibitor of Schwann cell myelin differentiation.
As mentioned earlier, expression of c-Jun appears to be negatively correlated 
with the myelinating Schwann cell phenotype, both in vivo and in vitro (Parkinson et 
al., 2004, 2008). This leaves the intriguing possibility that c-Jun expression may 
actually antagonize Schwann cell myelin differentiation. To resolve this issue, I took 
advantage o f the fact that c-Jun is constitutively expressed by dedifferentiated 
Schwann cells, maintained under quiescent conditions in culture. Schwann cell 
cultures were prepared from c-junm P5 mice and infected with an adenovirus 
expressing cre-recombinase (Ad-Cre) in order to create c-jun-null Schwann cells 
(Fig.4.8, A-D). Schwann cells were maintained in DM and 0.5% HS during Ad-Cre 
infection and the medium was then changed to DM after 24 hours. 48 hours after the 
Ad-Cre infection, I induced these Schwann cells to ‘myelin-differentiate’ using two
CjC
separate methods. Some c-jun and c-jun-null Schwann cells were infected with a 
Krox-20 expressing adenovirus (Ad-Krox-20), for 48 hours, to activate myelin genes,
f / fwhereas other c-jun and c-jun-null Schwann cells were treated with a combination 
o f ImM  dbcAMP plus 20ng/ml NRG1 (dbcAM P/NRGl), for 72 hours, in order to 
induce myelin gene expression (see Chapter 3). Activation of the myelin gene, Po, in
f / fc-jun-nu\\ Schwann cells was greatly enhanced, compared to c-jun , with an increase 
from 48.1 +/-3.0% to 79.4 +/-5.5% P0 positive cells, when infected with Ad-Krox-20 
(n=4)(p<0.001)(Fig. 4.8, E-I) and an increase from 15.2 +/-0.5% to 38.6 +/-5.9% P0 
positive cells, when treated with dbcAMP/NRGl (n=4)(p<0.01)(Fig. 4.8, J-L). 
However, genetic removal of c-jun alone or in addition to treatment with ImM  
dbcAMP was not sufficient to activate significant expression o f the myelin genes, 
Krox-20, with 0 and 0.35 + /-0 .1% positive cells, or Po, with 0.5 +/-0.7% and 4 +/- 
4.2% positive cells, in their respective conditions (n=4) (p=0.2).
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Collectively, these results demonstrate that although removal o f c-jun alone is 
not sufficient to activate myelin gene expression, the constitutive endogenous 
expression o f c-Jun in cultured mouse Schwann cells acts as a brake on myelin gene 
activation.
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Figure 4.8: c-Jun acts as a negative regulator of myelin differentiation in 
cultured Schwann cells.
(A-D) EfTicency o f removal of c-jun from c-junlt Schwann cells (c-jun-null) using an 
adenovirus expressing cre-recombinase (Ad-Cre). (A and B) Immunocytochemistry 
for c-Jun in c-junm and c-jun-nu\\ Schwann cell cultures, respectively. (C and D)
f , i '
Immuncytochemistry for cre-recombinase in c-jun and c-jun-null Schwann cell 
cultures, respectively. Cells were co-stained with hoescht nuclear dye (Ho). In c-jun11 
cultures, 94.4 +/-4.1% of Schwann cells expressed c-Jun whereas in c-junm cultures 
treated with Ad-Cre only 2.6 +/-0.2% of cells expressed c-Jun, 48 hours after 
infection (n=3). Scale bar, 50pm.
(E-H) Genetic removal o f c-jun greatly increases expression of Po in Schwann cells (E 
and F) when infected with an adenovirus expressing Krox-20/GFP (Ad-Krox-20) (G 
and H). Cells were co-stained with hoescht nuclear dye (Ho). Scale bar, 50pm.
f / f(I) The number of Po expressing Schwann cells in c-jun and c-jun-null Schwann 
cells 48 hours after infection with Ad-Krox-20. Error bars show the standard 
deviation o f the mean.
(J and K) Enhanced Po expression by c-jun-null Schwann cells, in comparison to c-
f/Fju n  Schwann cells, when cultures were treated with ImM  dbcAMP and 20ng/ml o f 
NRG-1 (dbcAM P/NRGl) for 72 hours. Cells were co-stained with hoescht nuclear 
dye (Ho). Scale bar, 50pm.
(L) The number o f Po expressing Schwann cells in c-junm and c-jun-null Schwann 
cells 72 hours after treatment with dbcAM P/NRGl. Error bars show the standard 
deviation of the mean.
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4.2.6. Differential requirements for c-jun in Schwann cell proliferation, 
depending on stimuli.
Previous studies have identified a requirement for the JNK/c-Jun pathway in 
NRG1 induced Schwann cell proliferation, through use of chemical inhibitors 
(Parkinson et al., 2004). I decided to test the requirement for c-Jun in NRG-1 induced 
Schwann cell proliferation in culture. As in section 4.2.5, c-jun-nu\\ Schwann cells 
were created by infecting P5 c-junm cells with Ad-Cre. 48 hours after infection, cells 
were maintained in DM and treated with 20ng/ml NRG1 for a further 72 hours, with 
BrdU added for the last 24 hours of the experiment. Cells were then fixed and 
immunolabelled with a monoclonal antibody to BrdU. In the absence of c-jun, 
Schwann cells showed a reduced level o f BrdU incorporation in response to NRG1, 
with 51.3 +/-2.4% of BrdU positive c-junV{ cells in comparison to 25.6 + /-0 .1% of 
BrdU positive c-jun-nu\\ Schwann cells (n=3)(p<0.05)(Fig.4.9, A). Therefore, c-Jun is 
necessary for the full proliferative effect of NRG1 on cultured Schwann cells.
After peripheral nerve injury, activated Schwann cells enter the cell cycle. 
Proliferation rates peak around 3 to 5 days after nerve injury in rodents (see section 
1.6.4; Friede and Johnstone, 1967; Carroll et al., 1997), which also coincides with c- 
Jun expression in Schwann cells along the distal stump (Parkinson et al., 2008). I 
wanted to investigate whether c-jun had a role in Schwann cell proliferation after
• • • • F'Fnerve transection in vivo. To test this, I performed sciatic nerve transections on c-jun 
and c-junAs. 5 days after the injury, mice were injected, intra-peritoneally, with BrdU 
solution for 2 hours before animals were sacrificed and both the injured and the 
contralateral uninjured sciatic nerves were dissected and frozen (see section 2.8). 
10pm thick cryosections of nerves were cut and co-immunolabelled with a 
biotinylated-BrdU antibody and a S I00(3 antibody, to recognise Schwann cells
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undergoing DNA synthesis. A total of 15 separate areas over 3 different sections were 
analysed for each nerve and the total number of proliferating cells per 1mm2 of nerve 
was calculated.
As expected, uninjured contralateral sciaitc nerves from c-jun1,1 and c-jun** 
showed no evidence of BrdU incorporation in endoneurial cells (n=4) (Fig.4.9, B and 
C). However, 5 days after sciatic nerve transection there was a large increase in BrdU 
incorporation in endoneurial cells yet, surprisingly, there was no significant difference 
in the number o f BrdU positive cells between the two genotypes, with 202 +/-24 
cells/mm2 in c-junm mice and 255 +/-47 cells/mm2 in the c-junss mice (n=4)(p=0.2, 
Mann-Whitney U test)(Fig.4.9, D-F). These experiments indicate that while c-jun is 
required for the full mitogenic effect of NRG1 on dedifferentiated Schwann cells in 
culture, c-jun appears to be dispensable for the induction of Schwann cell DNA 
synthesis after peripheral nerve injury.
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Figure 4.9: c-jun is required for NRG1 induced Schwann cell DNA synthesis in 
vitro but is not necessary for Schwann cell proliferation after peripheral nerve 
injury.
(A) The percentage o f Schwann cells that incorporate BrdU in c-junm and c-jun-null
f / f{c-jun + Ad-Cre) cultures, when treated with the mitogen NRG1 for 72 hours. Error 
bars show the standard deviation of the mean. Note lower rates o f DNA synthesis in 
c-jun-null Schwann cells.
(B-E) Immunohistochemistry for BrdU and SlOO^on c-junm and c-junAs uninjured 
nerves (B and C) and nerves 5 days after sciatic nerve transection at 5mm distal to the 
injury site (D and E). Scale bar, 50pm.
(F) The number o f BrdU positive nuclei per 1mm2 of nerve, 5 days after sciatic nerve 
transection, at 5mm distal to the injury site. Error bars show the standard deviation of 
the mean. Note that there is no significant difference in the rates o f DNA synthesis 
between control and c-junAs Schwann cells within the distal stump.
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4.2.7. In the chronically injured peripheral nerve, Schwann cell number is 
reduced in the absence of c-jun.
Since injury induced Schwann cell DNA synthesis does not appear to require o  
jun , I wanted to confirm these results by examining the number of Schwann cell 
nuclei present in both the c-junm and c-junAs nerves at long time points after injury. 
Schwann cell nuclei were sampled in transverse, ultra-thin resin sections of the tibial 
nerve, at mid thigh level and identified by their association with basal lamina (see 
Fig.4.7, H and I). Fibroblasts and endothelial cells were easily identifiable and were 
not confused with Schwann cells due to their lack of a basal lamina. Furthermore, 
macrophages were recognized by their multiple processes, condensed peripheral 
nuclear chromatin and frequently they contained multiple digestion chambers full of 
myelin debris (see Fig.4.7, J and K). Schwann cell numbers were then standardised 
against the total tibial nerve area and expressed per 10,000pm2 of nerve.
In uninjured c-jun{f and c-jun** nerves there was no difference in the number of 
Schwann cell nuclei, with 11 +/-2 nuclei/10,000pm2 of nerve in both genotypes (n=3). 
28 days after nerve cut, there was a significant increase in Schwann cell nuclei
2 • f / fcompared to uninjured nerves, with 37 +/-7 nuclei/10,000pm of nerve in c-jun mice 
(p<0.01) and 23 +/-7 nuclei /10,000pm2 of nerve in c-junss mice (p<0.05). 
Interestingly, there was also a significant difference between the number of nuclei at 
28 days in c-junm and c-junAs cut nerves (n=4)(p<0.05). 70 days after nerve crush, the
number of Schwann cell nuclei was also significantly increased in both genotypes
2 r fcompared to uninjured controls, with 49 +/-8 nuclei/10,000pm of nerve in c-jun 
mice (p<0.01) and 41 +/-10 nuclei/10,000pm2 of nerve in c-junAs mice (p<0.01). 
However, there was no significant difference between Schwann cell nuclei number 
between c-junf f and c-junAs nerves, 70 days after nerve crush (n=5)(p=0.2)(Fig.4.10,
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A). These results demonstrate that, although there is an increase in Schwann cell 
number in both c-juni[ and c-jun** nerves after nerve cut and crush compared to 
uninjured nerves, there are relatively fewer Schwann cells in c-jun** cut nerves 
compared to c-junm cut nerves, 28 days after transection. However, 70 days after 
nerve crush there are similar numbers of Schwann cells in the distal stump of c-jun111 
and c-jun** animals.
The above results were surprising, especially given that there was no difference 
in Schwann cell proliferation rates, 5 days after nerve cut, in the absence of c-jun 
(section 4.2.6). However, recent findings have shown that adult mouse Schwann cells 
are susceptible to apoptotic death after peripheral nerve injury, particularly after nerve 
cut (Yang et al., 2008). Thus, it was important to check whether there was increased 
apoptosis in the c-jun1* nerve after transection, which might explain the reduction in
• . . f/fSchwann cell nuclei at 28 days after cut. To investigate this possibility, c-jun and c- 
ju n AS nerves were cut and 5 days after the operation, a time point reported to be the 
peak o f Schwann cell apoptotic death (Yang et al., 2008), nerves were dissected and 
frozen. lOpm-thick cryosections were cut and immunolabelled using the TUNEL 
technique to detect nuclear fragmentation (see section 2.12). In c-junm and c-junAs 
uninjured nerves, no TUNEL positive nuclei were detected (data not shown), whereas
f / f  •5 days after nerve cut, 1 +/-0.6% of cells were TUNEL positive in c-jun mice and 
0.8 +/-0.1% of cells were TUNEL positive in c-jun** mice. However there was no 
statistical difference between the two genotypes (n=3)(Fig.4.10, B). Thus, without c- 
ju n  there is no significant change in immediate Schwann cell apoptosis, 5 days after 
sciatic nerve transection in adult mice.
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Figure 4.10: Schwann cell number and rate of apoptosis after nerve injury, in c- 
ju n tlf and c-junAs animals.
(A) The number o f Schwann cell nuclei in uninjured sciatic nerves, sciatic nerves 28 
days after nerve transection and 70 days after nerve crush, in c-junm and c-jun** mice. 
Error bars show the standard deviation of the mean. Statistical significance was 
determined by the Mann-Whitney U test.
(B) The percentage o f TUNEL positive cells in the sciatic nerve o f c-junM and c-junAs 
mice, 5 days after transection at 5mm from the site of injury. Error bars show the 
standard deviation o f the mean. Statistical significance was determined by the Mann- 
Whitney U test.
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4.2.8. Schwann cell dedifferentiation is retarded in the absence of c-jun.
After Schwann cells lose contact with axons they begin to dedifferentiate, 
returning to a phenotype that partly resembles the immature Schwann cell. This 
cellular transformation not only requires downregulation o f myelin-associated genes, 
by the myelinating Schwann cell, but also the upregulation o f many genes that are 
normally suppressed by the myelinating phenotype. In section, 4.2.4, I demonstrated 
that c-Jun was an important regulator of the removal of myelin proteins after 
denervation, both in vivo and in vitro. I now wanted to test whether this delay in 
demyelination, when Schwann cells do not have c-jun , was also accompanied by 
delayed transition to the ‘immature-like’ phenotype. To test this, I used an in vivo and 
an in vitro paradigm, since Schwann cells after nerve cut display a very similar 
phenotype to Schwann cells allowed to dedifferentiate in culture (Jessen and Mirsky,
2005). I analysed the phenotype of dedifferentiated c-junm and c-junAs Schwann cells, 
either in lOpm-cryosections of nerves, 7 days after sciatic nerve transection, or during 
a 10 day demyelination assay in culture (see section 4.2.4.3). Both sections and cell 
cultures were immunolabelled with antibodies to L I, N-cadherin, p75NTR and NCAM, 
all markers that are re-expressed during Schwann cell dedifferentiation (see Chapter 
1).
In the c-junss nerve, 7 days after nerve transection, Schwann cells in the distal 
stump expressed recognizably lower levels of the adhesion molecule L I, compared to
f/fc-jun Schwann cells (Fig.4.11, A and B). Similarly, after 10 days in culture only 
47.8 +/-2.3% of c-junAs Schwann cells managed to re-express LI protein compared to 
94.7 +/-3.9% of c-jun{{ Schwann cells (n=5)(p<0.0001)(Fig.4.11, C-G). Furthermore, 
Schwann cells in the c-jun^s nerve were unable to induce normal levels of expression 
of N-cadherin, 7 days after nerve transection (Fig.4.12, A and B).
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Figure 4.11: c-junAs Schwann cells fail to properly re-express LI after 
denervation.
(A and B) Confocal images of immunohistochemistry for the adhesion molecule, LI 
in c-jun{f and c-junAs nerves, 7 days after sciatic nerve transection, at a distance of 
5mm from the site o f injury. Sections are co-stained with hoescht nuclear dye (Ho). 
Scale bar, 50pm.
(C-F) Dissociated Schwann cells from c-junm and c-junAS P8 nerves, after 10 days in 
culture. Cells are labelled with antibodies to the Schwann cell marker, SlOOp and to 
LI and also with hoescht nuclear stain (Ho). (D and F) Arrowheads demonstrate c- 
ju n As Schwann cells, positive for S I00(3, that do not express LI. Scale bar, 50pm.
(G) The percentage of LI positive c-junf{ and c-jun** Schwann cells over a lOday 
period o f culturing. Error bars show the standard deviation of the mean. Statistical 
significance was determined using two-way ANOVA and the unpaired students t-test.
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When I examined the expression of N-cadherin in Schwann cells in culture, I found 
that although all c-junAs Schwann cells managed to re-express some N-cadherin 
protein, only 8 +1-3.1% o f c-jun** Schwann cells were able to express high levels of 
N-cadherin, compared to 84 +/-3.7% of c-juni{ Schwann cells, after 10 days in culture 
(n=4)(p<0.0001)(Fig.4.12, C-E). The level of expression o f p75N1R, 7 days after nerve 
cut appeared to be similar in both c-junm and c-jun** animals (Fig.4.13, A and B). 
However, c-jun** cultured Schwann cells showed defects in p75N1R upregulation, in 
comparison to c-junm Schwann cells. Only 58.9 +1-5% o f c-jun** Schwann cells 
expressed a high level o f p75NrR protein after 10 days in culture, whereas 99 +/-1.7% 
o f c-junM Schwann cells demonstrated strong p75NIR staining at this time point 
(n=4)(p<0.0001)(Fig.4.13, C-G). In contrast to the impaired upregulation o f L I, N- 
cadherin and p75NIR, in c-jun-null Schwann cells, NCAM appeared to be more 
strongly upregulated in the c-jun** nerve than in the c-junm nerve, 5 days after nerve 
cut (Fig.4.14, A and B). Additionally, NCAM was expressed by all c-junm and c-jun** 
Schwann cells, after 3 days in culture, yet c-jun** Schwann cells always demonstrated
• f / fmuch stronger staining for NCAM than c-jun cells at all time points investigated 
(Fig.4.14, C and D).
In summary, these results show that expression of c-Jun is critical for the 
normal dedifferentiation of Schwann cells after loss o f axonal contact, both in vitro 
and in vivo. However, it is clear that not all markers of denervated Schwann cells are 
regulated in the same way, since expression of L I, N-cadherin and p75NTR are all 
reduced in the absence of c-jun whereas NCAM appears to be upregulated.
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Figure 4.12: Re-expression of N-cadherin in c-jurf* Schwann cells is perturbed
after denervation.
(A and B) Confocal images o f immunohistochemistry for the adhesion molecule, N- 
cadherin in c-junm and c-jun** nerves, 7 days after sciatic nerve transection, at a 
distance o f 5mm from the site of injury. Sections are co-stained with hoescht nuclear 
dye (Ho). Scale bar, 50pm.
(C and D) Dissociated Schwann cells from c-jun1 { and c-jun^  P8 nerves, after 10 days 
in culture. Cells are labelled with an antibody to N-cadherin and also with hoescht 
nuclear stain (Ho). (D) Arrowheads demonstrate c-junAS Schwann cells that only
f / fexpress a low level o f N-cadherin compared to c-jun cells in (C). Scale bar, 50pm. 
(G) The percentage o f N-cadherin positive c-junm and c-jun** Schwann cells over a 
lOday period o f culturing. Error bars show the standard deviation of the mean. 
Statistical significance was determined using two-way ANOVA and the unpaired 
students t-test.
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Figure 4.13: Abnormalities in the up-regulation of p75NTR in c-jun*s Schwann
cells after denervation.
NTR f/f'
(A and B) Confocal images of immunohistochemistry for p75 in c-jun and c- 
ju n As nerves, 7 days after sciatic nerve transection, at a distance of 5mm from the site 
o f injury. Scale bar, 50pm.
(C-F) Dissociated Schwann cells from c-junm and c-junAS P8 nerves, after 10 days in 
culture. Cells are labelled with antibodies to the Schwann cell marker, SlOOp and to 
p75NTR and also with hoescht nuclear stain (Ho). (D and F) Arrowheads demonstrate 
c-junAS Schwann cells, positive for SlOOp, that express low levels of p75NrR. Scale 
bar, 50pm.
(G) The percentage of p75NTR positive c-junm and c-jun** Schwann cells over a lOday 
period o f culturing. Error bars show the standard deviation of the mean. Statistical 
significance was determined using two-way ANOVA and the unpaired students t-test.
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Figure 4.14: NCAM is more strongly expressed by denervated Schwann cells, in 
the absence of c-jun,
(A and B) Confocal images of immunohistochemistry for the adhesion molecule, 
NCAM in c-junm and c-jun** nerves, 5 days after sciatic nerve transection, at a 
distance o f 5mm from the site of injury. Scale bar, 50pm.
(C and D) Dissociated Schwann cells from c-junm and c-junAs P8 nerves, after 10 days 
in culture. Cells are labelled with an antibody to NCAM and also with hoescht nuclear 
stain (Ho). Pictures were captured using the same exposure time. Scale bar, 50pm.
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4.2.9. The role of Schwann cell derived c-jun in peripheral nerve regeneration
The reaction o f the Schwann cell to injury is thought to underlie much o f the 
success of peripheral nerve regeneration (see Chapter 1). However, to date, there are 
no studies that clearly demonstrate how important Schwann cell activation is in 
promoting peripheral nerve injury. In the previous sections, I have identified c-jun as 
a key regulator o f Schwann cell demyelination and dedifferentiation after peripheral 
nerve injury. In the c-junAs mice, these key events during Wallerian degeneration are 
greatly impeded. Thus, this provided me with a unique situation to investigate 
whether Schwann cell activation after nerve injury was necessary for successful 
peripheral nerve regeneration.
4.2.9.I. Both motor and sensory functional recovery after sciatic nerve crush are 
severely impaired in c-jun*s mice.
To analyse peripheral nerve regeneration in c-junm and c-jun** mice, right 
sciatic nerve crushes were performed at the level o f the sciatic notch. Nerve crush was 
used instead o f nerve transection as the experimental paradigm in this situation since 
nerve crush, while effectively destroying all axons distally, maintains the structural 
connection between the proximal and distal stumps, including the Schwann cell basal 
lamina tubes. This allows for faster axonal regeneration and better functional recovery 
after injury, compared to nerve transection (Nguyen et al., 2002; Raivich and 
Makwana, 2007). Functional recovery after sciatic nerve crush was measured by two 
methods. Firstly, the presence of a toe-spreading reflex was recorded after, both c- 
ju n m and c-jun** mice, were lifted gently by the tail (Gutmann et al., 1942; Siconolfi 
and Seeds, 2001). Mice demonstrating full extension o f the hind limb and full 
extension and abduction o f all five toes so that clear space can be seen between each
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toe were given a toe-spreading reflex score of 2. Whereas, mice that showed a partial 
toe spreading reflex, such as improper hind limb extension or only abduction and 
extension o f some but not all five toes were given a toe-spreading reflex score of 1. 
Mice that showed no abduction of all 5 toes, in response to being lifted by their tail, 
were given a score of 0. Secondly, recovery of pressure and pain sensitivity was tested 
on c-juni{ and c-jun** mice, by pinching the most distal part of the lateral three toes, 
which derive sensation from the sciatic nerve, on both uninjured and injured limbs, 
with a number 5 forceps. Hind limb withdrawal and/or vocalization were recorded as 
positive responses, demonstrating functional sensory regeneration after injury 
(Siconolfi and Seeds, 2001). Both tests were performed before surgery to test that all 
mice responded normally in an uninjured situation and immediately after surgery, 
when mice were awake, to check that the operation had successfully removed all 
sciatic nerve function prior to regeneration. Mice were then tested every two to three 
days up until 30 days after surgery, at this point mice were then tested once a week up 
until 70 days after surgery.
For the toe-spreading reflex test, c-junss mice showed a strong impairment in 
regaining a normal toe spread. Whereas, all c-junm mice (n=l 1), obtained a score o f 2 
by day 23, even at day 70 only 1 out o f 8 of the c-jun** mice achieved a score of 2, 
with the remaining c-junAs mice scoring 1 (p<0.0001, two-way ANOVA)(Fig.4.15, 
A). Most c-junAS mice always showed some impairment throughout the analysis, often 
abducting some but not all o f their toes on the injured limb. At later stages of the 
experiment, c-junss mice, unlike c-jun{{ mice, would initially withhold extension of 
their hind limb in response to being lifted by the tail. Furthermore, the hind paw on 
the injured side o f c-juns% mice usually adopted a ‘claw-paw’ phenotype. (Fig.4.15, B 
and C). The data from the toe-reflex test can also be illustrated by time taken until the
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first response, which is sustained thereafter in subsequent tests. In this case a score of 
1 or 2 was counted as a response. Thus, c-junli animals achieved a positive response 
by day 10 +/-2, whereas c-junAs mice showed a positive response by day 17 +/-2 
(n=7)(p<0.01, Mann-Whitney U test)(Fig.4.15, D). This demonstrates that the general 
reinnervation o f the hind paw is delayed in c-jun** mice compared to c-jnnm animals.
Recovery of toe pinch responses in the lateral three toes of c-junss mice showed 
a greater functional impairment than in the toe reflex tests. c-junm animals achieved a 
positive response in toe 3 by day 18 +/-5, toe 4 by day 20 +/-4 and toe 5 by day 23 +/- 
7. In contrast, 6 out o f 8 c-jun** mice never showed a positive response when toes 3 
and 4 were pinched and 8 out 8 c-jun** mice never showed a positive response when 
toe 5 was pinched, over the entire 70 day period of analysis (p<0.01, two-way 
ANOVA).
Together, this data demonstrates that in the absence of c-jun in Schwann cells, 
the peripheral nerve is no longer capable of promoting successful regeneration and 
functional recovery after sciatic nerve crush.
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Figure 4.15: Recovery of both motor and sensory function is severely impeded 
after sciatic nerve crush, in c-junAs mice.
(A) The percentage o f c-junvr (n=l 1) and c-jun** (n=8) mice analysed that achieved a 
toe spreading reflex score of 2 at various time points over a 70 day period. 
Comparison o f toe reflex scores between c-junm and c-junAs mice at each time point 
showed a statistical difference from day 12 through to day 70 (p<0.05). Statistical 
significance was determined by two-way ANOVA and unpaired student’s t-test.
(B and C) Demonstration of the toe-spreading reflex in c-jtmm and c-jun** mice, 70 
days after right sciatic nerve crush. Arrows indicate toe spread on the operated limbs
f / fof both genotypes. Both uninjured and injured c-jun limbs show a normal reflex. 
Note how the c-junAs mouse holds the injured limb in towards the body. There is also 
a noticeable claw paw phenotype on the paw of the injured limb whereas the 
uninjured limb shows a normal reflex in response to being lifted by the tail.
(D) Time taken for an initial toe spread response (a score of 1 or 2 was counted as a 
response) that is sustained in subsequent tests, in c-junm and c-junAs mice. Error bars 
show the standard deviation of the mean. Statistical significance was determined by 
the Mann-Whitney U test.
(E-G) The percentage of c-junm (n = ll)  and c-junAs (n=8) mice analysed that 
demonstrated a positive response (either foot withdrawal and/or vocalisation) to 
pinching o f the most distal portion of toes 3, 4 and 5, at various time points over a 70 
day period. Comparison of toe pinch responses between c-junm and c-junAs mice, at 
each time point, showed a statistical difference from day 21 through to day 70 
(p<0.05). Statistical significance was determined by two-way ANOVA and unpaired 
student’s t-test.
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4.2.9.2. c-jun*s Schwann cells are unable to support efficient axonal regeneration.
Since recovery of both motor and sensory functions are so strongly impeded in 
c-junAs mice, I wanted to investigate whether an element o f this was due to a failure in 
axonal regeneration as opposed to purely being a problem with reinnervation of 
original targets. Thus, I decided to examine the regenerated tibial nerve from c-jun* * 
and c-jun** mice, 70 days after nerve crush at a distance of 5mm from the crush site, 
in resin semithin and ultrathin sections by light and electron microscopy respectively. 
On first analysis it was quite clear, that c-jun** regenerated nerves contained fewer 
myelinated axons, than c-jun* * regenerated nerves (Fig.4.16, A and B). I counted the 
total number o f myelinated axons in both c-junm and c-junAs regenerated tibial nerves 
using merged images o f semithin sections stained with toluidine blue. I found there 
was a 51% reduction in the total number of myelinated axons in the c-jun** nerve, 70 
days after nerve crush, containing only 1298 +/-199 axons compared to 2622 +/-195 
axons in c-jun11* regenerated nerves (n=4)(p<0.05, Mann-Whitney U test)(Fig.4.16, 
C). Since earlier experiments determined there were no overt abnormalities and 
normal numbers o f axons in the uninjured c-junAs nerve (section 4.2.3), these results 
demonstrate that over half the myelinated axons fail to regenerate into the distal 
stump o f the c-jun** nerve after sciatic nerve crush.
4.2.9.3. Myelinated dorsal root axons but not ventral root axons are lost in c- 
ju n A8 mice, after sciatic nerve crush.
After adult sciatic nerve cut or crush, motor neuron survival is not affected 
whereas there are differing rates of sensory neuron survival, dependent on the 
neuronal subtype (Romanes, 1946; Lowrie et al., 1994; Coggeshall et al., 1997 
Tandrup et al., 2000; Ma et al., 2001; Groves et al., 2003). In the dorsal root ganglion
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(DRG), the large A-cells that give rise to myelinated axons in the dorsal root and in 
the nerve are not susceptible to sciatic nerve injury. However, up to 50% of the small 
B-cells, which give rise to unmyelinated axons, are lost from the DRG by 32 weeks 
after either sciatic nerve cut or crush (Coggeshall et al., 1997; Tandrup et al., 2000). I 
therefore wanted to assess the survival rates of both motor and sensory neurons in 
both c-junm and c-jun** mice, 70 days after sciatic nerve crush.
Motorneurons project into the sciatic nerve from spinal levels L3-L6, with the 
majority coming from L4 and L5 (Swett et al., 1986), whereas 98-99% of sciatic 
sensory neurons originate solely from the L4 and L5 DRGs (Swett et al., 1991). 
Counting the total number of myelinated axons in the L5 dorsal root can be used as an 
indication o f the sensory A-cell neuronal numbers in the corresponding DRG, since 
one DRG neuron will project one axon into the dorsal root (Coggeshall et al., 1997). 
In the uninjured L5 dorsal root there were 2432 +/-262 and 2215 +/-35 myelinated
axons in c-junm and c-junAs mice, respectively. After sciatic nerve crush there were
f/f
2379 +/-208 myelinated axons in the c-jun L5 dorsal root, suggesting that there was 
no loss of myelinated sensory axons after injury. In contrast, there was a dramatic loss 
o f 36% of the myelinated axons in the c-junAs L5 dorsal root, with only 1421 +/-156 
axons remaining, 70 days after sciatic nerve crush (n=4)(p<0.05, Mann-Whitney U 
test)(Fig.4.16, D).
Closer observation of the c-junAs L5 dorsal root, 70 days after sciatic nerve 
crush, demonstrated that there were still signs of ongoing axon loss, including many 
demyelinating profiles, shrunken axons and the presence of macrophages full of
• • f / fmyelin debris. These phenomena were rarely seen in c-jun dorsal roots after nerve 
crush (Fig.4.16, F-H). In addition, there appear to be many abnormal unmyelinated 
axon profiles in the c-jun** dorsal root after nerve crush, particularly axons that are
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swollen or starting to fragment. Again, these observations are not seen in the c-jun11 
dorsal roots 70 days after nerve crush, suggesting that there may be a greater loss of 
unmyelinated axons in c-jun** mice than is normally expected after nerve injury 
(Fig.4.16, la n d  J).
I also analysed the L5 ventral root, in order to get an assessment of the potential 
numbers of surviving motorneurons after sciatic nerve crush. In the uninjured c-junin 
and c-jun** mice, there are 981 +/-79 and 973 +/-106 myelinated axons in the L5 
ventral root, respectively (n=3). These numbers do not significantly change, 70 days 
after nerve crush, with 956 +/-44 axons in the c-junm (n=6) and 942 +/-31 axons in 
the c-jun** (n=4) L5 ventral root (p=0.6, Mann-Whitney U test)(Fig.4.16, E).
These experiments demonstrate that potentially a large population of A-cell 
sensory neurons, that are not normally susceptible after peripheral nerve injury, are 
dying when they try to regenerate into the c-jun1* distal stump after sciatic nerve 
crush. In addition there may also be a greater loss o f small B-cell sensory neurons in 
c-jun** mice after nerve injury. Interestingly, although there are large defects in the 
dorsal roots o f c-jun** mice after sciatic nerve injury, the ventral roots appear normal, 
which suggests that motor neuron survival is likely to be unaffected.
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Figure 4.16: Myelinated axon loss in the distal stump of the tibial nerve and in
the L5 dorsal root, 70 days after sciatic nerve crush in c-junAs mice.
(A and B) Electron micrographs of the c-junm and c-jun** tibial nerve, 70 days after 
sciatic nerve crush, at a distance of 5mm from the site o f injury. Note that although 
there are fewer myelinated axons in the c-junAs nerve, the thickness of their myelin
f/f'sheaths appears similar to axons in the c-jun nerve. Scale bar, 10pm.
(C) The total number of myelinated axons in both the c-jun11 and c-jun** tibial nerve, 
70 days after sciatic nerve crush, at a distance of 5mm from the site o f injury. Error 
bars show the standard deviation of the mean.
(D) The total number of myelinated axons in L5 dorsal roots of the c-junVi and c-jun1* 
mice, 70 days after sciatic nerve crush. Error bars show the standard deviation o f the 
mean.
(E) The total number of myelinated axons in L5 ventral roots of the c-juni/f and c-jun** 
mice, 70 days after sciatic nerve crush. Error bars show the standard deviation o f the 
mean.
(F and G) Electron micrographs showing a representative field from the L5 dorsal 
roots of the c-junf i and c-jun'* mice, 70 days after sciatic nerve crush. (G) Arrows 
point to shrunken axons, detaching from their myelin sheath. Arrowheads mark 
demyelinating profiles in the c-jun*5 dorsal root that are devoid o f an axon. Neither of 
these phenomena appeared to be fixation artefacts since they were commonly seen in 
dorsal roots from 3 separate c-jun'* mice and rarely observed in c-junm roots (n=3), 
after nerve crush. Scale bar, 5pm.
(H) Electron micrograph demonstrating a macrophage, full of myelin debris, present 
in the c-jun'* dorsal root, 70 days after sciatic nerve crush. Arrowhead marks the 
nucleus of the macrophage. Scale bar, 2pm.
(I and J) Electron micrographs showing unmyelinated axons in the c-junm and c-jun'* 
mice, 70 days after sciatic nerve crush. Arrowheads in (I) demonstrate normal axon
f / f  •profiles in the c-jun dorsal root whereas arrowheads in (J) show swollen and 
fragmenting axons in the c-jun'* dorsal root. Scale bar, 500nm.
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4.3 DISCUSSION
The cellular and biochemical changes that Schwann cells undergo after they 
lose axonal contact during peripheral nerve injury have been intensely documented 
over the last 50 years. However, relatively little is understood about the mechanism 
through which Schwann cells can make this transformation and additionally not much 
is known about how relevant these changes are for promoting successful peripheral 
axonal regeneration.
In this study, I sought to understand the role played by the transcription factor,
c-Jun in regulating the Schwann cell reaction to peripheral nerve injury. Using the
sWld mouse, I found that c-Jun expression is regulated by the timing of axonal 
degeneration during nerve injury. Furthermore, through use of a conditional knockout 
mouse, I found that c-Jun controls the rate of Schwann cell demyelination after loss of 
axonal contact, both in vitro and in vivo. Additionally, c-Jun is required for proper 
Schwann cell dedifferentiation after nerve injury but appears to be dispensable for 
injury induced Schwann cell proliferation. Finally, I sought to investigate the role 
Schwann cell derived c-Jun played in peripheral nerve regeneration. Functional 
recovery after sciatic nerve crush was severely inhibited, even 10 weeks after the 
injury, in the absence of c-jun in Schwann cells. Moreover, there was a substantial 
loss o f axons in the distal stump of the nerve and surprisingly, in the corresponding 
dorsal root as well. Thus Schwann cell derived c-Jun is crucial for adequate peripheral 
nerve regeneration and potentially for the survival o f regenerating neurons after 
injury.
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4.3.1. The tim ing of axonal degeneration regulates activation of Schwann cells 
after nerve injury.
As mentioned in Chapter 1, in the absence of axonal degeneration, Schwann 
cells appear not to respond to nerve injury in Wlds mice (Lunn et al., 1989; Glass et 
al., 1993). Furthermore, in normal situations, Schwann cells appear to start breaking 
up their myelin sheath into ovoids, only 20-32 hours after the initial injury (Lubinska, 
1977), which corresponds well with the length of delay before axons begin to 
degenerate (Coleman, 2005).
This switch in Schwann cell phenotypes after injury can be marked by the 
downregulation o f the axon dependent myelin transcription factor, Krox-20 and the 
upregulation o f c-Jun (Parkinson et al., 2008). The fact that 7 days after sciatic nerve 
cut in Wlds mice Schwann cells maintain Krox-20 expression and do not upregulate c- 
Jun confirms that Schwann cells do not react to the injury if axons remain intact. 
However, Schwann cells in Wlds mice do eventually lose expression of Krox-20 and 
upregulate c-Jun expression, 28 days after injury, when the majority of axons have 
degenerated. This confirms original observations that Wlds Schwann cells do have the 
capacity to become active after injury (Glass et al., 1993) but it seems likely that their 
activation depends on the timing of degeneration of the axon that they ensheath.
At a molecular level, it appears that the loss of Krox-20 expression is sufficient 
to activate Schwann cells in the absence of injury (Decker et al., 2006). Thus a 
possible mechanism through which Schwann cells could ‘sense’ injury may involve 
the upregulation o f a demyelination programme, through derepression (Decker et al.,
2006). Expression o f factors that could potentially regulate denervated Schwann cells, 
such as c-Jun, Sox-2 and components of the Notch pathway, are normally suppressed 
in myelinating Schwann cells, most likely by a mechanism involving Krox-20
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(Parkinson et al., 2004, 2008; Le et al., 2005a; Aswhin Woodhoo, unpublished 
observations). However, once myelinating Schwann cells lose contact with the axon 
after axonal degeneration, they lose expression of Krox-20 and these factors would 
become derepressed and, thus, potentially able to activate Schwann cells.
4.3.2. c-jun is dispensable in Schwann cells for normal peripheral nerve 
development.
In order to investigate the role of c-Jun in regulating the phenotype of 
denervated Schwann cells, I created a mouse that had a Schwann cell specific deletion 
o f c-jun. The resulting c-junAS mouse showed successful deletion o f the c-jun gene in 
the peripheral nerve by PCR and Schwann cells from these mice did not re-express c- 
Jun protein after nerve injury or during culture. The adult tibial nerve of c-junAS mice 
appears to contain a normal number o f myelinated axons and there is no significant 
difference in the thickness of their myelin sheaths, in comparison to c-junli mice. 
Thus, c-jun is not required for myelination or myelin sheath maintenance in Schwann 
cells, which is consistent with the absence o f detectable c-Jun expression in 
myelinating Schwann cells (Parkinson et al., 2004). However, c-Jun is still expressed, 
albeit at low levels, in adult non-myelinating Schwann cells in the peripheral nerve 
(Shy et al., 1996). Yet, the number of non-myelinating Schwann cells and of 
unmyelinated axons in the tibial nerve was not significantly different in c-junAS mice. 
Since the P0 CRE  allele is expressed from around E l3.5 and has been shown to lead 
to recombination in non-myelinating Schwann cells in two previous studies (Feltri et 
al., 2002; D ’Antonio et al., 2006b), one may assume that it would lead to 
recombination in non-myelinating Schwann in this situation. Furthermore, around 
95% of Schwann cells purified from the P5 c-junAs sciatic nerve did not express c-Jun
231
in culture suggesting that recombination must have occurred in non-myelinating cells, 
since they make up around 20-30% of the Schwann cells in such cultures (data not 
shown). Thus, these findings suggest that c-jun may not be crucial for the 
development o f non-myelinating Schwann cells either.
4.3.3. c-jun controls demyelination in Schwann cells.
Schwann cells normally upregulate c-Jun within 24 hours after nerve injury and 
within 6 hours after culturing (Parkinson et al., 2008). In the absence of c-jun , 
denervated Schwann cells are unable to rapidly demyelinate. This is observed after 
nerve injury in both neonatal and adult c-jun** mice (neonatal data not shown, see 
Parkinson et al., 2008), where myelin sheaths fragment more slowly than in c-jun11 
mice and in culture, where neonatal c-junAs Schwann cells are unable to rapidly 
remove myelin proteins from their cytoplasm. The mechanism by which Schwann 
cells can digest parts of their myelin sheath is almost completely unknown, though it 
may involve processes similar to phagocytosis (Bigbee et al., 1987) or autophagy 
(Holtzman and Novikoff, 1965). Various enzymes are certainly very likely to play a 
role in myelin sheath digestion in Schwann cells, especially since mice with null 
mutations in genes for PLA 2 and MMP-9 showed delayed demyelination after 
peripheral nerve injury (see Chapter 1; De et al., 2003; Shubayev et al., 2006). 
Interestingly, AP-1 sites are present in nearly all MMP genes with two consensus AP- 
1 sites present in the human MMP-9 gene and AP-1 can also regulate expression of 
human collagenase-1 in a monocyte-like cell line (Benbow and Brinckerhoff, 1997; 
Doyle et al., 1997). Additionally, as described in chapter 1, extracellular signalling 
also seems to be important in regulating the rate of demyelination, particularly as 
knockout mice for iNOS and Toll receptors show slower demyelination after nerve
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injury (Levy et al., 2001; Boivin et al., 2007). Furthermore, a recent study has found 
that iNOS is directly regulated by c-Jun/AP-1 in hepatocytes (Hasselblatt et al., 2007).
In addition to the involvement of c-Jun in the early stages of demyelination, 
such as myelin sheath fragmentation and myelin protein clearance, it appears that c- 
Jun is also crucial for the removal of the majority o f myelin lipid from the injured
nerve. The fact that the majority of remaining myelin debris and lipid appears to
reside in abnormally large macrophages in the c-junAs nerve, 28 days after sciatic
nerve cut, suggests a more complex interaction between Schwann cells and
macrophages. Since the Schwann cells appear to be unable to process the myelin 
debris properly in the absence of c-jun, macrophages may ingest too much myelin and 
subsequently be unable to digest it efficiently. The other possibility is that 
macrophages may be unable to properly digest myelin unless they receive adequate 
signalling from Schwann cells, which may be altered without c-Jun. Certainly, further 
investigation is required to resolve these issues, possibly by co-culturing Schwann 
cells and macrophages together and investigating the effects of Schwann cell 
conditioned medium from c-junm and c-jun** mice on macrophage myelin 
phagocytosis. Hopefully, a greater understanding of the mechanisms by which 
Schwann cells break down myelin sheaths and cooperate with macrophages in 
clearance o f myelin debris will lead to a better understanding of how Schwann cell c- 
Jun contributes to these processes.
4.3.4. c-Jun is a negative regulator of myelin gene activation.
Removal o f c-jun in cultured Schwann cells can enhance myelin gene activation 
by either Krox-20 or a combined dbcAMP/NRGl signal. Thus the constitutive 
expression o f c-Jun in cultured Schwann cells acts as a brake to myelin
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differentiation. Furthermore, enforced expression o f c-Jun inhibits myelin gene 
expression in cultured Schwann cells and in myelinating Schwann cell-neuron co­
cultures (Parkinson et al., 2008). Since, c-jun is an inhibitor of myelin differentiation, 
one might expect there to be enhanced myelination in c-jun** neonatal mice or during 
remyelination after nerve crush. Preliminary analysis of newborn and P5 c-junAs 
sciatic nerves shows no signs of precocious myelination or hypermyelination (data not 
shown; Parkinson et al., 2008). Furthermore there appear to be no overt differences in 
the thickness o f the myelin sheath of the axons that do regenerate in c-junAs mice 
compared to c-juntlf mice (see Fig.4.16, A and B). This suggests that removal o f c-jun 
does not greatly affect the myelination process or the overall thickness o f the myelin 
sheath after remyelination. This effect is not surprising, however, since c-Jun 
expression is downregulated in the sciatic nerve during myelination and remyelination 
(Shy et al., 1996; Parkinson et al., 2008). Thus, it appears that the ability to inhibit 
myelin differentiation, in the case of c-Jun, demonstrates part of a functionally 
opposing programme to myelination that seems to be more important for driving 
Schwann cell activation after nerve injury.
A number o f factors have been identified that are inhibitory to myelin gene 
activation or the myelination process. In addition to c-Jun, these include, NRG1, 
FGF-2, ERK1/2, Sox-2, Oct-6 (Pou3fl), Id-2 (inhibitor of DNA binding-2), p57kip2 
and components o f the Notch and p38MAPK pathway (Zanazzi et al., 2001; Ogata et 
al., 2004; Harrisingh et al., 2004; Le et al., 2005a; Ryu et al., 2007; Mager et al., 
2008; Heinen et al., 2008; A. Woodhoo and A. Bhaskaran, unpublished observations). 
Like c-Jun, the expression of a number of these factors is downregulated during 
myelination in the peripheral nerve and in the case of Oct-6 and the Notch pathway 
continuous constitutive expression actually antagonizes the myelination process in
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vivo (Jessen and Mirsky, 2005; Ryu et al., 2007; A. Woodhoo, unpublished 
observations). Thus, it would be interesting to test, in vivo, whether downregulation of 
c-Jun in Schwann cells, during postnatal development, is actually necessary for 
myelination to proceed. This could be achieved by creating a transgenic mouse that 
constitutively expresses c-Jun in Schwann cells during postnatal development.
4.3.5. Differential requirements for c-jun in Schwann cell proliferation and 
survival.
In many different systems c-jun is required for cell cycle progression. In 
particular, c-jun null fibroblasts appear to be capable of only one or two divisions in 
culture before they undergo pseudo-senescence (Johnson et al., 1993; Shaulian and 
Karin, 2001). Many studies point to a requirement for c-jun for cells to progress 
beyond the G l-S  phase of the cell cycle, though c-jun may also be involved at later 
stages as well (Shaulian and Karin, 2001). In Schwann cells, I find that c-jun is 
required for the full mitogenic effect of NRG1 on cultured Schwann cells. This 
corroborates previous findings that JNK/c-Jun pathway activity is required for NRG1 
induced Schwann cell proliferation in culture (Parkinson et al., 2004). However, in 
contrast to c-jun null Schwann cells in vitro, c-jun^s Schwann cells in vivo show 
normal levels o f BrdU incorporation 5 days after sciatic nerve cut. At this time point 
after injury Schwann cell proliferation rates have peaked (Friede and Johnstone, 1967; 
Carroll et al., 1997), arguing against a potential delay in proliferation rates in c-junAs 
mice. In confirmation of this, I also assayed BrdU incorporation at 3 and 7 days after 
cut and saw no visible differences between c-jun™ and c-junAs mice (data not shown). 
Thus, these findings would suggest that the mechanisms that regulate growth factor 
induced and injury induced proliferation in Schwann cells may be different. Certainly,
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recent studies have shown mechanistic differences between embryonic, postnatal and 
injury induced Schwann cell proliferation (Kim et al., 2000; Antanasoski et al., 2001; 
Atanasoski et al., 2008), and while NRG1 is a potent mitogen for cultured Schwann 
cells, NRGl/erbB2 signalling appears not to be involved in injury induced Schwann 
cell proliferation (Atanasoski et al., 2006).
At long time points after nerve transection there is a reduction in the number of 
Schwann cell nuclei in transverse profile in c-jun** mice compared to c-junm mice. 
However, as mentioned previously, there is no difference in Schwann cell DNA 
synthesis after nerve injury between the two genotypes. This disparity in these results 
may be reconciled in one of two ways. Firstly, BrdU incorporation only marks the S 
phase of the cell cycle and thus would not identify any block later in the cell cycle. 
Thus, it would be useful to look at the expression of a marker for the G2-M phase, 
such as phospho-histone H3 in order to substantiate these findings. Secondly, this 
difference may reflect increased loss of Schwann cells at long time points after nerve 
injury, in the absence of c-jun. Initially after nerve cut, Schwann cell numbers 
increase but at long time points after nerve transection Schwann cell numbers begin to 
decrease (Abercrombie, 1946; Weinberg and Spencer, 1978). Furthermore, a 
proportion o f Schwann cells in the mouse sciatic nerve have been shown to undergo 
apoptosis at both short and long time points after nerve cut (Ferri and Bisby, 1999; 
Yang et al., 2008). However, at 5 days after nerve cut there was no difference in the 
number of apoptotic nuclei between the c-junm and c-juns% sciatic nerves but this does 
not preclude increased apoptotic death at later time points after injury in c-jun** 
nerves or indeed death by necrosis. Interestingly, there is no significant difference in 
the number o f Schwann cell nuclei in transverse section, between c-junm and c-junAs 
mice, 70 days after nerve crush. A potential reason for this difference between cut
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and crush might be that, at long time points after injury, the presence of axons confers 
greater survival ability to the Schwann cells of the distal stump (Weinberg and 
Spencer, 1978).
Naturally, c-jun is more commonly linked with induction of cell death rather 
than survival (Shaulian and Karin, 2001) and in Schwann cells, blocking the JNK/c- 
Jun pathway can protect cultured Schwann cells from apoptotic cell death (Parkinson 
et al., 2001, 2004). However, c-jun can potentially act as a prosurvival factor in other 
systems, since early in embryogenesis there is massive apoptotic cell death in the liver 
in the absence o f c-jun (Eferl et al., 1999). Clearly, further investigation needs to be 
carried out to clarify the role of c-jun in Schwann cell survival, particularly during 
development, which has not been addressed in this study. Nevertheless, there remains 
the intriguing possibility that c-jun may demonstrate both pro-survival and pro-death 
abilities in Schwann cells depending on the cellular context and developmental stage.
4.3.6. c-Jun controls Schwann cell ‘dedifferentiation’.
Dedifferentiation of myelinating Schwann cells is commonly thought of as 
combining the loss of expression of myelin associated genes and the upregulation o f a 
large number o f genes, many of which are also expressed by immature Schwann cells 
during development (Scherer and Salzer, 2001; Jessen and Mirsky, 2005). Results 
from this study demonstrate that, even when myelin and myelin proteins are 
eventually cleared from c-junss Schwann cells, this event is not always accompanied 
by the appropriate gene expression of molecules characteristic of dedifferentiated 
Schwann cells, judged by the deficits in L I, N-cadherin, p75NTR and NCAM 
expression both in vitro and in vivo. Thus there may be a more complex relationship 
than previously thought between Schwann cell demyelination and the upregulation of
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molecules associated with the denervated phenotype. In addition, it may be more 
correct to describe the Schwann cell phenotype after nerve injury as Schwann cell 
activation rather than dedifferentiation, since many genes that are expressed by 
denervated Schwann cells are different to those expressed by immature Schwann cells 
(see Chapter 6; Bosse et al., 2006; Le et al., 2005a; D ’Antonio et al., 2006a). 
Furthermore, non-myelinating Schwann cells are also seen to react after injury, 
downregulating expression of gal-C and 04 and upregulating MCP-1, IL-2 and IL-6 
(Jessen et al., 1987; Mirsky et al., 1990; Cheepudomwit et al., 2008). Since this study 
analysed Schwann cells from a mixed nerve, it would be particularly interesting to 
discern whether activation of both myelinating and non-myelinating Schwann cells is 
perturbed after nerve injury in the absence of c-jun. Hopefully, in vivo and in vitro 
studies using nerves containing purely myelinated (facial) or unmyelinated 
(sympathetic trunk) fibres should resolve this issue.
4.3.7. Schwann cell derived c-jun is required for successful peripheral nerve 
regeneration.
Both motor and sensory functional recovery are severely impaired in c-jun** 
mice after sciatic nerve crush. Furthermore this impairment appears to be permanent 
as there is no evidence of any improvement in c-jun** mice after day 40, a time point
F/Fwhen all c-jun mice have regained full motor and sensory responses in toe reflex and 
toe pinch tests. Further evidence to support these findings has come from analysing 
the functional improvement after sciatic nerve crush in c-junilf and c-jun** mice using 
a walking tract test and evaluating the sciatic functional index (SFI)(Inserra et al., 
1998). In this analysis, scores vary roughly between -100 (no function) to 0 (full
F/Ffunction) (Inserra et al., 1998). By 28 days after sciatic nerve crush, c-jun animals
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had regained normal function, obtaining a mean score of 0.23 +/-4.6 whereas, even by 
day 70 after nerve crush, c-jun** mice only recorded a mean SFI of -62.4 +/-8.9 
(D.Wilton and P. Arthur-Farraj, data not shown). In addition, analysis of the 
reinnervation o f whisker pads after facial nerve cut demonstrated a strong impairment 
in the return o f whisker movements in c-jun** mice in comparison to c-jun11 mice 
(G.Raivich, unpublished observations).
The reason for such a strong inhibition of nerve regeneration in c-jun** mice 
appears to be due to the large reduction in myelinated fibres and potentially non­
myelinated fibres in the c-jun** nerve after injury. These axon counts were performed 
70 days after nerve crush and at a distance relatively close to the crush site (5mm 
distal), thus the axon counts are likely to reflect the total number of surviving 
regenerated axons in the nerve. This reduction in axon number in the distal stump of 
the c-jun1* sciatic nerve is likely due to a loss of 36% of the myelinated axons in the 
L5 dorsal root o f c-jun** mice, after nerve crush. These axons belong to sensory A- 
cells in the DRG and are not normally susceptible to death after sciatic nerve cut or 
crush (Coggeshall et al., 1997; Tandrup et al., 2000). In addition, the fact there 
appeared to be few remaining healthy unmyelinated axons in either the L5 dorsal root 
or the tibial nerve, in c-junss mice, suggests that there is most likely to be an increased 
loss o f B-cells in the c-jun** DRG as well. These findings, of course, need to be 
corroborated with counts o f A and B cells within the DRG, but do propose a potential 
explanation to the reason why c-jun** mice score so badly in the mechanosensory and 
nocieceptive toe pinch tests. Moreover, these results demonstrate that c-jun in 
Schwann cells is actually required for regenerating sensory neuron survival in the 
crushed sciatic nerve. In light of this it would be particularly interesting to investigate
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the growth factor expression of c-jun** Schwann cells in comparison to c-junil 
Schwann cells.
Curiously, the L5 ventral root of c-jun1* mice showed no difference to that of c- 
ju n t{ mice after sciatic nerve crush, signifying that motor neuron survival is likely to 
be unchanged. Yet c-junAs mice show impairment in both the speed of the initial 
motor response and the quality of the eventual motor recovery after sciatic nerve 
crush. Studies from the facial nerve demonstrate that motor neurons have a 
moderately reduced growth rate in the c-jun** distal stump after nerve crush 
(G.Raivich, unpublished observations), which correlates with the increase in time 
taken to observe the initial toe reflex response in c-jun** mice. However, further 
investigation is required in order to discover why motor recovery does not eventually 
return to normal in c-jun** mice, after sciatic nerve crush. Potentially, experiments 
using retrograde tracing techniques to quantify the number of neurons that reconnect 
with a given muscle could identify whether there is a problem with motorneuron 
reinnervation o f targets in c-jun** mice after sciatic nerve crush.
Since c-jun** mice show such a strong impairment in peripheral nerve 
regeneration, this study underlines the importance of the Schwann cell in this process. 
Importantly, the deficit in axon and potentially neuronal survival is unlikely to be due 
to a reduced number o f Schwann cells in the c-jun** distal stump because, as 
mentioned earlier, there was no statistically significant difference between the number 
o f Schwann cell nuclei in transverse section between c-junm and c-jun** mice, 70 days 
after sciatic nerve crush. However, the deficit is more likely to be due to a 
combination o f the delayed myelin clearance in the c-jun** nerve and the improper 
activation o f c-jun** Schwann cells. The relative importance of each of these to 
peripheral nerve regeneration still remains to be determined although other transgenic
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animals that demonstrate similar delays in myelin sheath removal after nerve injury 
mice do not appear to have such severe regeneration deficits as c-junAs mice (Levy et 
al., 2001; Ramaglia et al., 2007; A. Woodhoo and D. Wilton, unpublished 
observations)
Overall this study has demonstrated that Schwann cells actively respond to clear 
myelin debris, interact with macrophages and promote peripheral nerve regeneration 
after nerve injury, and that the transcription factor c-jun is crucial in regulating these 
processes.
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CHAPTER 5: Investigation of the functional properties of a mutant 
form of Egr2 (S382R/D383Y) in Schwann cells.
5.1 INTRODUCTION
The early growth response gene 2 (Egr2; also named Krox-20) and the 
associated proteins N abl and 2 are essential transcriptional regulators of Schwann cell 
myelination (Topilko et al., 1994; Nagarajan et al., 2001; Le et al., 2005a, 2005b). 
Therefore, it is not surprising that mutations in EGR2 can lead to myelin 
abnormalities and severe peripheral neuropathies in humans. These include congenital 
hypomyelinating neuropathy (CHN), Dejerine Sottas syndrome (DSS) and Charcot- 
Marie-Tooth 1 (CMT1). At present 11 different mutations have been identified in 
EGR2 (Bellone et al., 1998; Warner et al., 1998; Timmerman et al., 1999; Pareyson et 
al., 2000; Yoshihara et al., 2001; Vandenberghe et al., 2002; Numakura et al., 2003; 
Mikesova et al., 2005; Szigeti et al., 2007).
The majority of these mutations occur in the DNA binding domain and follow a 
dominant mode o f inheritance in affected families. The autosomal dominant S382R, 
D383Y double point mutation is associated with the most serious clinical phenotype, 
identified in a seven year-old girl diagnosed with CHN. A sural nerve biopsy revealed 
absence or loss o f myelin in virtually all axons and her nerve conduction velocities 
were severely slowed (under 10 m/s; Warner et al., 1998). The underlying mechanism 
by which this mutation leads to such severe disruption of the myelination process is of 
great interest. It is known that this mutant has minimal DNA binding activity but 
retains the ability to weakly transactivate an artificial luciferase promoter with Egr2 
binding sites (W arner et al., 1999). Furthermore, experiments in mouse and rat 
Schwann cells in vitro demonstrated that in contrast to wild-type Egr2, this mutant
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fails to activate transcription of myelin genes, and that it acts as a dominant-negative 
protein by inhibiting myelin gene expression driven by wild-type Egr2 (Nagarajan et 
al., 2001; Le Blanc et al., 2007). This mechanism would help to explain why the 
mutation is inherited in a dominant fashion since studies on mouse mutants reveal that 
one copy of Egr2 is sufficient to sustain normal myelination (Topilko et al., 1994; 
Zorick et al., 1999).
In the present work I have examined the functional properties o f the 
S382R/D383Y Egr2 mutant using cultured rat Schwann cells. In agreement with 
previous work, I found that mutant Egr2 prevents wild-type Egr2 from inducing the 
expression o f the major myelin protein, Po. Furthermore, mutant Egr2 fails to induce 
Po expression. Nevertheless, I found that mutant Egr2 retains some functions o f the 
wild-type protein. It induces endogenous expression of the myelin-related protein 
periaxin and Nab2, albeit at lower levels than wild-type Egr2. Moreover, mutant Egr2 
is at least as effective as the wild-type protein in preventing Schwann cell death and in 
common with wild-type Egr2, it suppresses expression of c-Jun. Significantly, I found 
that mutant Egr2 induces aberrant effects when expressed in Schwann cells. Mutant 
Egr2, under normal culture conditions or in the presence of NRG 1, induces Schwann 
cell proliferation, activates the ERK/MAPK pathway and suppresses expression o f the 
cell cycle inhibitor p27. This stands in clear contrast to wild-type Egr2, which inhibits 
Schwann cell proliferation (Parkinson et al., 2004). These effects are less marked 
when mutant Egr2 is expressed at higher levels within Schwann cells, when it behaves 
more like a wild-type allele. These observations add significant new aspects to the 
functional repertoire of the S382R/D383Y EGR2 mutant protein and will contribute 
to a comprehensive understanding of why this protein has such devastating 
consequences when expressed in human Schwann cells.
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5.2 RESULTS
5.2.1 Mutant Egr2 dominant-negatively inhibits Po protein expression induced by 
wild-type Egr2.
Previous experiments show that in mouse Schwann cells mutant Egr2 (S382R, 
D383Y) can dominant-negatively inhibit myelin gene mRNA expression using 
adenoviral co-infection with a wild-type Egr2 construct (Nagarajan et al., 2001). To 
confirm these findings at the protein level and in the rat model, I used rat Schwann 
cells that had been retrovirally infected with wild-type Egr2 and then drug selected. 
These cells were subsequently infected with either a GFP control adenovirus or an 
adenovirus expressing GFP and mutant Egr2 for 72 hours. In this way, I ensured that 
the population o f Schwann cells examined expressed both wild-type Egr2 and the 
control or mutant Egr2 constructs. Myelin gene expression was monitored by 
immunocytochemical labelling for the myelin gene Po. I found, as expected, that 
mutant Egr2 strongly inhibited the expression of Po protein (p<0.001), normally 
induced by wild-type Egr2 (Fig. 5.1, A-E).
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Figure 5.1: Mutant Egr2 inhibits wild-type Egr2 induced Po protein expression.
Following retroviral infection o f Schwann cells with wild-type Egr2 (Egr2 WT), cells 
were also infected with either GFP control (GFP cont, A and B) or GFP/mutant Egr2 
adenoviruses (Egr2 Mut, C and D), to test whether mutant Egr2 could repress PO 
induction by wild-type Egr2. Immunolabelling for PO reveals strong PO suppression in 
cells co-infected with mutant Egr2 (e.g. arrowheads in C and D) whereas cells co­
infected with GFP control virus (e.g. arrows in A and B) still express PO. Schwann 
cell nuclei are labelled with Hoescht nuclear dye (Ho). Bar, 20pM. (E) The 
percentage o f cells expressing PO in Schwann cell cultures infected with wild-type 
Egr2 and GFP control (Egr2 WT + GFP cont) and wild-type Egr2 and GFP/mutant 
Egr2 (Egr2 WT + Egr2 Mut). Error bars represent one standard deviation of the mean.
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Figure 5.1
Egr 2 WT + GFP cont Egr2 WT + Egr2 Mut
+ GFP cont + Egr2 Mut
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5.2.2 Mutant Egr2 retains several functions of the wild-type protein.
It has previously been shown by a transfection and electro-mobility shift assay, 
that the Egr2 (S382R, D383Y) mutant can weakly bind DNA and can activate weak 
expression o f an artificial promoter when ectopically expressed in CV-1 cells (Warner 
et al., 1999). However, expression of mutant Egr2 for 24 hours in mouse Schwann 
cells failed to induce myelin gene mRNA expression (Nagarajan et al, 2001). I wished 
to determine more conclusively whether this Egr2 mutant retained properties in 
common with the wild-type allele in Schwann cells or whether it was, in fact, 
functionally equivalent to a null allele.
5.2.2.1 Mutant Egr2 induces periaxin and Nab2 expression.
First, I tested whether mutant Egr2 induced expression of any myelin related 
genes in rat Schwann cells. Schwann cell cultures were infected with adenoviruses 
expressing GFP and wild-type Egr2, GFP and mutant Egr2 or GFP alone. Seventy- 
two hours later the cells were assessed for expression of Po, periaxin and Nab2 by 
either western blot or immunocytochemistry. Mutant Egr2 did not induce Po (Fig. 5.2, 
A), even when I infected with five times the amount o f virus normally used for these 
experiments (results not shown). In contrast, mutant Egr2 still demonstrated an 
unambiguous ability to induce periaxin, although periaxin levels were significantly 
lower than those induced by wild-type Egr2 as shown by western blot (Fig. 2 B) and 
immunocytochemistry (n=3)(p<0.05)(Fig. 5.2, C-G). Furthermore, I found that mutant 
Egr2 induced nuclear expression of Nab2 (25.8 +/- 3.7%), though, again, this effect 
was substantially reduced compared to that of wild-type Egr2 (99 +/-0.7%) 
(n=3)(p<0.05)(Fig. 5.2, H-M).
247
Figure 5.2: Mutant Egr2 induces periaxin and Nab2 expression.
Schwann cell cultures were infected with GFP control (GFP cont), GFP/wild-type 
Egr2 (Egr2 W T) or GFP/mutant Egr2 (Egr2 Mut) adenoviruses and assessed for P0 
expression by immunolabelling (A), periaxin expression by western blot (B) and 
immunolabelling (C-G), and Nab2 by immunolabelling (H-M). Bar, 20pM. Note that 
mutant Egr2 does not induce Po but does induce periaxin and Nab2. However this 
induction is clearly less than that seen with wild-type Egr2. Arrowheads in L and M 
signify Schwann cells that express a low level of mutant Egr2 adenovirus and fail to 
upregulate Nab2. Schwann cell nuclei are labelled with Hoescht nuclear dye (Ho). P- 
Tubulin was used as a loading control for the western blot. Error bars on the graphs 
represent one standard deviation of the mean.
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5.2.2.2 Mutant Egr2 suppresses c-Jun and protects against TGFp induced death.
W ild-type Egr2, in addition to inducing myelin genes, also downregulates the 
expression of molecular components of the Jun-NH2 -terminal kinase/c-Jun pathway in 
cultured Schwann cells (Parkinson et al., 2004). To test whether mutant Egr2 down­
regulates the expression o f c-Jun, I infected cells with GFP control or mutant Egr2 
adenoviruses for 72 hours. Western blotting showed a substantial c-Jun 
downregulation in cells expressing mutant Egr2 (Fig. 5.3 A).
Adenoviral expression of wild-type Egr2 prevents Schwann cell death in 
response to transforming growth factor p (TGF p), an effect related to the ability of 
Egr2 to suppress the JNK/c-Jun pathway (Parkinson et al., 2001, 2004). To test 
whether mutant Egr2 could also block TGF p induced Schwann cell death, survival 
assays were performed on immunopanned Schwann cells prepared from newborn 
animals. Following infection with GFP control, wild-type Egr2 or mutant viruses, cell 
survival was measured over a period of 24 hours with or without TGF p. This 
revealed that, in the presence of TGF P, Schwann cells expressing mutant Egr2 
survived (n=3)(p<0.01) at least as well as wild-type Egr2 cells (Fig. 5.3 B). 
Additionally, immunolabelling demonstrated that c-Jun was downregulated in the 
mutant and wild-type Egr2-expressing cells (results not shown). The medium used in 
this series o f experiments was serum-free. Proliferation was, therefore, essentially 
absent from all experimental conditions (see below). This was confirmed by 
measuring BrdU incorporation (not shown; see section 5.3).
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Figure 5.3: Mutant Egr2 suppresses c-Jun and cell death.
(A) Western blot of c-Jun in Schwann cells infected with GFP control (GFP cont), 
GFP/wild-type Egr2 (Egr2 WT) or GFP/mutant Egr2 (Egr2 Mut) showing that mutant 
Egr2 reduces the expression of c-Jun, a protein associated with immature Schwann 
cells. P-Tubulin was used as a loading control.
(B) The graph demonstrates that mutant Egr2 functions similarly to wild-type Egr2 by 
inhibiting TGFp induced Schwann cell death. Immunopanned Schwann cells were 
infected with GFP control (GFP cont), GFP/wild-type Egr2 (Egr2 WT) and 
GFP/mutant Egr2 (Egr2 Mut) adenoviruses for 48 hours in DM. Some cultures were 
then fixed (time zero control) or cultured with or without TGFp (5ng/ml) for a further 
24 hours. Values are given for the number of surviving GFP-positive cells as a 
percentage o f the number o f GFP-positive Schwann cells at time zero. The error bars 
represent one standard deviation of the mean.
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5.2.3 Mutant Egr2 shows gain-of-function effects that are the converse of those 
seen with the wild-type protein.
Egr2 has a key role in removing Schwann cells from the cell cycle at the onset 
of myelination. Thus, expression of Egr2 is sufficient to block Schwann cell 
proliferation in the presence of the axonal mitogen NRG1 and in Egr2 -/- and Egr2 lo/1° 
mice Schwann cells continue to proliferate and do not myelinate (Topilko et al., 1994; 
Zorick et al., 1999; Parkinson et al., 2004; Le et al., 2005a). To test whether mutant 
Egr2 could also block proliferation in response to NRG1, I infected Schwann cells 
with GFP control virus, wild-type Egr2 or mutant Egr2 viruses for 72 hours. 48 hours 
after infection, some coverslips were treated with NRG1 (20ng/ml) while others 
served as controls. BrdU was added for the last 20 hours of the experiment. 
Surprisingly, I found that mutant Egr2, rather than inhibiting proliferation in the 
presence o f NRG1, boosted the level of BrdU incorporation by 29.2 +1-4.19% 
(n=3)(P<0.01)(Fig. 5.4, A). Furthermore, even in the absence of NRG1, mutant Egr2 
raised the levels o f Schwann cell BrdU incorporation to 22.5 +/-2.99% 
(n=3)(P<0.01)(Fig. 5.4, B). Under these normal culture conditions proliferation rates 
are minimal in control cells and, as expected, wild type Egr2 fails to promote 
Schwann cell proliferation (Fig. 5.4, B)(Parkinson et al., 2004). The routine culture 
medium in these experiments included 0.5% foetal calf serum (see Chapter 2). In the 
complete absence o f serum mutant Egr2 was unable to induce DNA synthesis (data 
not shown).
Because the MEK/ERK pathway has been implicated in Schwann cell 
proliferation (Kim et al., 1997) I examined the levels of phosphorylated ERK1/2 in 
cells expressing mutant Egr2. This revealed that in contrast to wild-type Egr2, mutant 
Egr2 stimulated ERK1/2 phosphorylation (Fig. 5.4, C). In line with this observation,
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an inhibitor o f ERK1/2 phosphorylation, the MEK inhibitor, U0126, blocked BrdU 
incorporation stimulated by mutant Egr2 both in the absence and presence of NRG 1 
(n=5)(P<0.05 and <0.000005 respectively, Fig. 5.4, D). The JNK inhibitor, SP600125 
also inhibited mutant Egr2 induced BrdU incorporation in the absence and presence of 
NRG1 (n=5)(P<0.005 and <0.0005 respectively, Fig. 5.4, D) a result confirmed by 
using the highly specific JNK blocking peptide, D-JNK1 (Borsello et al., 2003)(n=5) 
(P<0.05 and <0.0005 respectively)(Fig. 5.4, E). These results are consistent with the 
known involvement of the JNK/c-Jun pathway in Schwann cell proliferation in vitro 
(Parkinson et al., 2004; see Chapter 4).
In further contrast to the function of the wild-type protein, mutant Egr2 also 
markedly suppressed levels of the cell cycle inhibitor p27 (Fig. 5.4, F and G). P27 
protein is present in quiescent Schwann cells but its expression is elevated by wild- 
type Egr2, presumably as part of the mechanism through which wild-type Egr2 
inhibits cell division (Tikoo et al., 2000; Parkinson et al., 2004).
As expected, given the mitogenic effect of mutant Egr2, we found that mutant 
Egr2, even in the absence of N RG -1, induced nuclear expression of the early cell 
cycle marker, cyclin D1 (n=4)(P<0.001)(Fig. 5.5, A-D). Furthermore, in cells 
expressing mutant Egr2, the G l-S  phase cell cycle enzyme, cdk2 was shifted from the 
cytoplasm to the nucleus (Fig. 5.5, E and F, I and J). Wild-type Egr2, in contrast, 
caused a reduction in cdk2 levels (Fig. 5.5, G and H).
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Figure 5.4: Mutant Egr2 induces DNA synthesis, ERK1/2 phosphorylation and 
the downregulation of p27.
(A) The proliferation of Schwann cells in DM and 0.5% FCS, measured by BrdU 
incorporation, infected with GFP control (GFP cont), GFP/wild-type Egr2 (Egr2 WT) 
and GFP/mutant Egr2 (Egr2 Mut) adenoviruses, in the presence of NRG1 (20ng/ml).
(B) BrdU incorporation in Schwann cells infected with GFP control (GFP cont), 
GFP/wild-type Egr2 (Egr2 WT) and GFP/mutant Egr2 (Egr2 Mut) and maintained in 
DM and 0.5% FCS without NRG1. Note that wild-type Egr2 inhibits proliferation in 
the presence o f NRG1 and that mutant Egr2 stimulates DNA synthesis.
(C) Western blot of phosphorylated ERK1 (44kDa band) and ERK2 (42kDa band) in 
Schwann cells infected with GFP control (GFP), GFP/Egr2 wild type (Egr2 WT) and 
GFP/mutant Egr2 (Egr2 Mut) showing that mutant Egr2 induces phosphorylation of 
ERK1 and ERK2. p-Tubulin was used as a loading control.
(D) The graph shows the percentage of BrdU incorporation in Schwann cell cultures 
infected with mutant Egr2 adenovirus and treated with DMSO as a control, the JNK 
inhibitor, SP600125 (30pM); The MEK inhibitor, U0126 (20pM). The addition of 
NRG1 (20ng/ml) to the cultures is indicated by the black bars whereas white bars 
represent mutant Egr2 infected Schwann cells cultured in DM and 0.5% FCS 
(DM/FCS). Error bars represent one standard deviation of the mean.
(E) The inhibition of the JNK pathway, using a soluble JNK blocking peptide 
(DJNK1, 10pM), blocks mutant Egr2 mediated Schwann cell proliferation in DM and 
0.5% FCS, with (black bars) and without (white bars) the addition of NRG1 
(20ng/ml). Error bars represent one standard deviation of the mean.
(F) Western blot of the cell cycle inhibitor, p27, in GFP control (GFP cont) and 
GFP/mutant Egr2 (Egr2 Mut) infected Schwann cells showing that p27 is 
downregulated in mutant Egr2 expressing Schwann cells. p-Tubulin was used as a 
loading control.
(G) The graph shows the percentage of p27 positive Schwann cells showing nuclear 
staining from immunolabelling experiments, infected with GFP control (GFP cont), 
GFP/wild-type Egr2 (Egr2 WT) and GFP/mutant Egr2 (Egr2 Mut) adenoviruses for 
72 hours. Error bars represent one standard deviation of the mean.
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Figure 5.5: Mutant Egr2 regulates cyclin D1 and cdk2.
(A) Western blot o f cyclin D1 in GFP control (GFP cont), GFP/wild-type Egr2 (Egr2 
WT) and GFP/mutant Egr2 (Egr2 Mut) infected Schwann cells confirming that 
mutant Egr2 can induce the expression of cyclin D l. p-Tubulin was used as a loading 
control.
(B and C) Immunolabelling of Schwann cells, maintained without NRG-1 in 
DM/0.5% FCS, infected with GFP/mutant Egr2 (Egr2 Mut) adenovirus for cyclin D l 
demonstrates nuclear staining, a characteristic o f proliferating Schwann cells (Kim et 
al., 2000). Bar, 20pM. (D) The percentage of cyclin D l positive Schwann cells 
infected with GFP control (GFP cont), wild-type Egr2 (Egr2 WT) and mutant Egr2 
(Egr2 Mut) adenoviruses and maintained without NRG-1. (E-J) Immunolabelling 
showing cy cl in-dependant kinase 2 (CDK2) in Schwann cells infected with GFP 
control (GFP cont; E and F), GFP/wild-type Egr2 (Egr2 WT; G and H) and 
GFP/mutant Egr2 (Egr2 Mut; I and J) adenoviruses. Schwann cell nuclei are labelled 
with Hoescht nuclear dye (Ho). Bar, 20pM. cdk2 is expressed both in the nucleus and 
the cytoplasm in GFP control cultures and has reduced expression in cells infected 
with wild-type Egr2. In contrast, cells infected with mutant Egr2 show a distinctly 
nuclear localisation o f cdk2 (arrows in I and J), another characteristic of proliferating 
Schwann cells (Tikoo et al., 2000).
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5.2.4 At higher concentrations, mutant Egr2 behaves more like wild-type Egr2.
Mutant Egr2 binds DNA less strongly than wild-type Egr2. Intriguingly, it 
demonstrates some normal functions and some aberrant functions (see above). To test 
whether the aberrant effects were more prominent at lower Egr2 levels, when DNA 
binding is likely to be weak, I infected Schwann cells with varying concentrations of 
mutant Egr2 adenovirus and then measured the amount o f periaxin, c-Jun and BrdU 
incorporation. I found that increasing the level of mutant Egr2 by infecting with up to 
5-fold the normal virus quantity increased periaxin induction and reduced c-Jun 
protein levels still further (P<0.001 and P<0.001 respectively)(Fig. 5.6, A). This is 
likely to be because increasing the mutant Egr2 concentration increases the amount of 
mutant Egr2 bound to DNA. The level of BrdU incorporation also fell by 20.2 +/- 
1.78% in Schwann cells infected with 5-fold concentration of mutant Egr2 adenovirus 
(P<0.0001)(Fig. 5.6, B). To confirm this finding, I double labelled Schwann cells 
infected with low concentrations o f mutant Egr2 adenovirus with antibodies to Egr2 
and BrdU. Schwann cells with intense GFP fluorescence, expressed high levels of 
mutant Egr2 and were BrdU negative, whereas the faintly Egr2 and GFP positive cells 
were much more likely to be BrdU positive (Fig. 5.6, C and D). I also double labelled 
Schwann cells under the same conditions with antibodies to periaxin and BrdU and 
found that the cell population that expressed periaxin and the one that incorporated 
BrdU were non-overlapping (Fig. 5.6, E and F) as expected from previous reports that 
myelin differentiation and proliferation are incompatible (Morgan et al., 1991).
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Figure 5.6: Mutant Egr2 shows concentration-dependent effects.
(A) Increasing the amount of mutant Egr2 adenovirus used to infect Schwann cells up 
to 5 fold can induce a higher percentage of Schwann cells to express periaxin and 
fewer to express c-Jun, judged by immunocytochemistry and cell counting. Error bars 
represent one standard deviation of the mean. Statisical analysis was performed using 
one-way ANOVA and Tukey’s Multiple Comparison test.
(B) Increasing the amount of mutant Egr2 adenovirus used to infect Schwann cell 
cultures, up to 5-fold, can reduce the level of BrdU incorporation. These cultures were 
maintained without NRG1 in DM/0.5%FCS. Error bars represent one standard 
deviation o f the mean. Statisical analysis was performed using one-way ANOVA and 
Tukey’s Multiple Comparison test.
(C and D) Double immunolabelling for Egr2 and BrdU in Schwann cell cultures 
infected with low concentrations of GFP/mutant Egr2 (Egr2 Mut) adenovirus. Arrows 
demonstrate Schwann cells expressing high levels of mutant Egr2 and GFP, which do 
not incorporate BrdU. Arrowheads show Schwann cells expressing low levels of 
mutant Egr2 and GFP, which have incorporated BrdU. Bar, 20pM.
(E and F) Double immunolabelling for periaxin and BrdU in Schwann cell cultures 
infected with low concentrations of GFP/mutant Egr2 (Egr2 Mut) adenovirus. 
Arrowheads show cells that express periaxin are strongly infected, judged by GFP 
expression, and do not incorporate BrdU. Arrows demonstrate Schwann cells weakly 
expressing GFP and mutant Egr2 (Egr2 Mut) that do not express periaxin but clearly 
incorporate BrdU. Bar, 20|uM.
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5.3 DISCUSSION
I have investigated the functional properties of the S382R/D383Y Egr2 mutant 
in rat Schwann cells. I found that this mutation does not create an allele that is 
functionally-null, but one that retains a number of functions typical o f the wild-type 
allele. Increasing levels of mutant Egr2 within Schwann cells causes this allele to 
function more like a wild-type Egr2 molecule, presumably by increasing levels of 
binding to DNA (Warner et al., 1999). Most importantly for understanding mutant 
EGR2-related pathology, mutant Egr2 also demonstrates aberrant effects in Schwann 
cells, namely the induction of proliferation, cyclin D l and nuclear cdk2 and the 
suppression o f the mitotic inhibitor, p27 that are the converse of the properties of 
wild-type Egr2. These gain-of-function effects provide additional insight into how 
this mutation leads to the development of such a severe form of inherited peripheral 
neuropathy.
5.3.1 M utant Egr2 can function as a wild-type Egr2 molecule.
As mentioned previously, the EGR2 S382R, D383Y mutant was initially 
identified as a molecule that showed a greatly reduced binding of the Egr2 consensus 
binding site in an electrophoretic mobility shift assay (Warner et al., 1999). Further 
analysis demonstrated that the Egr2 S382R, D383Y mutant could not activate 
transcription o f the myelin-related genes periaxin, myelin associated glycoprotein 
(MAG), Po and PMP22, unlike wild-type Egr2 (Nagarajan et al., 2001). The initial 
aim was to identify whether the S382R, D383Y mutant retained any Egr2 wild-type 
functions because it weakly activates a luciferase reporter construct containing Egr2 
binding sites (W arner et al., 1999). As expected, I found mutant Egr2 could not 
induce Po expression but could still induce low levels of periaxin protein. This finding
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is in contrast to that of Nagarajan et al, (2001). One possibility for this disparity is that 
it may reflect a species difference because I used rat Schwann cells for these 
experiments whereas Nagarajan et al, (2001) used mouse Schwann cells. Furthermore, 
Nagarajan et al, (2001) also measured periaxin mRNA at 24 hours after infection of 
Schwann cells with mutant Egr2 whereas I assayed protein levels after both 48 and 72 
hours. It is possible that, due to its weakened DNA binding ability, the induction of 
periaxin can only be observed at longer time points after adenoviral infection.
My findings also raise the possibility that there are differences in the Egr2- 
mediated induction o f Po compared to that of periaxin. The fact that mutant Egr2 
never induces Po expression suggests that a strong Egr2/DNA interaction is required 
whereas a weaker Egr2/DNA interaction is sufficient to induce periaxin. In a recent 
study, it was shown that Egr2 directly induces Po expression in Schwann cells through 
Egr2 binding sites found in a conserved element within the first intron of the Po gene 
(LeBlanc et al., 2006). It is still not known whether Egr2 directly induces periaxin 
expression in Schwann cells, as Egr2 was unable to activate a reporter construct 
containing an 8kb fragment of the periaxin promoter (Parkinson et al., 2003). It 
should be noted that, it is more correct to think of Egr2 as elevating pre-existing 
expression o f periaxin and Po in Schwann cells, at the onset of myelination, as both 
proteins can be detected in Schwann cells before Egr2 is upregulated (Lee et al., 1997; 
Parkinson et al., 2003). Thus both genes can be regulated by Egr2-independent 
mechanisms (Peirano et al., 2000; Parkinson et al., 2003).
An important function of wild-type Egr2 is its ability to promote survival of 
Schwann cells, even in the presence of death signals such as TGF P (Parkinson et al., 
2001, 2004). This is correlated with the observation that there is increased postnatal 
Schwann cell death in the Krox-20 null mouse (Zorick et al., 1999; see section
263
1.5.4.1). Furthermore, inhibition of the JNK/c-Jun pathway can block Schwann cell 
death, in vitro and thus the increased survival of Egr2 positive Schwann cells is 
related to its ability to downregulate c-Jun (Parkinson et al., 2001; 2004). If the 
S382R, D383Y Egr2 mutant had failed to promote Schwann cell survival, this might 
have suggested a further explanation for the severe hypomyelination observed in 
humans. Surprisingly, mutant Egr2 protects newborn Schwann cells from TGF p 
induced death at least as efficiently as wild-type Egr2 and was also able to 
downregulate expression of c-Jun. The survival experiments were carried out in serum 
free medium and therefore these results were unaffected by cell proliferation (see 
section 5.3.2). This finding argues against a mechanism involving increased Schwann 
cell death contributing to the CHN phenotype seen in the patient carrying the S382R, 
D383Y mutation. In addition, it is remarkable that even though mutant Egr2 has 
reduced DNA binding it still maintains fully the ability to promote Schwann cell 
survival. This suggests that the mechanisms that control Egr2 mediated myelin gene 
expression may differ from those that direct Egr2 mediated cell survival.
5.3.2 M utant Egr2 also displays effects that are the converse of wild-type Egr2.
Schwann cells expressing mutant Egr2 demonstrate increased levels of DNA 
synthesis not only in the presence o f the axonally-derived mitogen NRG1 but also 
when NRG1 is absent from the culture medium. Considering the established role of 
wild-type Egr2 in causing Schwann cell cycle exit, even in the presence o f NRG1, this 
observation was very surprising (Zorick et al., 1999; Parkinson et al., 2004). 
Nevertheless, it has important consequences considering that a biopsy of the sural 
nerve o f a patient carrying this mutation revealed numerous onion bulbs containing 
supernumerary Schwann cells, characterisic of increased proliferation of Schwann
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cells (W arner et al., 1998). Furthermore, evidence from the rat model of CMT1A 
demonstrates that Schwann cells in demyelinated axonal segments, that presumably 
give rise to the supernumerary Schwann cells within onion bulbs, express nuclear 
cyclin D l and proliferate (Atanasoski et al., 2002), as 1 observe with mutant Egr2 
expressing Schwann cells.
The routine medium for these experiments contained 0.5% calf serum. When 
this was omitted from the culture medium I failed to observe significant Schwann cell 
DNA synthesis. This suggests that the mechanism by which mutant Egr2 stimulates 
Schwann cell proliferation involves changes in the response to potential mitogens in 
the cellular environment. Mutant Egr2 can induce nuclear expression o f cyclin D l and 
cdk2 and reduce levels o f the cell cycle inhibitor, p27. Either or both of these 
responses may contribute to the increased proliferative response o f mutant Egr2 
expressing Schwann cells. Evidence from cyclin D l-null Schwann cells demonstrates 
that it is required for Schwann cells to proliferate in culture and after nerve transection 
(Kim et al., 2000; Atanasoski et al, 2001). Furthermore, overexpression of cyclin D l 
in Schwann cells using a retrovirus caused DNA synthesis in a significant proportion 
o f Schwann cells in the absence o f growth factor treatment, such as PDGF (Kim et al., 
2001). Although reduction in p27 levels is correlated with cell proliferation (Tikoo et 
al., 2000), it is unknown whether loss o f p27 is sufficient to induce Schwann cells to 
proliferate in culture.
The findings that mutant Egr2 increases ERK1/2 phosphorylation and that the 
inhibition o f the MEK/ERK1/2 and c-Jun/JNK pathways reduces DNA synthesis 
induced by mutant Egr2, may indicate that mutant Egr2 controls Schwann cell 
proliferation upstream of the cell cycle regulatory proteins. For instance, mutant Egr2 
could increase the expression o f growth factor receptors or their activity. I found,
265
however, that the levels of the erbB2 and erbB3 receptor proteins remained
unchanged in mutant Egr2 infected cells (not shown). Furthermore, I found that
proliferation induced by mutant Egr2 was not inhibited by the use of either of the 
erbB2 tyrosine-kinase inhibitors, AG 1478 (Lyons et al., 2005) or GW2974 (not 
shown). This suggests that mutant Egr2 does not increase erbB2 receptor activity and 
that it exerts its influence on targets downstream of this receptor. It remains possible 
that mutant Egr2 alters the expression or phosphorylation state of other growth factor 
receptors, such as the PDGF receptor. Another possibility arises from the observation 
that mutant Egr2 induces a significant cell flattening (see Fig. 6.5, I) suggesting that 
adhesion between the cells and the substrate may be increased in Schwann cells 
expressing mutant Egr2. This may be important because Schwann cells were plated 
onto a laminin substrate and one set of adhesion molecules that may be altered by 
mutant Egr2 are the integrins, some o f which are activated on binding to laminin 
(Previtali et al., 2001; Wrabetz and Feltri, 2005). This is particularly significant given
that one o f the functions of the integrin receptors is to modulate growth factor
signalling (for review see Guo and Giancotti, 2004).
5.3.3 M utant Egr2 demonstrates concentration-dependent effects.
Schwann cells tend to incorporate BrdU when they express lower levels of 
mutant Egr2 whereas Schwann cells expressing higher levels of mutant Egr2 are less 
likely to proliferate but instead tend to differentiate and express myelin related 
markers such as periaxin. The difference in functional consequence to the Schwann 
cell, depending on the level of mutant Egr2 expressed, may be linked with either the 
level o f DNA binding o f mutant Egr2 or with its ability to associate with other 
proteins. A recent publication showed that peripheral nerve myelination requires co­
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operation between Egr2 and its co-factors Nabl and Nab2 and that Egr2 induces Nabl 
and Nab2 as well (Le et al., 2005b). Mutant Egr2 has reduced ability to induce Nab2 
and this may contribute to the dysfunction of this protein. Interestingly, when Egr2 is 
expressed in the absence of both Nabl and Nab2, it not only fails to induce significant 
levels o f myelin genes, such as Po, PMP22 and periaxin but also activates genes that 
are not activated when Nabl and Nab2 are present (see section 1.5.4.1). In addition, 
the Egr2 I268N mutant, which does not bind Nab proteins and causes recessive CHN, 
also activates aberrant genes (Nagarajan et al., 2001; Le et al., 2005b; Desmazieres et 
al., 2008).
5.3.4 Egr2 mutations in inherited peripheral neuropathies.
The fact that mutant Egr2 can induce proliferation may help explain the 
presence o f supernumerary Schwann cells in nerves biopsies from patients carrying 
this mutation (W arner et al, 1998). Other studies have shown that the Egr2 S382R, 
D383Y mutant can dominantly-inhibit wild-type Egr2 function (Nagarajan et al., 
2001; Le Blanc et al., 2007). We confirm that this mutant can act as a dominant- 
negative molecule, which is particularly important since this mutation follows an 
autosomal dominant pattern of inheritance (Warner et al., 1998). A recent publication 
demonstrated that dominant-negative Egr2 mutants actually perturb Sox 10 binding at 
Egr2/Soxl0 binding sites in the Po intron element thus preventing cooperative Sox 10 
and wild-type Egr2 mediated myelin gene expression (LeBlanc et al., 2006, 2007). 
However, these mutations may induce subtly different molecular and cellular 
phenotypes since they lead to peripheral neuropathies of varying severity. One 
potential explanation is that the various DNA binding mutants may have different 
affinities for Sox 10 (LeBlanc et al., 2007). Yet, in the case of 3 EGR2 DNA binding
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mutants, it has also been shown that the increasing ability to bind DNA also correlates 
with the increasing severity of peripheral neuropathy that they cause (Warner et al., 
1999). In view of the complex spectrum of normal and abnormal functions shown by 
the Egr2 S382R, D383Y mutant, it will be important for future studies to investigate 
the functional properties of other EGR2 DNA binding mutants in order elucidate the 
particular mechanisms by which these mutations lead to peripheral nerve dysfunction.
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CHAPTER 6: General Discussion
Since the advent of the unveiling of the double helical structure of DNA 
(Watson and Crick, 1953) the focus of cell biology has been strongly concentrated on 
the molecules involved in the control of cellular processes such as proliferation, 
survival and differentiation. Within the last twenty years much progress has been 
made in understanding some of the signals and cellular mechanisms involved in many 
aspects o f Schwann cell biology. This knowledge has in turn aided understanding of 
disease processes in peripheral nerves, when systems do not work as they should. In 
particular, the discovery of proteins associated with myelinating Schwann cells and 
some o f the transcription factors that control their expression have lead to the 
identification of many of these molecules as being deficient or mutated in many forms 
of inherited peripheral neuropathies.
Within this thesis I aimed to identify new roles for factors involved in 
regulating the differentiation of Schwann cells. I have investigated how cyclic AMP 
and NRG1 signals and the transcription factor CREB regulate Schwann cell myelin 
differentiation (Chapter 3). Additionally, I examined the involvement o f the 
transcription factor, c-Jun in Schwann cells in response to nerve injury (Chapter 4). 
Finally, I observed the functional consequences for Schwann cells of a mutation in the 
transcription factor Egr-2, which leads to CHN in humans (Chapter 5). A common 
theme that has developed within the projects described in this thesis is the positive 
and negative regulation o f Schwann cell myelination. In particular, this thesis 
demonstrates that genes that negatively regulate myelination may also have important 
roles in controlling the phenotype of Schwann cells after nerve injury.
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One o f the most surprising findings was that cyclic AMP analogue treatment 
was insufficient to induce Schwann cell myelin differentiation in cultured mouse 
Schwann cells whereas it has been known for over twenty years to perform this 
function in cultured rat Schwann cells. This finding in itself presents intriguing 
opportunities to investigate why there is such a difference considering the relatively 
close phylogenetic relationship between rats and mice. In addition it also raises the 
question o f how accurate predictions from studying rodents can be for understanding 
mechanisms in human cells. This is why the work using human Schwann cells, 
pioneered by the Bunge laboratory, is essential to identify similarities and differences 
with work done in rodent Schwann cells or indeed other species (Morrissey et al., 
1991). However, the very nature of this species difference allowed me to identify a 
potential mechanism for how NRG1 signalling might contribute to Schwann cell 
myelin differentiation. Future work will be able to discern how cyclic AMP 
modulates NRG1 signalling and identify whether this is an important mechanism in 
vivo.
In addition, I have identified a potential role for the CREB family of 
transcription factors in regulating Schwann cell myelin differentiation. This finding 
potentially adds to the list o f transcription factors now known to play a role in 
myelination, which consist o f Krox-20 (Egr-2), Oct-6, SoxlO and NFkB (lessen and 
Mirsky, 2005). Future investigation will no doubt determine whether CREB or the 
related transcription factors ATF1 and CREM play a role in Schwann cell 
differentiation in vivo.
Studying the role of c-Jun in Schwann cells, particularly after nerve injury, 
provided me with a very unique opportunity to open up debate and investigation on 
relatively unstudied facets of Schwann cell biology, namely the mechanism of
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Schwann cell demyelination and the contribution of the Schwann cells to axonal 
regeneration and neuronal integrity after peripheral nerve injury. The involvement of 
the Schwann cell in events during Wallerian degeneration and peripheral nerve 
regeneration have been the subject of conjecture since the time of Cajal though there 
is a distinct lack o f evidence to outline the relative importance o f the Schwann cell in 
these processes. Results in this thesis clearly show that Schwann cells actively 
respond to nerve injury and this response is required for adequate myelin removal, 
axonal regeneration, neuronal survival and nerve repair. Thus Schwann cells appear to 
be key regulators of successful nerve repair and these findings can now be used as a 
platform to investigate the mechanisms involved in these processes and the relative 
contribution o f c-Jun to these phenotypes.
These results also provide a strong argument to redefine our current perspective 
o f the Schwann cell lineage (Fig.6.1). Many researchers refer to Schwann cells 
returning to an immature-like phenotype after nerve injury due to re-expression of 
molecules such as L I, p75NTR and NCAM (Scherer and Salzer, 2001; lessen and 
Mirsky, 2005). However, denervated Schwann cells also demonstrate 
phagocytic/autophagic properties and furthermore these cells express many cytokines 
to mediate inflammatory responses (see Chapters 1 and 4). In addition, immature 
Schwann cells express the 04 antigen during development whereas denervated 
Schwann cells do not express 04 (Mirsky et al., 1990). Denervated Schwann cells 
have also been shown to express N-cadherin, a marker that is expressed by Schwann 
cell precursors and only at very low levels on immature Schwann cells (Padilla et al., 
1999; Wanner et al., 2006b). These are two examples of the divergence in the 
phenotype o f denervated Schwann cells from that of immature Schwann cells. 
Furthermore, microarray analysis has also identified that only 47% of genes regulated
271
after nerve injury are also regulated during development (Bosse et al., 2006). Thus 
these findings argue that the denervated Schwann cell be identified as phenotypically 
distinct from the immature Schwann cell.
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Figure 6.1: The adapted Schwann cell lineage: A case for a new m em ber?
Schematic o f the Schwann cell lineage in light o f observations of the phenotypic 
differences between denervated Schwann cells and the rest of the Schwann cell 
lineage. Dotted arrows demonstrate the ability of denervated Schwann cells to 
differentiate into myelinating or non-myelinating Schwann cells after associating with 
regenerating axons during peripheral nerve repair.
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Finally, investigating the functional consequences of a mutation in Egr-2 
demonstrated that the mutant protein retained some aspects of its wild-type 
counterpart while it also demonstrated novel aberrant functions, particularly in its 
ability to induce Schwann cell proliferation whereas wild-type Egr-2 inhibited 
Schwann cell proliferation. While these observations add to the bank of knowledge 
regarding the potential mechanisms resulting in the onset of CHN in patients with this 
mutation (W arner et al., 1998; Warner et al., 1999; Nagarajan et al., 2001; Le et al., 
2005a; LeBlanc et al., 2007) they also extend the opportunity to investigate how 
mutant Egr2 and wild-type Egr2 have opposing effects upon the cell cycle. This could 
add to the understanding of how Egr2 controls Schwann cell proliferation under 
normal conditions (Topilko et al., 1994; Zorick et al., 1996; Parkinson et al., 2004; Le 
et al., 2005b; Desmazieres et al., 2008).
In summary, through the investigations described in this thesis I have identified 
new roles for the factors c-Jun, CREB and cyclic AMP and NRG1 in addition to 
outlining the functions of a mutant form of Egr-2 in Schwann cells. These projects 
enabled me to view at first hand the evolving nature of the scientific process and 
marvel in the beauty o f how an unexpected finding can sometimes lead to a 
completely new perspective on an old idea.
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APPENDIX I
5X Laemmli Buffer 
0 .16M Tris pH 6.8 
10% SDS 
50% glycerol 
25% (3-Mercaptoethanol 
Bromophenol blue 
In UPH20
IPX Running Buffer 
0.25M Trizma base 
1.92M Glycine 
1% SDS 
In UPH20
IX Transfer Buffer 
48mM Trizma base 
40mM Glycine 
10% SDS 
In UPH20
IPX TBS
0.5M TrisHCl pH 7.4 
1.5M NaCl 
In UPH20
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APPENDIX II
Primers and PCR conditions for genotyping-
c-iun floxed allele
LoxPCRS: 5’-CTC ATA CCA GTT CGC ACA GGC GGC-3’
LoxPCR6: 5’-CCG CTA GCA CTC ACG TTG GTA GGC-3’
PCR reaction conditions: 1 initial cycle of 2 minutes at 94°C followed by 37 cycles of 
40 seconds at 94°C, 40 seconds at 57°C and 1 minute and 30 seconds at 72°C, before 
a final extension period of 7 minutes at 72°C.
f / fIn case of c-jun mice, a single band of 350bp resulted from the amplification 
reaction. In case of c-junf/+ mice, two bands of 350bp (floxed) and 300bp (wt) were 
amplified.
c-jun deleted allele
Floxl: 5’-CTC ATA CCA GTT CGC ACA GGC G-3’
Flox2: 5’-CAG GGC GTT GTG TCA CTG AGC T-3’
PCR reaction conditions: 1 initial cycle of 3 minutes at 94°C followed by 35 cycles of 
40 seconds at 94°C, 40 seconds at 57°C and 1 minute at 72°C, before a final extension 
period of 10 minutes at 72°C.
In the presence of ere recombinase, deletion of c-jun was identified by the 
amplification of a single band of 500bp.
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IL-2
IL-2F: 5’-CTA GGC CAC AGA ATT GAA AGA TCT-3’ 
IL-2R: 5’-GTA GGT GGA A AT TCT AGC ATC ATC C-3’
PCR reaction conditions: 1 initial cycle of 3 minutes at 94°C followed by 35 cycles of
40 seconds at 94°C, 40 seconds at 57°C and 1 minute at 72°C, before a final extension
period of 10 minutes at 72°C.
A single band of 300bp was produced by this amplification 
Pn Cre
PoCreF: 5’-GCT GGC CCA AAT GTT GCT GG-3’
PoCreR: 5’-CCA CCA CCT CTC CAT TGC AC-3’
PCR reaction conditions: 1 initial cycle of 4 minutes at 94°C followed by 30 cycles of 
30 seconds at 94°C, 1 minute at 50°C and 1 minute at 72°C, before a final extension 
period of 10 minutes at 72°C.
In the presence of cre recombinase a band of 480kb was amplified
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Krox-20/LacZ
K20 430C: 5’-ACA TGA CTG GAG AGA AGA GAC CCC T-3’
K20 1233NC: 5-G C G  TTT TGC TGG GCC TGT TAG GGT A-3’
LacZ 159INC: 5’-TTG GTG TAG ATG GGC GCA TCG TAA C-3’
PCR reaction conditions: 1 initial cycle of 3 minutes at 94°C followed by 40 cycles of 
30 seconds at 94°C, 30 seconds at 59°C and 30 seconds at 72°C, before a final 
extension period of 3 minutes at 72°C.
In case of Krox-20+/+ mice, a single band of 600bp resulted from the amplification 
reaction. In case of Krox-204/' mice, two bands of 600bp (wild-type) and 500bp 
(deleted) were amplified. In case of Krox-20 " mice, one band of 500bp (deleted) was 
amplified.
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APPENDIX I I I
Buffer B l:
0.1M Tris-HCl 
0 .15M NaCl 
in UPH2 O
Buffer B2:
Buffer B l + l%heat inactivated goat serum
Buffer B3.
0 .1M Tris (pH 9.5)
0 .1M NaCl and 50mM MgCl2 
in UPH20
Buffer B4:
Buffer B3 containinig:
3.5mg/ml NBT (Roche Diagnostics, Germany) 
3.5mg/ml BCIP (Roche Diagnostics, Germany) 
0.24 mg/ml levamisole (Sigma, UK)
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Hybridisation Buffer:
IX SALTS
50% formamide (Sigma, UK)
0.1 mg/ml yeast total RNA (Invitrogen, UK)
10% w/v dextran sulphate (Fluka chemicals Ltd, Switzerland) 
IX  Denhart’s (Sigma, UK) 
in autoclaved UP H2 O.
IPX SALTS 
2M NaCl 
50mM EDTA 
lOOmM Tris-Cl (pH 7.5)
50mM NaH2P 0 4.2H20  
50mM Na2H P 04 
in autoclaved UP H20
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